

HLTH CORP  
Form 10-Q  
November 10, 2008

Table of Contents

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

Form 10-Q

- QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the quarterly period ended **September 30, 2008**
- or
- TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**  
For the transition period from \_\_\_\_\_ to \_\_\_\_\_

Commission file number: **0-24975**

**HLTH CORPORATION**

*(Exact name of registrant as specified in its charter)*

**Delaware**  
*(State of incorporation)*  
**669 River Drive, Center 2**  
**Elmwood Park, New Jersey**  
*(Address of principal executive office)*

**94-3236644**  
*(I.R.S. employer identification no.)*  
**07407-1361**  
*(Zip code)*

**(201) 703-3400**

*(Registrant's telephone number including area code)*

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting

Edgar Filing: HLTH CORP - Form 10-Q

company in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes  No

As of November 5, 2008, there were 185,561,083 shares of HLTH Common Stock outstanding (including unvested shares of restricted HLTH Common Stock issued under our equity compensation plans).

---

**HLTH CORPORATION**  
**QUARTERLY REPORT ON FORM 10-Q**  
**For the period ended September 30, 2008**

**TABLE OF CONTENTS**

	<b>Page Number</b>
<u>Forward-Looking Statements</u>	3
<u>PART I</u> <u>Financial Information</u>	
<u>Item 1.</u> <u>Financial Statements:</u>	
<u>Consolidated Balance Sheets as of September 30, 2008 (unaudited) and December 31, 2007</u>	4
<u>Unaudited Consolidated Statements of Operations for the three and nine months ended September 30, 2008 and 2007</u>	5
<u>Unaudited Consolidated Statements of Cash Flows for the three and nine months ended September 30, 2008 and 2007</u>	6
<u>Notes to Consolidated Financial Statements</u>	7
<u>Item 2.</u> <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	32
<u>Item 3.</u> <u>Quantitative and Qualitative Disclosures About Market Risk</u>	71
<u>Item 4.</u> <u>Controls and Procedures</u>	71
<u>PART II</u> <u>Other Information</u>	
<u>Item 1.</u> <u>Legal Proceedings</u>	72
<u>Item 2.</u> <u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	72
<u>Item 6.</u> <u>Exhibits</u>	72
<u>Signatures</u>	73
<u>Exhibit Index</u>	E-1
<u>EX-31.1</u>	
<u>EX-31.2</u>	
<u>EX-32.1</u>	
<u>EX-32.2</u>	

WebMD®, WebMD Health®, CME Circle®, eMedicine®, MedicineNet®, Medscape®, MEDPOR®, Medsite®, POREX®, RxList®, Subimo®, Summex®, theheart.org® and The Little Blue Book™ are among the trademarks of HLTH Corporation or its subsidiaries.

**Table of Contents**

**FORWARD-LOOKING STATEMENTS**

This Quarterly Report on Form 10-Q contains both historical and forward-looking statements. All statements, other than statements of historical fact, are or may be, forward-looking statements. For example, statements concerning projections, predictions, expectations, estimates or forecasts and statements that describe our objectives, future performance, plans or goals are, or may be, forward-looking statements. These forward-looking statements reflect management's current expectations concerning future results and events and can generally be identified by the use of expressions such as may, will, should, could, would, likely, predict, potential, continue, future, expect, anticipate, intend, plan, foresee, and other similar words or phrases, as well as statements in the future tense.

Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance and achievements expressed or implied by these statements. The following important risks and uncertainties could affect our future results, causing those results to differ materially from those expressed in our forward-looking statements:

failure to achieve sufficient levels of usage of WebMD's public portals;

inability to successfully deploy new or updated applications or services;

failure to achieve sufficient levels of utilization and market acceptance of new or updated products and services;

difficulties in forming and maintaining relationships with customers and strategic partners;

inability to attract and retain qualified personnel;

anticipated benefits from acquisitions not being fully realized or not being realized within the expected time frames;

general economic, business or regulatory conditions affecting the healthcare, information technology, Internet and plastics industries being less favorable than expected; and

the other risks and uncertainties described in this Quarterly Report on Form 10-Q under the heading "Management's Discussion and Analysis of Financial Condition and Results of Operations - Factors That May Affect Our Future Financial Condition or Results of Operations."

These factors are not necessarily all of the important factors that could cause actual results to differ materially from those expressed in any of our forward-looking statements. Other factors, including unknown or unpredictable ones, could also have material adverse effects on our future results.

The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date of this Quarterly Report. Except as required by law or regulation, we do not undertake any obligation to update any forward-looking statements to reflect subsequent events or circumstances.

**Table of Contents**

**PART I  
FINANCIAL INFORMATION**

**ITEM 1. Financial Statements**

**HLTH CORPORATION**

**CONSOLIDATED BALANCE SHEETS  
(In thousands, except share and per share data)**

	<b>September 30, 2008 (Unaudited)</b>	<b>December 31, 2007</b>
<b>ASSETS</b>		
Current assets:		
Cash and cash equivalents	\$ 1,380,179	\$ 536,879
Short-term investments	284,789	290,858
Accounts receivable, net of allowance for doubtful accounts of \$1,261 at September 30, 2008 and \$1,165 at December 31, 2007	78,148	86,081
Due from EBS Master LLC		1,224
Prepaid expenses and other current assets	27,190	71,090
Assets of discontinued operations	119,891	262,964
Total current assets	1,890,197	1,249,096
Marketable equity securities	2,175	2,383
Property and equipment, net	51,766	49,554
Goodwill	211,414	217,323
Intangible assets, net	28,917	36,314
Investment in EBS Master LLC		25,261
Other assets	36,534	71,466
<b>TOTAL ASSETS</b>	<b>\$ 2,221,003</b>	<b>\$ 1,651,397</b>
<b>LIABILITIES AND STOCKHOLDERS EQUITY</b>		
Current liabilities:		
Accrued expenses	\$ 44,305	\$ 49,598
Deferred revenue	81,740	76,401
Liabilities of discontinued operations	100,464	123,131
Total current liabilities	226,509	249,130
1.75% convertible subordinated notes due 2023	350,000	350,000
31/8% convertible notes due 2025	300,000	300,000
Other long-term liabilities	21,184	21,137
Minority interest in WHC	139,250	131,353

## Commitments and contingencies

## Stockholders' equity:

Preferred stock, \$0.0001 par value; 5,000,000 shares authorized; no shares outstanding

Common stock, \$0.0001 par value; 900,000,000 shares authorized; 457,943,786 shares issued at September 30, 2008; 457,803,361 shares issued at December 31, 2007

Additional paid-in capital	46	46
Treasury stock, at cost; 273,397,698 shares at September 30, 2008; 275,786,634 shares at December 31, 2007	12,504,151	12,479,574
Accumulated deficit	(2,556,347)	(2,564,948)
Accumulated other comprehensive income	(8,764,576)	(9,320,748)
	786	5,853
Total stockholders' equity	1,184,060	599,777
<b>TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</b>	<b>\$ 2,221,003</b>	<b>\$ 1,651,397</b>

See accompanying notes.

**Table of Contents****HLTH CORPORATION****CONSOLIDATED STATEMENTS OF OPERATIONS****(In thousands, except per share data, unaudited)**

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
Revenue	\$ 100,367	\$ 86,034	\$ 271,185	\$ 235,112
Costs and expenses:				
Cost of operations	35,322	30,021	99,655	87,636
Sales and marketing	26,441	22,459	77,731	67,258
General and administrative	22,928	25,718	67,253	81,111
Depreciation and amortization	7,265	7,390	21,468	20,954
Interest income	9,386	10,864	29,384	30,638
Interest expense	4,636	4,660	13,871	13,985
Gain on sale of EBS Master LLC			538,024	
Impairment of auction rate securities			60,108	
Other (expense) income, net	(997)	989	(5,807)	5,267
Income from continuing operations before income tax provision	12,164	7,639	492,700	73
Income tax provision	7,679	2,977	34,623	4,404
Minority interest in WHC income (loss)	1,845	1,800	(929)	2,758
Equity in earnings of EBS Master LLC		8,005	4,007	22,679
Income from continuing operations	2,640	10,867	463,013	15,590
Income (loss) from discontinued operations, net of tax	93,241	5,704	93,159	(38,780)
Net income (loss)	\$ 95,881	\$ 16,571	\$ 556,172	\$ (23,190)
Basic income (loss) per common share:				
Income from continuing operations	\$ 0.01	\$ 0.06	\$ 2.53	\$ 0.09
Income (loss) from discontinued operations	0.51	0.03	0.51	(0.22)
Net income (loss)	\$ 0.52	\$ 0.09	\$ 3.04	\$ (0.13)
Diluted income (loss) per common share:				
Income from continuing operations	\$ 0.01	\$ 0.06	\$ 2.06	\$ 0.08
Income (loss) from discontinued operations	0.50	0.03	0.41	(0.21)
Net income (loss)	\$ 0.51	\$ 0.09	\$ 2.47	\$ (0.13)
Weighted-average shares outstanding used in computing income (loss) per common share:				
Basic	183,716	179,811	182,838	178,681



Diluted	187,527	188,071	228,653	188,486
---------	---------	---------	---------	---------

See accompanying notes.

Table of Contents**HLTH CORPORATION****CONSOLIDATED STATEMENTS OF CASH FLOWS****(In thousands, unaudited)**

	<b>Nine Months Ended</b>	
	<b>September 30,</b>	
	<b>2008</b>	<b>2007</b>
<b>Cash flows from operating activities:</b>		
Net income (loss)	\$ 556,172	\$ (23,190)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:		
(Income) loss from discontinued operations, net of tax	(93,159)	38,780
Depreciation and amortization	21,468	20,954
Minority interest in WHC (loss) income	(929)	2,758
Equity in earnings of EBS Master LLC	(4,007)	(22,679)
Amortization of debt issuance costs	2,248	2,179
Non-cash advertising	1,736	2,489
Non-cash stock-based compensation	18,974	26,246
Deferred income taxes	11,934	3,710
Gain on sale of EBS Master LLC and 2006 EBS Sale	(538,024)	(399)
Impairment of auction rate securities	60,108	
Changes in operating assets and liabilities:		
Accounts receivable	7,933	14,835
Prepaid expenses and other, net	4,174	(198)
Accrued expenses and other long-term liabilities	(3,639)	(45,878)
Deferred revenue	5,339	3,253
Net cash provided by continuing operations	50,328	22,860
Net cash provided by discontinued operations	28,497	24,366
Net cash provided by operating activities	78,825	47,226
<b>Cash flows from investing activities:</b>		
Proceeds from maturities and sales of available-for-sale securities	117,539	356,492
Purchases of available-for-sale securities	(177,150)	(694,522)
Purchases of property and equipment	(15,115)	(14,427)
Proceeds related to sales of ViPS, EBS, EPS and ACS/ACP, net of expenses	821,706	14,565
Decrease in net advances to EBS Master LLC	1,224	19,921
Other	148	
Net cash provided by (used in) continuing operations	748,352	(317,971)
Net cash used in discontinued operations	(4,265)	(3,785)
Net cash provided by (used in) investing activities	744,087	(321,756)
<b>Cash flows from financing activities:</b>		
Proceeds from issuance of HLTH and WHC common stock	20,725	114,077
Purchases of treasury stock under repurchase program		(47,120)

Edgar Filing: HLTH CORP - Form 10-Q

Other	343	4,300
Net cash provided by continuing operations	21,068	71,257
Net cash used in discontinued operations	(76)	(130)
Net cash provided by financing activities	20,992	71,127
Effect of exchange rates on cash	(604)	1,042
Net increase (decrease) in cash and cash equivalents	843,300	(202,361)
Cash and cash equivalents at beginning of period	536,879	614,691
Cash and cash equivalents at end of period	\$ 1,380,179	\$ 412,330

See accompanying notes.

**Table of Contents**

**HLTH CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**(In thousands, except share and per share data, unaudited)**

**1. Background and Basis of Presentation**

**Background**

HLTH Corporation ( HLTH or the Company ) is a Delaware corporation that was incorporated in December 1995 and commenced operations in January 1996 as Healtheon Corporation. HLTH's Common Stock began trading on the Nasdaq National Market under the symbol HLTH on February 11, 1999 and now trades on the Nasdaq Global Select Market. The Company changed its name to Healtheon/WebMD Corporation in November 1999 and to WebMD Corporation in September 2000. In October 2005, WebMD Corporation changed its name to Emdeon Corporation in connection with the initial public offering of equity securities of WebMD Health Corp. ( WHC ). In connection with the November 2006 sale of a 52% interest in the Company's Emdeon Business Services segment, the Company transferred its rights to the name Emdeon and related intellectual property to Emdeon Business Services. Accordingly, in May 2007, the Company changed its name to HLTH Corporation.

WHC's Class A Common Stock began trading on the Nasdaq National Market under the symbol WBMD on September 29, 2005 and now trades on the Nasdaq Global Select Market. As of September 30, 2008, the Company owned 48,100,000 shares of WHC Class B Common Stock, which represented 83.1% of the total outstanding Class A Common Stock (after accounting for the impact of certain WHC shares to be issued pursuant to the purchase agreement for the acquisition of Subimo, LLC) and Class B Common Stock of WHC. WHC Class A Common Stock has one vote per share, while WHC Class B Common Stock has five votes per share. As a result, the WHC Class B Common Stock owned by the Company represented, as of September 30, 2008, 96.2% of the combined voting power of WHC's outstanding Common Stock.

**Basis of Presentation**

The accompanying consolidated financial statements include the consolidated accounts of HLTH Corporation and its subsidiaries and have been prepared in United States dollars, and in accordance with U.S. generally accepted accounting principles ( GAAP ). The consolidated accounts include 100% of the assets and liabilities of the majority-owned WHC and the ownership interests of minority stockholders of WHC are recorded as minority interest in WHC in the accompanying consolidated balance sheets.

The Company's 48% ownership in EBS Master LLC was accounted for under the equity method through February 8, 2008, the date of the sale of the Company's investment in EBS Master LLC. See Note 3 for further details.

On February 21, 2008, the Company announced its intention to sell its ViPS and Porex businesses. On July 22, 2008, the Company completed the sale of ViPS. Accordingly, the results of the Company's ViPS and Porex segments are presented as discontinued operations in the accompanying consolidated financial statements. See Note 2 for further details.

**Interim Financial Statements**

The unaudited consolidated financial statements of the Company have been prepared by management and reflect all adjustments (consisting of only normal recurring adjustments) that, in the opinion of management, are necessary for a fair presentation of the interim periods presented. The results of operations for the three and nine months ended

Edgar Filing: HLTH CORP - Form 10-Q

September 30, 2008 are not necessarily indicative of the operating results to be expected for any subsequent period or for the entire year ending December 31, 2008. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted under the Securities and Exchange Commission's (the SEC) rules and regulations.

**Table of Contents**

**HLTH CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The unaudited consolidated financial statements and notes included herein should be read in conjunction with the Company's audited consolidated financial statements and notes for the year ended December 31, 2007, which are included in the Company's Current Report on Form 8-K filed with the SEC on June 27, 2008.

**Accounting Estimates**

The preparation of financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business factors, and various other assumptions that the Company believes are necessary to consider to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic, environmental and political factors, and changes in the Company's business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company's financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company's operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to the consolidated financial statements. Significant estimates and assumptions by management affect: the allowance for doubtful accounts, the carrying value of prepaid advertising, the carrying value of long-lived assets (including goodwill and intangible assets), the amortization period of long-lived assets (excluding goodwill), the carrying value, capitalization and amortization of software and Web site development costs, the carrying value of investments in auction rate securities, the provision for income taxes and related deferred tax accounts, certain accrued expenses, revenue recognition, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.

**Seasonality**

The timing of the Company's revenue is affected by seasonal factors. Advertising and sponsorship revenue within the WebMD Online Services segment is seasonal, primarily as a result of the annual budget approval process of the advertising and sponsorship clients of the public portals. This portion of revenue is usually the lowest in the first quarter of each calendar year, and increases during each consecutive quarter throughout the year. Private portal licensing revenue within the WebMD Online Services segment is historically highest in the second half of the year as new customers are typically added during this period in conjunction with their annual open enrollment periods for employee benefits. Finally, the annual distribution cycle within the WebMD Publishing and Other Services segment results in a significant portion of the revenue in this segment being recognized in the second and third quarter of each calendar year.

**Net Income (Loss) Per Common Share**

Basic income (loss) per common share and diluted income (loss) per common share are presented in conformity with Statement of Financial Accounting Standards (SFAS) No. 128, Earnings Per Share (SFAS 128). In accordance with SFAS 128, basic income (loss) per common share has been computed using the weighted-average number of shares of common stock outstanding during the period, increased to give effect to the participating rights of the convertible

redeemable exchangeable preferred stock. Diluted income (loss) per common share has been computed using the weighted-average number of shares of common stock outstanding during the period, increased to give effect to potentially dilutive securities and assumes that any dilutive convertible notes were converted, only in the periods in which such effect is dilutive. Additionally, for purposes of calculating diluted income (loss) per common share of the Company, the numerator has been adjusted to consider the effect of potentially dilutive securities of WHC, which can dilute the portion of

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

WHC's net income (loss) otherwise retained by the Company. The following table presents the calculation of basic and diluted income (loss) per common share (shares in thousands):

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
<b>Numerator:</b>				
Income from continuing operations	\$ 2,640	\$ 10,867	\$ 463,013	\$ 15,590
Convertible redeemable exchangeable preferred stock fee				174
Income from continuing operations - Basic	2,640	10,867	463,013	15,764
Interest expense on convertible notes, net of tax			8,324	
Effect of WHC dilutive securities	(203)	(436)	(326)	(658)
Income from continuing operations - Diluted	\$ 2,437	\$ 10,431	\$ 471,011	\$ 15,106
Income (loss) from discontinued operations, net of tax				
Basic and Diluted	\$ 93,241	\$ 5,704	\$ 93,159	\$ (38,780)
<b>Denominator:</b>				
Common stock	183,716	179,811	182,838	171,643
Convertible redeemable exchangeable preferred stock				7,038
Weighted-average shares - Basic	183,716	179,811	182,838	178,681
Employee stock options, restricted stock and warrants	3,811	8,260	3,800	9,805
Convertible notes			42,015	
Adjusted weighted-average shares after assumed conversions - Diluted	187,527	188,071	228,653	188,486
<b>Basic income (loss) per common share:</b>				
Income from continuing operations	\$ 0.01	\$ 0.06	\$ 2.53	\$ 0.09
Income (loss) from discontinued operations	0.51	0.03	0.51	(0.22)
Net income (loss)	\$ 0.52	\$ 0.09	\$ 3.04	\$ (0.13)
<b>Diluted income (loss) per common share:</b>				
Income from continuing operations	\$ 0.01	\$ 0.06	\$ 2.06	\$ 0.08
Income (loss) from discontinued operations	0.50	0.03	0.41	(0.21)
Net income (loss)	\$ 0.51	\$ 0.09	\$ 2.47	\$ (0.13)





**Table of Contents****HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The Company has excluded convertible subordinated notes and convertible notes, as well as certain outstanding warrants, restricted stock and stock options, from the calculation of diluted income (loss) per common share during the periods in which such securities were anti-dilutive. The following table presents the total number of shares that could potentially dilute income (loss) per common share in the future that were not included in the computation of diluted income (loss) per common share during the periods presented (shares in thousands):

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
Options, restricted stock and warrants	28,806	21,054	32,879	20,175
Convertible notes	42,015	42,015		42,015
	70,821	63,069	32,879	62,190

**Income Taxes**

The income tax provision of \$7,679 and \$34,623 for the three and nine months ended September 30, 2008, respectively, and \$2,977 and \$4,404 for the three and nine months ended September 30, 2007, respectively, represents taxes for federal, state and other jurisdictions. The Company recorded an income tax provision related to discontinued operations of \$8,813 and \$8,143 for the three and nine months ended September 30, 2008, respectively, and an income tax provision of \$823 and \$1,461 for the three and nine months ended September 30, 2007, respectively, included in loss from discontinued operations, net of tax in the accompanying consolidated statements of operations. While the majority of the gain on the 2008 EBSCo Sale (as defined in Note 3) was offset by net operating loss ( NOL ) carryforwards, certain alternative minimum tax and other state taxes were not offset resulting in a provision of approximately \$24,000 for the nine months ended September 30, 2008. The income tax provision for the nine months ended September 30, 2008 excludes a benefit for the impairment of auction rate securities, as it is currently not deductible for tax purposes.

**Recent Accounting Pronouncements**

On May 9, 2008, the Financial Accounting Standards Board ( FASB ) issued FASB Staff Position ( FSP ) Accounting Principles Board ( APB ) Opinion No. 14-1, Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement) ( FSP APB 14-1 ). The FSP will require cash settled convertible debt to be separated into debt and equity components at issuance and a value to be assigned to each. The value assigned to the debt component will be the estimated fair value, as of the issuance date, of a similar bond without the conversion feature. The difference between the bond cash proceeds and this estimated fair value will be recorded as a debt discount and amortized to interest expense over the life of the bond. Although FSP APB 14-1 would have no impact on the Company's actual past or future cash flows, it will require the Company to record a significant amount of non-cash interest expense as the debt discount is amortized. As a result, there will be a material adverse impact on the results of operations and earnings per share. In addition, if the convertible debt is redeemed or converted prior to maturity, any unamortized debt discount will result in a loss on extinguishment. FSP APB 14-1 will become effective

January 1, 2009, and will require retrospective application.

On April 25, 2008, the FASB issued FSP FAS 142-3, Determination of the Useful Life of Intangible Assets. This FSP amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under SFAS No. 142, Goodwill and Other Intangible Assets ( SFAS 142 ). The intent of this FSP is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142 and the period of expected cash flows used to measure the fair value of the asset under SFAS No. 141 (Revised 2007), Business Combinations, and other U.S. GAAP. This FSP is effective for financial statements issued for fiscal years beginning after December 15,

**Table of Contents****HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

2008, and interim periods within those fiscal years. Early adoption is prohibited. The Company is currently evaluating the impact that this FSP will have on its operations, financial position and cash flows.

In December 2007, the FASB issued SFAS No. 141 (Revised 2007), Business Combinations ( SFAS 141R ), a replacement of SFAS No. 141. SFAS 141R is effective for fiscal years beginning on or after December 15, 2008 and applies to all business combinations. SFAS 141R provides that, upon initially obtaining control, an acquirer shall recognize 100 percent of the fair values of acquired assets, including goodwill, and assumed liabilities, with only limited exceptions, even if the acquirer has not acquired 100 percent of its target. As a consequence, the current step acquisition model will be eliminated. Additionally, SFAS 141R changes current practice, in part, as follows: (1) contingent consideration arrangements will be fair valued at the acquisition date and included on that basis in the purchase price consideration; (2) transaction costs will be expensed as incurred, rather than capitalized as part of the purchase price; (3) pre-acquisition contingencies, such as legal issues, will generally have to be accounted for in purchase accounting at fair value; and (4) in order to accrue for a restructuring plan in purchase accounting, the requirements in SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities, would have to be met at the acquisition date. While there is no expected impact to the Company's consolidated financial statements on the accounting for acquisitions completed prior to December 31, 2008, the adoption of SFAS 141R on January 1, 2009 could materially change the accounting for business combinations consummated subsequent to that date and for tax matters relating to prior acquisitions settled subsequent to December 31, 2008.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements An Amendment of ARB No. 51 ( SFAS 160 ). SFAS 160 requires the recognition of a noncontrolling interest (minority interest) as equity in the financial statements and separate from the parent's equity. The amount of net income attributable to the noncontrolling interest will be included in consolidated net income on the face of the results of operations. SFAS 160 clarifies that changes in a parent's ownership interest in a subsidiary that do not result in deconsolidation are equity transactions if the parent retains its controlling financial interest. In addition, this statement requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss will be measured using the fair value of the noncontrolling equity investment on the deconsolidation date. SFAS 160 also includes expanded disclosure requirements regarding the interests of the parent and its noncontrolling interest. SFAS 160 is effective for financial statements issued for fiscal years beginning after December 15, 2008 and is to be applied prospectively as of the beginning of the fiscal year in which the statement is applied. Early adoption is not permitted. The Company is currently evaluating the impact that SFAS 160 will have on its operations, financial position and cash flows.

**2. Discontinued Operations**

In November 2007, the Company announced its intention to explore potential sales transactions for its ViPS and Porex businesses and in February 2008, the Company announced its intention to divest these segments. As a result, the financial information has been reclassified to discontinued operations in the accompanying consolidated financial statements.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)*****Porex***

Summarized operating results for Porex for the three and nine months ended September 30, 2008 and 2007 are as follows:

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
Statement of Operations Data:				
Revenue	\$ 23,131	\$ 21,867	\$ 71,518	\$ 69,579
Earnings before taxes	5,001	4,820	13,002	15,587

The major classes of assets and liabilities of Porex as of September 30, 2008 and December 31, 2007 are as follows:

	<b>September 30,</b>		<b>December 31,</b>	
	<b>2008</b>		<b>2007</b>	
Assets of discontinued operations:				
Accounts receivable, net	\$	12,955	\$	12,922
Inventory		12,121		11,772
Property and equipment, net		22,231		21,176
Goodwill		42,960		43,283
Intangible assets, net		24,750		24,872
Deferred tax asset		1,420		1,420
Other assets		3,454		3,554
Total Assets	\$	119,891	\$	118,999
Liabilities of discontinued operations:				
Accounts payable	\$	1,983	\$	1,533
Accrued expenses		6,587		7,684
Deferred tax liability		24,583		24,375
Other long-term liabilities				101
Total Liabilities	\$	33,153	\$	33,693

***ViPS***

On July 22, 2008, the Company completed the sale of its ViPS segment ( ViPS Sale ) to an affiliate of General Dynamics Corporation ( General Dynamics ) for \$224,842 in cash, which reflects the effect of a preliminary estimate of

the amount of a customary working capital adjustment to the contractual purchase price of \$225,000 in cash. The actual amount of the working capital adjustment has not yet been determined. The Company incurred approximately \$1,337 of professional fees and other expenses associated with the ViPS Sale during the three months ended September 30, 2008. In connection with the sale, the Company recognized a pre-tax gain of \$96,566, which is included in income from discontinued operations in the accompanying consolidated statements of operations during the three months ended September 30, 2008.

**Table of Contents****HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Summarized operating results for ViPS for the periods July 1, 2008 through July 22, 2008, January 1, 2008 through July 22, 2008 and the three and nine months ended September 30, 2007 are as follows:

	<b>For the Period July 1, 2008 to July 22, 2008</b>	<b>Three Months Ended September 30, 2007</b>	<b>For the Period January 1, 2008 to July 22, 2008</b>	<b>Nine Months Ended September 30, 2007</b>
Statement of Operations Data:				
Revenue	\$ 5,292	\$ 24,307	\$ 57,497	\$ 76,851
Earnings before taxes	270	1,412	8,121	4,211

The major classes of assets and liabilities of ViPS as of December 31, 2007 are as follows:

Assets of discontinued operations:	
Accounts receivable, net	\$ 17,240
Property and equipment, net	4,020
Goodwill	71,253
Intangible assets, net	47,815
Deferred tax asset	804
Other assets	2,833
<b>Total Assets</b>	<b>\$ 143,965</b>
Liabilities of discontinued operations:	
Accounts payable	\$ 1,599
Accrued expenses and other	4,370
Deferred revenue	10,982
Deferred tax liability	16,924
<b>Total Liabilities</b>	<b>\$ 33,875</b>

**ACS/ACP Business**

As of December 31, 2007, the Company, through WHC, entered into an Asset Sale Agreement and completed the sale of certain assets and certain liabilities of its medical reference publications business, including the publications *ACP Medicine* and *ACS Surgery: Principles and Practice*. The assets and liabilities sold are referred to below as the ACS/ACP Business. *ACP Medicine* and *ACS Surgery* are official publications of the American College of Physicians

and the American College of Surgeons, respectively. As a result of the sale, the historical financial information of the ACS/ACP Business has been reclassified as discontinued operations in the accompanying consolidated financial statements for the prior year period. The Company will receive net cash proceeds of \$2,809, consisting of \$1,734 received during the quarter ended March 31, 2008 and the remaining \$1,075 to be received during the quarter ending December 31, 2008. The Company incurred approximately \$800 of professional fees and other expenses associated with the sale of the ACS/ACP Business. In connection with the sale, the Company recognized a gain of \$3,394 in the three months ended December 31, 2007. Summarized operating results for the discontinued operations of the ACS/ACP Business for the three and nine months ended September 30, 2007 were as follows:

	<b>Three Months Ended September 30, 2007</b>	<b>Nine Months Ended September 30, 2007</b>
Statement of Operations Data:		
Revenue	\$ 1,100	\$ 3,327
(Loss) earnings before taxes	(10)	210



Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)*****EPS***

On September 14, 2006, the Company completed the sale (the *EPS Sale*) of Emdeon Practice Services, Inc. (together with its subsidiaries, *EPS*) to Sage Software, Inc. (*Sage Software*). The Company has certain indemnity obligations to advance amounts for reasonable defense costs for initially ten, and now eight, former officers and directors of *EPS*, who were indicted in connection with the previously disclosed investigation by the United States Attorney for the District of South Carolina (the *Investigation*), which is more fully described in Note 12, *Commitments and Contingencies*. In connection with the *EPS Sale*, the Company agreed to indemnify Sage Software relating to these indemnity obligations. During the quarter ended June 30, 2007, based on information it had recently received at that time, the Company determined a reasonable estimate of the range of probable costs with respect to its indemnification obligation and accordingly, recorded a pre-tax charge of \$57,774, which represented the Company's estimate of the low end of the probable range of costs related to this matter. The Company had reserved the low end of the probable range of costs because no estimate within the range was a better estimate than any other amount. That estimate included assumptions as to the duration of the trial and pre-trial periods, and the defense costs to be incurred during these periods. During the quarter ended December 31, 2007 and again during the quarter ended June 30, 2008, the Company updated the estimated range of its indemnification obligation based on new information received during those periods, and as a result, recorded additional pre-tax charges of \$15,573 and \$16,980, respectively, each of which reflected the increases in the low end of the probable range of costs related to this matter. The probable range of future costs with respect to this matter is estimated to be approximately \$47,400 to \$70,400, as of September 30, 2008 which includes costs that have been incurred prior to, but were not yet paid, as of September 30, 2008. The ultimate outcome of this matter is still uncertain, and the estimate of future costs includes assumptions as to the duration of the trial and the defense costs to be incurred during the remainder of the pre-trial period and during the trial period. Accordingly, the amount of cost the Company may ultimately incur could be substantially more than the reserve the Company has currently provided. If the recorded reserves are insufficient to cover the ultimate cost of this matter, the Company will need to record additional charges to its consolidated statement of operations in future periods. The accrual related to this obligation was \$47,399 and \$55,563 as of September 30, 2008 and December 31, 2007, respectively, and is included within liabilities of discontinued operations in the accompanying consolidated balance sheets.

Also included within liabilities of discontinued operations related to this matter is \$19,912 which represents reimbursements received from the Company's insurance carriers between July 31, 2008 and September 30, 2008. The Company deferred recognizing these insurance reimbursements within the statement of operations given the pending Coverage Litigation. For more information regarding the Coverage Litigation, see Note 12.

**3. Emdeon Business Services**

On November 16, 2006, the Company completed the sale of a 52% interest in its Emdeon Business Services segment (*2006 EBS Sale*) to an affiliate of General Atlantic LLC (*GA*). The 2006 EBS Sale was structured so that the Company and *GA* each own interests in a limited liability company, *EBS Master LLC* (*EBSCo*), which owns the entities comprising *EBS* through a wholly owned limited liability company, *Emdeon Business Services LLC*. During the three months ended June 30, 2007, the Company recognized a gain of \$399 which related to the finalization of the working capital adjustment in connection with the *2006 EBS Sale*.

Beginning on November 17, 2006, the Company's remaining 48% ownership interest in *EBSCo* was reflected as an investment in the Company's consolidated financial statements, accounted for under the equity method and the

Company's share of EBSCO's net earnings was reported as equity in earnings of EBS Master LLC in the accompanying consolidated statements of operations through February 8, 2008.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

On February 8, 2008, the Company entered into a Securities Purchase Agreement and simultaneously completed the sale of its 48% minority ownership interest in EBSCo (the 2008 EBSCo Sale ) for \$575,000 in cash to an affiliate of GA and affiliates of Hellman & Friedman, LLC. In connection with the 2008 EBSCo Sale, the Company recognized a pre-tax gain of \$538,024. The Company expects to utilize a portion of its federal NOL carryforwards to offset a portion of the tax liability that would otherwise result from the 2008 EBSCo Sale.

The Company's share of EBSCo's net earnings is reported as equity in earnings of EBS Master LLC in the accompanying consolidated statements of operations for the three and nine months ended September 30, 2007 and for the period January 1, 2008 through February 8, 2008, the closing date of the 2008 EBSCo Sale. The difference between the equity in earnings of EBS Master LLC in the accompanying consolidated statements of operations and 48% of the net income of EBSCo is principally due to the amortization of the excess of the fair value of EBSCo's net assets as adjusted for in purchase accounting, over the carryover basis of the Company's investment in EBSCo. The following is summarized financial information of EBSCo for the period January 1, 2008 through February 8, 2008 and for the three and nine months ended September 30, 2007:

	<b>For the Period January 1, 2008 to February 8, 2008</b>	<b>Three Months Ended September 30, 2007</b>	<b>Nine Months Ended September 30, 2007</b>
Statement of Operations Data:			
Revenue	\$ 94,481	\$ 202,954	\$ 602,589
Cost of operations	44,633	94,712	280,786
Net income	5,551	9,999	26,798

**4. Termination of Proposed Merger with WHC**

On February 20, 2008, the Company and WHC entered into an Agreement and Plan of Merger (the Merger Agreement ), pursuant to which the Company would merge into WHC (the WHC Merger ), with WHC continuing as the surviving corporation. The Merger Agreement was amended on May 6, 2008 and September 12, 2008. Pursuant to the terms of a Termination Agreement entered into on October 19, 2008 (the Termination Agreement ), the Company and WHC mutually agreed, in light of recent turmoil in financial markets, to terminate the Merger Agreement. The termination was by mutual agreement of the companies and was unanimously approved by the Board of Directors of each of the companies and by a special committee of independent directors of WHC. The Termination Agreement maintains the Company's obligation, under the terms of the Merger Agreement, to pay the expenses of WHC incurred in connection with the merger. Under the Termination Agreement, the Company and WHC also agreed to amend the Amended and Restated Tax Sharing Agreement, dated as of February 15, 2006, between them (the Tax Sharing Agreement ) so that, for tax years beginning after December 31, 2007, the Company will no longer be required to reimburse WHC for use of NOL carryforwards attributable to WHC that may result from certain extraordinary transactions by the Company. The Tax Sharing Agreement has not, other than with respect to certain extraordinary transactions by the Company, required either the Company or WHC to reimburse the other party for any net tax savings realized by the consolidated group as a result of the group's utilization of WHC's or the Company's NOL

carryforwards during the period of consolidation, and that will continue following the amendment. The Termination Agreement also provided for the Company to assign to WHC the Amended and Restated Data License Agreement, dated as of February 8, 2008, among the Company, EBSCO and certain affiliated companies.

**Table of Contents****HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****5. WebMD Health Corp.*****Gain Upon Sale of WHC Class A Common Stock***

The Company's WHC subsidiary issues its Class A Common Stock in various transactions from time to time, which result in the dilution of the Company's percentage ownership in WHC. The Company accounts for the issuance of WHC Class A Common Stock in accordance with the SEC's Staff Accounting Bulletin No. 51, Accounting for Sales of Stock by a Subsidiary. The issuances of WHC Class A Common Stock resulted in an aggregate gain to equity of \$1,768 and \$3,715 during the three and nine months ended September 30, 2008, respectively, related to the exercise of stock options and the release of restricted stock awards. As a result, the Company's ownership in WHC decreased to 83.1% as of September 30, 2008, from 83.5% as of December 31, 2007 (after accounting for the impact of certain WHC shares to be issued pursuant to the purchase agreement for the acquisition of Subimo, LLC).

**6. Segment Information**

Segment information has been prepared in accordance with SFAS No. 131, Disclosures about Segments of an Enterprise and Related Information (SFAS 131). The accounting policies of the segments are the same as the accounting policies for the consolidated Company. Inter-segment revenue represents certain services provided by the WebMD Online Services segment and WebMD Publishing and Other Services segment (which we refer to, together, as the WebMD Segments or, sometimes, as WebMD) to the Corporate segment. The performance of the Company's business is monitored based on earnings before interest, taxes, non-cash and other items. Other items include: legal expenses incurred by the Company, which reflect costs and expenses related to the investigation by the United States Attorney for the District of South Carolina and the SEC; income related to the reduction of certain sales and use tax contingencies; professional fees in 2008, primarily consisting of legal, accounting and financial advisory services related to the terminated WHC Merger; the gain on the 2008 EBSCo Sale; the gain recognized in connection with the working capital adjustment associated with the 2006 EBS Sale; and the impairment charge related to the Company's auction rate securities.

*Reclassification of Segment Information.* As a result of the Company's intention to divest the Porex segment and due to the ViPS Sale and the December 31, 2007 sale of WHC's ACS/ACP business, the financial information for these businesses has been reclassified to discontinued operations for the current and prior year periods. As a result of the discontinued operations presentation for ViPS and Porex, the Company's only remaining operating segment would have been WebMD. Accordingly, the Company expanded its segment disclosure for WebMD to provide additional information related to the WebMD Online Services segment and the WebMD Publishing and Other Services segment. This additional information for WebMD has been provided for all periods presented.

The WebMD Segments and Corporate segment are described as follows:

*WebMD Online Services* provides health information services to consumers, physicians, healthcare professionals, employees and health plans through its public and private online portals. The public portals for consumers enable them to obtain health and wellness information (including information on specific diseases and conditions), check symptoms, locate physicians, store individual healthcare information, receive periodic e-newsletters on topics of individual interest, enroll in interactive courses and participate in online communities with peers and experts. The public portals for physicians and healthcare professionals make it easier for them

to access clinical reference sources, stay abreast of the latest clinical information, learn about new treatment options, earn continuing medical education credit and communicate with peers. The private portals enable employers and health plans to provide their employees and plan members with access to personalized health and benefit information and decision-support technology that helps them make more informed benefit, provider and treatment choices.

Table of Contents

**HLTH CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

WebMD Online Services provides related services for use by such employees and members, including lifestyle education and personalized telephonic health coaching. WebMD Online Services also provides e-detailing promotion and physician recruitment services for use by pharmaceutical, medical device and healthcare companies.

*WebMD Publishing and Other Services* publishes *The Little Blue Book*, a physician directory, and *WebMD the Magazine*, a consumer magazine distributed to physician office waiting rooms. The Company also published medical reference textbooks until it divested this business on December 31, 2007. See Note 2 for further details.

*Corporate* includes personnel costs and other expenses related to functions that are not directly managed by one of the Company's segments or by the Porex and ViPS businesses included in discontinued operations. The personnel costs include executive personnel, legal, accounting, tax, internal audit, risk management, human resources and certain information technology functions. Other corporate costs and expenses include professional fees including legal and audit services, insurance, costs of leased property and facilities, telecommunication costs and software maintenance expenses. Corporate expenses are net of \$838 and \$2,572 for the three and nine months ended September 30, 2008, respectively, and \$845 and \$2,470 for the three and nine months ended September 30, 2007, respectively, which are costs allocated to WebMD for services provided by the Corporate segment. In connection with the 2006 EBS Sale, EPS Sale and the ViPS Sale, the Company entered into transition services agreements whereby the Company provided ViPS, EBSCo, and Sage Software certain administrative services, including payroll, accounting, purchasing and procurement, tax, and human resource services, as well as information technology support. Additionally, EBSCo provided certain administrative services to the Company. These services were provided through the Corporate segment, and the related transition services fees that the Company charged to ViPS, EBSCo, and Sage Software, net of the fee the Company paid to EBSCo, were also included in the Corporate segment, which were intended to approximate the cost of providing these services. The transition services agreement with Sage Software was terminated on December 31, 2007 and, therefore, net transition services fees are solely for services related to EBSCo and ViPS for the three and nine months ended September 30, 2008.

**Table of Contents****HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Summarized financial information for the WebMD Segments and Corporate segment and a reconciliation to income from continuing operations are presented below:

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
<b>Revenue</b>				
WebMD Online Services:				
Advertising and sponsorship	\$ 72,046	\$ 59,087	\$ 190,494	\$ 158,944
Licensing	22,139	20,001	65,928	59,915
Content syndication and other	392	490	1,154	2,027
Total WebMD Online Services	94,577	79,578	257,576	220,886
WebMD Publishing and Other Services	5,810	6,520	13,669	14,426
Inter-segment eliminations	(20)	(64)	(60)	(200)
	\$ 100,367	\$ 86,034	\$ 271,185	\$ 235,112
<b>Earnings before interest, taxes, non-cash and other items</b>				
WebMD Online Services	\$ 25,956	\$ 21,948	\$ 61,287	\$ 48,982
WebMD Publishing and Other Services	1,212	2,138	1,485	2,643
Corporate	(4,679)	(5,811)	(15,311)	(18,874)
	22,489	18,275	47,461	32,751
<b>Interest, taxes, non-cash and other items</b>				
Interest income	9,386	10,864	29,384	30,638
Interest expense	(4,636)	(4,660)	(13,871)	(13,985)
Income tax provision	(7,679)	(2,977)	(34,623)	(4,404)
Depreciation and amortization	(7,265)	(7,390)	(21,468)	(20,954)
Non-cash stock-based compensation	(6,531)	(9,285)	(18,974)	(26,246)
Non-cash advertising	(178)	(169)	(1,736)	(2,489)
Minority interest in WHC income (loss)	(1,845)	(1,800)	929	(2,758)
Equity in earnings of EBS Master LLC		8,005	4,007	22,679
Gain on sale of EBS Master LLC			538,024	
Impairment of auction rate securities			(60,108)	
Other (expense) income, net	(1,101)	4	(6,012)	358
Income from continuing operations	2,640	10,867	463,013	15,590
Income (loss) from discontinued operations, net of tax	93,241	5,704	93,159	(38,780)



Net income (loss)	\$ 95,881	\$ 16,571	\$ 556,172	\$ (23,190)
-------------------	-----------	-----------	------------	-------------

## 7. Stock-Based Compensation

The Company has various stock-based compensation plans (collectively, the Plans ) under which directors, officers and other eligible employees receive awards of options to purchase HLTH Common Stock and restricted shares of HLTH Common Stock. Additionally, WHC has two similar stock-based compensation plans that provide for stock options and restricted stock awards based on WHC Class A Common Stock. The Company also maintained an Employee Stock Purchase Plan through April 30, 2008, which provided

**Table of Contents****HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

employees with the ability to buy shares of HLTH Common Stock at a discount. The following sections of this note summarize the activity for each of these plans.

**HLTH Plans**

The Company had an aggregate of 5,936,018 shares of HLTH Common Stock available for future grants under the Plans as of September 30, 2008. In addition to the Plans, the Company has granted options to certain directors, officers and key employees pursuant to individual stock option agreements. At September 30, 2008, there were options to purchase 4,139,881 shares of HLTH Common Stock outstanding to these individuals. The terms of these grants are similar to the terms of the options granted under the Plans and accordingly, the stock option activity of these individuals is included in all references to the Plans. Beginning in April 2007, shares are issued from treasury stock when options are exercised or restricted stock is granted. Prior to this time, new shares were issued in connection with these transactions.

***Stock Options***

Generally, options under the Plans vest and become exercisable ratably over a three to five year period based on their individual grant dates subject to continued employment on the applicable vesting dates. The majority of options granted under the Plans expire within ten years from the date of grant. Options are granted at prices not less than the fair market value of HLTH Common Stock on the date of grant. The following table summarizes activity for the Plans for the nine months ended September 30, 2008:

	Shares	Weighted Average Exercise Price Per Share	Weighted Average Remaining Contractual Life (In Years)	Aggregate Intrinsic Value (1)
Outstanding at January 1, 2008	47,293,577	\$ 14.35		
Granted	120,000	13.40		
Exercised	(2,339,811)	7.65		
Cancelled	(1,405,760)	16.88		
Outstanding at September 30, 2008	43,668,006	\$ 14.63	3.0	\$ 33,489
Vested and exercisable at the end of the period	39,218,041	\$ 15.11	2.5	\$ 27,417

(1) The aggregate intrinsic value is based on the market price of HLTH's Common Stock on September 30, 2008, which was \$11.43, less the applicable exercise price of the underlying option. This aggregate intrinsic value

represents the amount that would have been realized if all of the option holders had exercised their options on September 30, 2008.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model, considering the assumptions noted in the following table. Expected volatility is based on implied volatility from traded options of HLTH Common Stock combined with historical volatility of HLTH Common Stock. Prior to January 1, 2006, only historical volatility was considered. The expected term represents the period of time that options are expected to be outstanding following their grant date, and was determined using historical exercise data. The risk-free rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date.

	<b>Nine Months Ended September 30,</b>	
	<b>2008</b>	<b>2007</b>
Expected dividend yield	0%	0%
Expected volatility	0.33	0.31
Risk-free interest rate	2.82%	4.67%
Expected term (years)	3.81	3.94
Weighted average fair value of options granted during the period	\$ 3.92	\$ 4.01

***Restricted Stock Awards***

HLTH Restricted Stock consists of shares of HLTH Common Stock which have been awarded to employees with restrictions that cause them to be subject to substantial risk of forfeiture and restrict their sale or other transfer by the employee until they vest. Generally, HLTH Restricted Stock awards vest ratably over a three to five year period from their individual award dates subject to continued employment on the applicable vesting dates. The following table summarizes the activity of non-vested HLTH Restricted Stock for the nine months ended September 30, 2008:

	<b>Shares</b>	<b>Weighted Average Grant Date Fair Value</b>
Balance at January 1, 2008	1,240,297	\$ 10.74
Vested	(181,769)	9.53
Forfeited	(35,837)	11.26
Balance at September 30, 2008	1,022,691	\$ 10.94

Proceeds received from the exercise of options to purchase HLTH Common Stock were \$10,624 and \$17,901 for the three and nine months ended September 30, 2008, respectively, and \$8,821 and \$107,635 for the three and nine months ended September 30, 2007, respectively. The intrinsic value related to the exercise of these stock options, as well as the fair value of shares of HLTH Restricted Stock that vested was \$6,513 and \$11,840 for the three and nine

months ended September 30, 2008, respectively, and \$4,703 and \$55,635 for the three and nine months ended September 30, 2007, respectively.

### **WebMD Plans**

During September 2005, WHC adopted the 2005 Long-Term Incentive Plan (the "WHC Plan"). In connection with the acquisition of Subimo, LLC, in December 2006, WHC adopted the WebMD Health Corp. Long-Term Incentive Plan for Employees of Subimo, LLC (the "Subimo Plan"). The terms of the Subimo Plan are similar to the terms of the WHC Plan but it has not been approved by WHC stockholders. Awards under the Subimo Plan were made on the date of the Company's acquisition of Subimo, LLC in reliance on the NASDAQ Global Select Market exception to shareholder approval for equity grants to new hires. No additional grants will be made under the Subimo Plan. The WHC Plan and the Subimo Plan are included in

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

all references as the WebMD Plans. The maximum number of shares of WHC Class A Common Stock that may be subject to options or restricted stock awards under the WebMD Plans is 9,480,574, subject to adjustment in accordance with the terms of the WebMD Plans. WHC had an aggregate of 2,440,150 shares of Class A Common Stock available for future grants under the WebMD Plans at September 30, 2008.

***Stock Options***

Generally, options under the WebMD Plans vest and become exercisable ratably over a four year period based on their individual grant dates subject to continued employment on the applicable vesting dates. The options granted under the WebMD Plans expire within ten years from the date of grant. Options are granted at prices not less than the fair market value of WHC's Class A Common Stock on the date of grant. The following table summarizes activity for the WebMD Plans for the nine months ended September 30, 2008:

	<b>Shares</b>	<b>Weighted Average Exercise Price Per Share</b>	<b>Weighted Average Remaining Contractual Life (In Years)</b>	<b>Aggregate Intrinsic Value (1)</b>
Outstanding at January 1, 2008	5,020,551	\$ 27.56		
Granted	609,800	32.19		
Exercised	(196,652)	17.56		
Cancelled	(373,551)	31.42		
Outstanding at September 30, 2008	5,060,148	\$ 28.23	7.8	\$ 32,163
Vested and exercisable at the end of the period	2,239,061	\$ 22.22	7.2	\$ 21,487

(1) The aggregate intrinsic value is based on the market price of WHC's Class A Common Stock on September 30, 2008, which was \$29.74, less the applicable exercise price of the underlying option. This aggregate intrinsic value represents the amount that would have been realized if all of the option holders had exercised their options on September 30, 2008.

The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model, considering the assumptions noted in the following table. Prior to August 1, 2007, expected volatility was based on implied volatility from traded options of stock of comparable companies combined with historical stock price volatility of comparable companies. Beginning on August 1, 2007, expected volatility is based on implied volatility from traded options of WHC Class A Common Stock combined with historical volatility of WHC Class A Common Stock. The expected term represents the period of time that options are expected to be outstanding following their

grant date, and was determined using historical exercise data of WHC employees who were previously granted HLTH stock options. The risk-free rate is based on the U.S. Treasury yield curve for periods equal to the expected term of the options on the grant date.

	<b>Nine Months Ended</b>	
	<b>September 30,</b>	
	<b>2008</b>	<b>2007</b>
Expected dividend yield	0%	0%
Expected volatility	0.44	0.45
Risk-free interest rate	2.46%	4.65%
Expected term (years)	3.25	3.34
Weighted average fair value of options granted during the period	\$ 10.75	\$ 18.16

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)*****Restricted Stock Awards***

WHC Restricted Stock consists of shares of WHC Class A Common Stock which have been awarded to employees with restrictions that cause them to be subject to substantial risk of forfeiture and restrict their sale or other transfer by the employee until they vest. Generally, WHC Restricted Stock awards vest ratably over a four year period from their individual award dates subject to continued employment on the applicable vesting dates. The following table summarizes the activity of non-vested WHC Restricted Stock for the nine months ended September 30, 2008:

	Shares	Weighted Average Grant Date Fair Value
Balance at January 1, 2008	307,722	\$ 29.46
Granted	19,000	28.32
Vested	(90,687)	21.59
Forfeited	(12,500)	21.86
Balance at September 30, 2008	223,535	\$ 32.98

Proceeds received from the exercise of options to purchase WHC Class A Common Stock were \$1,061 and \$3,453 for the three and nine months ended September 30, 2008, respectively, and \$2,767 and \$8,490 for the three and nine months ended September 30, 2007, respectively. The intrinsic value related to the exercise of these stock options, as well as the fair value of shares of WHC Restricted Stock that vested was \$3,299 and \$5,769 for the three and nine months ended September 30, 2008, respectively, and \$8,203 and \$15,291 for the three and nine months ended September 30, 2007, respectively.

**Employee Stock Purchase Plan**

The Company's 1998 Employee Stock Purchase Plan, as amended from time to time (the "ESPP"), allowed eligible employees the opportunity to purchase shares of HLTH Common Stock through payroll deductions, up to 15% of a participant's annual compensation with a maximum of 5,000 shares available per participant during each purchase period. The purchase price of the stock was 85% of the fair market value on the last day of each purchase period. The ESPP provided for annual increases equal to the lesser of 1,500,000 shares, 0.5% of the outstanding common shares, or a lesser amount determined by the Board of Directors. There were 49,125 and 34,610 shares issued under the ESPP during the nine months ended September 30, 2008 and 2007, respectively. The ESPP was terminated after the purchase period that ended on April 30, 2008.

**Other**

At the time of the WHC initial public offering and each year on the anniversary of the initial public offering, WHC issued shares of WHC Class A Common Stock to each non-employee director with a value equal to their annual board



and committee retainers. The Company recorded stock-based compensation expense of \$85 during the three months ended September 30, 2008 and 2007 and \$255 during the nine months ended September 30, 2008 and 2007 in connection with these issuances.

Additionally, the Company recorded stock-based compensation expense of \$279 for the three months ended September 30, 2008 and 2007, and \$837 and \$815 for the nine months ended September 30, 2008 and 2007, respectively, in connection with a stock transferability right for shares required to be issued in connection with the acquisition of Subimo, LLC by WHC.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****Summary of Stock-Based Compensation Expense**

The following table summarizes the components and classification of stock-based compensation expense:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
HLTH Plans:				
Stock options	\$ 2,127	\$ 2,791	\$ 5,743	\$ 9,040
Restricted stock	1,525	1,633	4,253	4,759
WHC Plans:				
Stock options	2,682	4,295	7,858	11,587
Restricted stock	456	820	1,260	2,429
Employee Stock Purchase Plan		42	51	127
Other	372	375	1,097	1,081
Total stock-based compensation expense	\$ 7,162	\$ 9,956	\$ 20,262	\$ 29,023
Included in:				
Cost of operations	\$ 1,005	\$ 1,597	\$ 2,950	\$ 4,159
Sales and marketing	1,222	1,252	3,624	3,889
General and administrative	4,304	6,436	12,400	18,198
Equity in earnings of EBS Master LLC		240		1,039
Income from continuing operations	6,531	9,525	18,974	27,285
Income from discontinued operations	631	431	1,288	1,738
Total stock-based compensation expense	\$ 7,162	\$ 9,956	\$ 20,262	\$ 29,023

As of September 30, 2008, approximately \$13,035 and \$31,887 of unrecognized stock-based compensation expense related to unvested awards (net of estimated forfeitures) is expected to be recognized over a weighted-average period of approximately 0.7 years and 1.5 years, related to the HLTH Plans and the WebMD Plans, respectively.

**8. Stockholders Equity***Pending Tender Offer*

On October 27, 2008, the Company commenced a tender offer to purchase up to 80,000,000 shares of its Common Stock at a price of \$8.80 per share (the Pending Tender Offer). The Pending Tender Offer is expected to be completed in November 2008, subject to a number of terms and conditions, including that a minimum of 40,000,000 shares be properly tendered and not withdrawn in the offer.

*Stock Repurchase Program*

In December 2006, the Company announced the authorization of a stock repurchase program (the Program ), at which time the Company was authorized to use up to \$100,000 to purchase shares of HLTH Common Stock from time to time beginning on December 19, 2006, subject to market conditions. As of September 30, 2008 and 2007, respectively, the Company had repurchased 4,280,931 and 4,268,895 shares at an aggregate cost of approximately \$58,447 and \$58,444 under the Program. No shares were repurchased during the nine months ended September 30, 2008. Repurchased shares are recorded under the cost method and are reflected as treasury stock in the accompanying consolidated balance sheets.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****9. Fair Value of Financial Instruments and Credit Facilities**

Effective January 1, 2008, the Company adopted SFAS No. 157, Fair Value Measurements ( SFAS 157 ), for assets and liabilities measured at fair value on a recurring basis. SFAS 157 establishes a common definition for fair value to be applied to existing GAAP that require the use of fair value measurements, establishes a framework for measuring fair value and expands disclosure about such fair value measurements. The adoption of SFAS 157 did not have an impact on the Company's financial position or operating results, but did expand certain disclosures.

SFAS 157 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, SFAS 157 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:

- Level 1:* Observable inputs such as quoted market prices in active markets for identical assets or liabilities, such as the Company's equity securities reflected in the table below.
- Level 2:* Observable market-based inputs or unobservable inputs that are corroborated by market data.
- Level 3:* Unobservable inputs for which there is little or no market data, which require the use of the reporting entity's own assumptions.

The Company did not have any Level 2 assets as of September 30, 2008. The following table sets forth the Company's Level 1 and Level 3 financial assets that were measured at fair value as of September 30, 2008:

	<b>Level 1</b>	<b>Level 3</b>	<b>Total</b>
Auction rate securities	\$	\$ 284,408	\$ 284,408
Equity securities	2,175		2,175

The following table reconciles the beginning and ending balances of the Company's Level 3 assets which consist of the Company's ARS:

Balance as of January 1, 2008	\$
Transfers to Level 3	363,700
Redemptions	(7,900)
Impairment charge included in earnings	(60,108)
Interest accretion included in earnings	632
Unrealized loss included in other comprehensive income	(11,916)
Fair Value as of September 30, 2008	\$ 284,408

The Company holds investments in action rate securities ( ARS ) which have been classified as Level 3 assets as described above. The types of ARS holdings the Company owns are backed by student loans, 97% of which are guaranteed under the Federal Family Education Loan Program (FFELP), and all had credit ratings of AAA or Aaa when purchased. Historically, the fair value of the Company s ARS holdings approximated face value due to the frequent auction periods, generally every 7 to 28 days, which provided liquidity to these investments. However, since February 2008, virtually all auctions involving these securities have failed. The result of a failed auction is that these ARS holdings will continue to pay interest in accordance with their terms at each respective auction date; however, liquidity of the securities will be limited until there is a successful auction, the issuer redeems the securities, the securities mature or until such time as other markets for these ARS holdings develop. During the three months ended March 31, 2008, the Company concluded that the estimated fair value of the ARS holdings no longer approximated the face value due to the lack of liquidity. The securities have been classified within Level 3 as their valuation requires substantial judgment

**Table of Contents**

**HLTH CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

and estimation of factors that are not currently observable in the market due to the lack of trading in the securities.

The Company estimated the fair value of its ARS holdings using an income approach valuation technique. Using this approach, expected future cash flows were calculated over the expected life of each security and were discounted to a single present value using a market required rate of return. Some of the more significant assumptions made in the present value calculations were (i) the estimated weighted average lives for the loan portfolios underlying each individual ARS, which range from 4 to 14 years and (ii) the required rates of return used to discount the estimated future cash flows over the estimated life of each security, which considered both the credit quality for each individual ARS and the market liquidity for these investments. As of March 31, 2008, the Company concluded the fair value of its ARS holdings was \$302,842 (of which \$141,044 relates to WHC), compared to a face value of \$362,950 (of which \$168,450 relates to WHC). The impairment in value, or \$60,108 (of which \$27,406 relates to WHC), was considered to be other-than-temporary and, accordingly, was recorded as an impairment charge within the statement of operations during the three months ended March 31, 2008.

In making the determination that the impairment was other-than-temporary, the Company considered (i) the current market liquidity for ARS, particularly student loan backed ARS, (ii) the long-term maturities of the loan portfolios underlying each ARS owned by the Company which, on a weighted average basis, extend to as many as 14 years and (iii) the ability and intent of the Company to hold its ARS investments until sufficient liquidity returns to the auction rate market to enable the sale of these securities or until the investments mature.

During the three and nine months ended September 30, 2008, the Company received \$5,100 (of which \$2,000 relates to WHC) and \$7,900 (of which \$3,700 relates to WHC), respectively, associated with the partial redemption of certain of its ARS holdings, which represented 100% of their face value. As a result, as of September 30, 2008, the total face value of the Company's ARS holdings was \$355,800, of which \$165,500 relates to WHC. During the three months ended June 30, 2008 and September 30, 2008, the Company reduced the carrying value of its ARS holdings by \$3,019 and \$8,897, respectively. The Company assessed these declines in fair market value to be temporary as they resulted from fluctuations in interest rate assumptions and, therefore, recorded these declines as an unrealized loss in other comprehensive income in the accompanying consolidated balance sheet.

The Company continues to monitor the market for ARS as well as the individual ARS holdings it owns. The Company may be required to record additional losses in future periods if the fair value of its ARS holdings deteriorates further.

**Credit Facilities**

On May 6, 2008, the Company and WHC each entered into a non-recourse credit facility (each a Credit Facility) with Citigroup that is secured by their respective ARS holdings (including, in some circumstances, interest payable on the ARS holdings), that will allow the Company and WHC to borrow up to 75% of the face amount of the ARS holdings pledged as collateral under the respective Credit Facilities. The Credit Facilities are each governed by a loan agreement, dated as of May 6, 2008, containing customary representations and warranties of the borrower and certain affirmative covenants and negative covenants relating to the pledged collateral. Under each of the loan agreements, the borrower and the lender may, in certain circumstances, cause the pledged collateral to be sold, with the proceeds of any such sale required to be applied in full immediately to repayment of amounts borrowed. No borrowings have been made under either Credit Facility to date. The Company and WHC can each make borrowings under the Credit Facility until May 2009. The interest rate applicable to such borrowings will be one-month LIBOR plus 250 basis

points. Any borrowings outstanding under the Credit Facility after March 2009 become demand loans, subject to 60 days notice, with recourse only to the pledged collateral.

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****10. Comprehensive Income (Loss)**

Comprehensive income (loss) is comprised of net income (loss) and other comprehensive (loss) income. Other comprehensive (loss) income includes foreign currency translation adjustments and certain changes in equity that are excluded from net income (loss), such as changes in unrealized holding gains and losses on available-for-sale marketable securities and 48% of the comprehensive income (loss) of EBSCo. The following table presents the components of comprehensive income (loss):

	<b>Three Months Ended September 30, 2008</b>		<b>Nine Months Ended September 30, 2008</b>	
Foreign currency translation (losses) gains	\$ (4,488)	\$ 1,554	\$ (1,200)	\$ 2,391
Unrealized holding (losses) gains on securities	(8,564)	(532)	(11,193)	2
EBSCo interest rate swap agreement		(5,918)	7,326	(2,429)
Other comprehensive loss	(13,052)	(4,896)	(5,067)	(36)
Net income (loss)	95,881	16,571	556,172	(23,190)
Comprehensive income (loss)	\$ 82,829	\$ 11,675	\$ 551,105	\$ (23,226)

Included in comprehensive income (loss) for the three and nine months ended September 30, 2007 is the Company's share of unrealized gains on the fair value of EBSCo's interest rate swap agreements, and for the nine months ended September 30, 2008 is the reversal, in connection with the 2008 EBSCo Sale, of the net cumulative loss related to these agreements.

Deferred taxes are not included within accumulated other comprehensive income because a valuation allowance was maintained for substantially all net deferred tax assets.

Accumulated other comprehensive income includes:

	<b>September 30, 2008</b>	<b>December 31, 2007</b>
Unrealized holding (losses) gains on securities	\$ (10,283)	\$ 910
Foreign currency translation gains	11,069	12,269
Comprehensive loss of EBSCo		(7,326)
Total accumulated other comprehensive income	\$ 786	\$ 5,853



**11. Goodwill and Other Intangible Assets**

The changes in the carrying amount of goodwill for the year ended December 31, 2007 and the nine months ended September 30, 2008 are as follows:

	<b>WebMD Online Services</b>	<b>WebMD Publishing and Other Services</b>	<b>Total</b>
Balance as of January 1, 2007	\$ 212,439	\$ 11,045	\$ 223,484
Reversal of income tax valuation allowance	(2,793)		(2,793)
Adjustments to finalize purchase price allocations	(3,368)		(3,368)
Balance as of January 1, 2008	206,278	11,045	217,323
Reversal of income tax valuation allowance	(5,761)		(5,761)
Adjustments to finalize purchase price allocations	(148)		(148)
Balance as of September 30, 2008	\$ 200,369	\$ 11,045	\$ 211,414

Table of Contents**HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Intangible assets subject to amortization consist of the following:

	September 30, 2008				December 31, 2007			
	Gross	Accumulated	Net	Weighted Average Remaining Useful Life (a)	Gross	Accumulated	Net	Weighted Average Remaining Useful Life (a)
	Carrying Amount	Amortization			Carrying Amount	Amortization		
Content	\$ 15,954	\$ (14,051)	\$ 1,903	1.7	\$ 15,954	\$ (12,581)	\$ 3,373	2.1
Customer relationships	33,191	(12,798)	20,393	8.8	33,191	(10,183)	23,008	9.2
Technology and patents	14,967	(12,844)	2,123	0.9	14,967	(10,126)	4,841	1.5
Trade names	7,817	(3,319)	4,498	7.1	7,817	(2,725)	5,092	7.7
Total	\$ 71,929	\$ (43,012)	\$ 28,917	7.5	\$ 71,929	\$ (35,615)	\$ 36,314	7.3

(a) The calculation of the weighted average remaining useful life is based on the net book value and the remaining amortization period (reflected in years) of each respective intangible asset.

Amortization expense was \$2,406 and \$7,397 for the three and nine months ended September 30, 2008, respectively, and \$3,320 and \$9,853 for the three and nine months ended September 30, 2007, respectively. Aggregate amortization expense for intangible assets is estimated to be:

Years Ending December 31:	
2008 (October 1st to December 31st)	\$ 2,318
2009	6,401
2010	3,337
2011	2,464
2012	2,464
Thereafter	11,933

**12. Commitments and Contingencies*****Investigations by United States Attorney for the District of South Carolina and the SEC***

As previously disclosed, the United States Attorney for the District of South Carolina is conducting an investigation of the Company, which the Company first learned about on September 3, 2003. Based on the information available to the Company, it believes that the investigation relates principally to issues of financial accounting improprieties relating to Medical Manager Corporation, a predecessor of the Company (by its merger into the Company in September 2000),

and, more specifically, its Medical Manager Health Systems, Inc. subsidiary. Medical Manager Health Systems was a predecessor to Emdeon Practice Services, Inc., a subsidiary that the Company sold to Sage Software in September 2006. The Company has been cooperating and intends to continue to cooperate fully with the U.S. Attorney's Office. As previously reported, the Board of Directors of the Company has formed a special committee consisting solely of independent directors to oversee this matter with the sole authority to direct the Company's response to the allegations that have been raised. As previously disclosed, the Company understands that the SEC is also conducting a formal investigation into this matter. In connection with the EPS Sale, the Company agreed to indemnify Sage Software with respect to this matter.

The United States Attorney for the District of South Carolina announced on January 10, 2005, that three former employees of Medical Manager Health Systems each had agreed to plead guilty to one count of mail fraud and that one such employee had agreed to plead guilty to one count of tax evasion for acts committed while they were employed by Medical Manager Health Systems. The three former employees include a Vice President of Medical Manager Health Systems responsible for acquisitions who was terminated for cause in January 2003; an executive who served in various accounting roles at Medical Manager Health Systems until his resignation in March 2002; and a former independent Medical Manager dealer who was a paid consultant to Medical Manager Health Systems until the termination of his services in 2002. According to the

**Table of Contents**

**HLTH CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Informations, Plea Agreements and Factual Summaries filed by the United States Attorney in, and available from, the District Court of the United States for the District of South Carolina – Beaufort Division, on January 7, 2005, the three former employees and other then unnamed co-schemers were engaged in schemes between 1997 and 2002 that included causing companies acquired by Medical Manager Health Systems to pay the former vice president in charge of acquisitions and co-schemers kickbacks which were funded through increases in the purchase price paid by Medical Manager Health Systems to the acquired companies and that included fraudulent accounting practices to artificially inflate the quarterly revenues and earnings of Medical Manager Health Systems when it was an independent public company called Medical Manager Corporation from 1997 through 1999, when and after it was acquired by Syntec, Inc. in July 1999 and when and after it became a subsidiary of the Company in September 2000. A fourth former officer of Medical Manager Health Systems pled guilty to similar activities later in 2005.

The fraudulent accounting practices cited by the government in the January 7, 2005 District Court filings included: causing companies acquired by Medical Manager Health Systems to reclassify previously recognized sales revenue as deferred income so that such deferred income could subsequently be reported as revenue by Medical Manager Health Systems and its parents in later periods; fabricating deferred revenue entries which could be used to inflate earnings when Medical Manager Health Systems acquired companies; causing companies acquired by Medical Manager Health Systems to inflate reserve accounts so that these reserves could be reversed in later reporting periods in order to artificially inflate earnings for Medical Manager Health Systems and its parents; accounting for numerous acquisitions through the pooling of interests method in order to fraudulently inflate Medical Manager Health Systems' quarterly earnings, when the individuals involved knew the transactions failed to qualify for such treatment; causing companies acquired by Medical Manager Health Systems to enter into sham purchases of software from Medical Manager Health Systems in connection with the acquisition which purchases were funded by increasing the purchase price paid by Medical Manager Health Systems to the acquired company and using these "round trip" sales to create fraudulent revenue for Medical Manager Health Systems and its parents; and causing Medical Manager Health Systems to book and record sales and training revenue before the revenue process was complete in accordance with GAAP and thereby fraudulently inflating Medical Manager Health Systems reported revenues and earnings. According to the Informations to which the former employees have pled guilty, the fraudulent accounting practices resulted in the reported revenues of Medical Manager Health Systems and its parents being overstated materially between June 1997 and at least December 31, 2001, and reported quarterly earnings being overstated by at least one cent per share in every quarter during that period.

The documents filed by the United States Attorney in January 2005 stated that the former employees engaged in their fraudulent conduct in concert with senior management, and at the direction of senior Medical Manager officers. In its statement at that time, the United States Attorney for the District of South Carolina stated that the senior management and officers referred to in the Court documents were members of senior management of the Medical Manager subsidiary during the relevant time period.

On December 15, 2005, the United States Attorney announced indictments of the following former officers and employees of Medical Manager Health Systems: Ted W. Dorman, a former Regional Vice President of Medical Manager Health Systems, who was employed until March 2003; Charles L. Hutchinson, a former Controller of Medical Manager Health Systems, who was employed until June 2001; Maxie L. Juzang, a former Vice President of Medical Manager Health Systems, who was employed until August 2005; John H. Kang, a former President of Medical Manager Health Systems, who was employed until May 2001; Frederick B. Karl, Jr., a former General Counsel of Medical Manager Health Systems, who was employed until April 2000; Franklyn B. Krieger, a former

Associate General Counsel of Medical Manager Health Systems, who was employed until February 2002; Lee A. Robbins, a former Vice President and Chief Financial Officer of Medical Manager Health Systems, who was employed until September 2000; John P. Sessions, a former President and Chief Operating Officer of Medical Manager Health Systems, who was employed until September 2003; Michael A. Singer, a former Chief Executive Officer of Medical Manager

**Table of Contents**

**HLTH CORPORATION**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

Health Systems and a former director of the Company, who was most recently employed by the Company as its Executive Vice President, Physician Software Strategies until February 2005; and David Ward, a former Vice President of Medical Manager Health Systems, who was employed until June 2005. The indictment charges the persons listed above with conspiracy to commit mail, wire and securities fraud, a violation of Title 18, United States Code, Section 371 and conspiracy to commit money laundering, a violation of Title 18, United States Code, Section 1956(h). The indictment charges Messrs. Sessions and Ward with substantive counts of money laundering, violations of Title 18, United States Code, Section 1957. The allegations set forth in the indictment describe activities that are substantially similar to those described above with respect to the January 2005 plea agreements.

On February 27, 2007, the United States Attorney filed a Second Superseding Indictment with respect to the former officers and employees of Medical Manager Health Systems charged under the prior Indictment, other than Mr. Juzang. The allegations set forth in the Second Superseding Indictment are substantially similar to those described above. The trial of the indicted former officers and directors of Medical Manager Health Systems has been scheduled for February 2, 2009. Mr. Robbins passed away on September 27, 2008 and on October 15, 2008 the court granted a motion to dismiss Mr. Robbins from the Second Superseding Indictment.

Based on the information it has obtained to date, including that contained in the court documents filed by the United States Attorney in South Carolina, the Company does not believe that any member of its senior management whose duties were not primarily related to the operations of Medical Manager Health Systems during the relevant time periods engaged in any of the violations or improprieties described in those court documents. The Company understands, however, that in light of the nature of the allegations involved, the U.S. Attorney's office has been investigating all levels of the Company's management. The Company has not uncovered information that it believes would require a restatement for any of the years covered by its financial statements. In addition, the Company believes that the amounts of the kickback payments referred to in the court documents have already been reflected in the financial statements of the Company to the extent required.

The Company has certain indemnity obligations to advance amounts for reasonable defense costs for the initial ten, and now eight, former officers and directors of EPS. During the year ended December 31, 2007, the Company recorded a pre-tax charge of \$73,347, related to its estimated liability with respect to these indemnity obligations. During the three months ended June 30, 2008, the Company recorded an additional pre-tax charge of \$16,980 which reflects an increase to the Company's estimated liability related to this matter. See Note 2 for a more detailed discussion regarding this charge.

***Directors & Officers Liability Insurance Coverage Litigation***

On July 23, 2007, the Company commenced litigation (the Coverage Litigation) in the Court of Chancery of the State of Delaware in and for New Castle County against ten insurance companies in which the Company is seeking to compel the defendant companies (collectively, the Defendants) to honor their obligations under certain directors and officers liability insurance policies (the Policies). The Company is seeking an order requiring the Defendants to advance and/or reimburse expenses that the Company has incurred and expects to continue to incur for the advancement of the reasonable defense costs of initially ten, and now eight, former officers and directors of the Company's former EPS subsidiary who were indicted in connection with the Investigation described above in this Note 12. The Company subsequently has settled with two of the insurance companies during January 2008, through which the Company received an aggregate amount of \$14,625. This amount was included within (loss) income from

discontinued operations in the statement of operations during the three months ended December 31, 2007 and was included within prepaid expenses and other current assets in the accompanying consolidated balance sheet as of December 31, 2007.

Pursuant to a stipulation among the parties, the Coverage Litigation was transferred on September 13, 2007 to the Superior Court of the State of Delaware in and for New Castle County. The Policies were issued to the Company and to EPS, a former subsidiary of the Company, which is a co-plaintiff with the Company in the Coverage Litigation (collectively, the Plaintiffs ). EPS was sold in September 2006 to Sage Software and

**Table of Contents****HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

has changed its name to Sage Software Healthcare, Inc. ( SSHI ). In connection with the Company's sale of EPS to Sage Software, the Company retained certain obligations relating to the Investigation and agreed to indemnify Sage Software and SSHI with respect to certain expenses in connection with the Investigation. The Company retained the right to assert claims and recover proceeds under the Policies on behalf of SSHI.

The Policies at issue in the Coverage Litigation consist of two separate groups of insurance policies. Each group of policies consists of several layers of coverage, with different insurers having agreed to provide specified amounts of coverage at various levels. The first group of policies was issued to EPS in the amount of \$20,000 (the EPS Policies ) and the second group of policies was issued to Synetic, Inc. (the former parent of EPS, which merged into the Company) in the amount of \$100,000, of which approximately \$3,600 was paid by the primary carrier with respect to another unrelated matter (the Synetic Policies ). As of September 30, 2008, \$50,950 has been paid by insurance companies representing the EPS Policies and the Synetic Policies through a combination of payment under the terms of the Policies, payment under reservation of rights and settlement. Of this amount, \$19,912 has been reimbursed by the insurance companies subsequent to the Court's order on July 31, 2008 (described in more detail below). The Company has deferred recognizing this amount as income given the fact that the Coverage Litigation is ongoing and accordingly this amount has been deferred on the balance sheet as of September 30, 2008 within Liabilities of Discontinued Operations. As a result of these payments, the Company has exhausted its coverage under the EPS Policies and has remaining coverage under the Synetic Policies of approximately \$60,000.

The carrier with the third level of coverage in the Synetic Policies filed a motion for summary judgment in the Coverage Litigation, which most of the carriers who have issued the Synetic policies joined, which sought summary judgment that any liability to pay defense costs should be allocated among the three sets of policies available to the Company (including the policies with respect to which the Coverage Litigation relates and a third set of policies the issuers of which had not yet been named by the Company) such that the Synetic Policies would only be liable to pay about \$23,000 of the \$96,400 total coverage available under such policies. The Company filed its opposition to the motion together with its motion for summary judgment against such carrier and several other carriers who have issued the Synetic Policies seeking to require such carriers to advance payment of the defense costs that the Company is obligated to pay while the Coverage Litigation is pending. On July 31, 2008, the Superior Court for the State of Delaware denied the motion filed by the carriers seeking allocation and granted the Company's motion for partial summary judgment to enforce the duty of such carriers to advance and reimburse these costs. Pursuant to the Court's order the issuers of the Synetic Policies have been reimbursing the Company for its costs. Unless the carriers ultimately prevail in the Coverage Litigation or obtain an interim ruling from the court to the contrary, the Company expects to collect from the remaining carriers under the Synetic Policies who are subject to the Court's order the costs that it is obligated to pay subject to the limits of each carrier's policy. The Company's insurance policies provide that under certain circumstances, amounts advanced by the insurance companies in connection with the defense costs of the indicted individuals, may have to be repaid by the Company, although the \$14,625 that the Company has received in settlement from certain carriers is not subject to being repaid. The Company has obtained an undertaking from each indicted individual pursuant to which, under certain circumstances, such individual has agreed to repay defense costs advanced on such individual's behalf.

On October 29, 2008 the Company filed a Motion for Leave to File a Second Amended Complaint with the Superior Court. The Second Amended Complaint would add four new insurance companies as defendants in the Coverage Action. These carriers are the issuers of a third set of policies (the Emdeon Policies ) that provide coverage with respect to the Company's indemnification obligations to the former officers and directors of the Company's former EPS



subsidiary who were indicted in connection with the Investigation described above in this Note 12. Additionally, the Second Amended Complaint would add back as a defendant in the Coverage Action the issuer of one of the EPS Policies with whom the Company settled who is also the issuer of the eighth level of coverage under the Synthetic Policies. At the time of that settlement the Company dismissed the eighth level carrier without prejudice with respect to that Synthetic Policy and based upon the

**Table of Contents****HLTH CORPORATION****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

current estimate of the anticipated costs of its indemnification obligations the Company has determined that it is necessary to add back the carrier with respect to the Synetic Policy. Although the Company believes that such eighth level carrier is situated similarly to the other Synetic Policies, the eighth level carrier indicated on September 9, 2008 its position that it was not bound by the Court's July 31, 2008 order regarding the duty of the Synetic carriers to advance and reimburse defense costs. This resulted in the Company including the eighth level carrier in the Motion for Leave to File a Second Amended Complaint, described above.

Notwithstanding the fact that the Company has prevailed in the summary judgment motions described above, there can be no assurance that the Company will ultimately prevail in the Coverage Litigation or that the Defendants will be required to provide funding on an interim basis pending the resolution of the Coverage Litigation. The Company intends to continue to satisfy its legal obligations to the indicted individuals with respect to advancement of amounts for their defense costs.

***Other***

In the normal course of business, the Company and its subsidiaries are involved in various other claims and legal proceedings. While the ultimate resolution of these matters has yet to be determined, including those discussed in Note 12 to the Consolidated Financial Statements included in the Company's Current Report on Form 8-K filed with the SEC on June 27, 2008 and in Note 12 to the Consolidated Financial Statements included in the Company's Form 10-Q for the quarterly period ended June 30, 2008, the Company does not believe that their outcome will have a material adverse effect on the Company's consolidated financial position, results of operations or liquidity.

**13. Other (Expense) Income, Net**

Other (expense) income, net consists of the following items:

	<b>Three Months Ended</b>		<b>Nine Months Ended</b>	
	<b>September 30,</b>		<b>September 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
Transition service fees (a)	\$ 104	\$ 985	\$ 205	\$ 4,909
Reduction of tax contingencies (b)	437	377	1,311	1,123
Legal expense (c)	(403)	(373)	(1,164)	(1,164)
Gain on 2006 EBS Sale (d)				399
Advisory expense (e)	(1,135)		(6,159)	
Other (expense) income, net	\$ (997)	\$ 989	\$ (5,807)	\$ 5,267

(a) Represents the net fees received from ViPS, Sage Software and EBSCo in relation to their respective transition services agreements.

- (b) Represents the reduction of certain sales and use tax contingencies resulting from the expiration of various statutes.
- (c) Represents the costs and expenses incurred by the Company related to the investigation by the United States Attorney for the District of South Carolina and the SEC.
- (d) Represents a gain recognized in connection with the working capital adjustment associated with the 2006 EBS Sale on November 16, 2006.
- (e) Represents professional fees, primarily consisting of legal, accounting and financial advisory services incurred by the Company related to the potential merger of HLTH into WHC.

#### **14. Pending Marketing Technology Solutions Inc. Acquisition**

On September 15, 2008, WHC announced that it had entered into a definitive agreement to acquire QualityHealth.com and its owner, Marketing Technology Solutions Inc. ( MTS ). MTS provides on-line performance-based marketing and media programs directed at pharmaceutical and other healthcare related advertisers. The purchase price for MTS is \$50 million in cash, payable at closing, and WHC has agreed to pay up to an additional \$25 million in cash if certain performance thresholds are achieved relating to calendar year 2009.

**Table of Contents**

**ITEM 2. *Management's Discussion and Analysis of Financial Condition and Results of Operations***

*This Item 2 contains forward-looking statements with respect to possible events, outcomes or results that are, and are expected to continue to be, subject to risks, uncertainties and contingencies, including those identified in this Item. See *Forward-Looking Statements* on page 3.*

**Overview**

Management's discussion and analysis of financial condition and results of operations, or MD&A, is provided as a supplement to the Consolidated Financial Statements and notes thereto included elsewhere in this Quarterly Report and to provide an understanding of our results of operations, financial condition and changes in financial condition. Our MD&A is organized as follows:

*Introduction.* This section provides a general description of our company, a brief discussion of our operating segments, a description of the termination of our proposed merger with WHC, a description of pending transactions and other recent transactions, other significant developments and trends, and a discussion on how our business is impacted by seasonality.

*Critical Accounting Policies and Estimates.* This section discusses those accounting policies that both are considered important to our financial condition and results of operations, and require us to exercise subjective or complex judgments in making estimates and assumptions. In addition, all of our significant accounting policies, including our critical accounting policies, are summarized in Note 1 to the Consolidated Financial Statements contained in our Current Report on Form 8-K filed with the SEC on June 27, 2008.

*Recent Accounting Pronouncements.* This section provides a summary of the most recent authoritative accounting standards and guidance that have either been recently adopted or may be adopted in the future.

*Results of Operations and Results of Operations by Operating Segment.* These sections provide our analysis and outlook for the significant line items on our consolidated statements of operations, as well as other information that we deem meaningful to understand our results of operations on both a company-wide and a segment-by-segment basis.

*Liquidity and Capital Resources.* This section provides an analysis of our liquidity and cash flows and discussions of our contractual obligations and commitments, as well as our outlook on our available liquidity as of September 30, 2008.

*Factors That May Affect Our Future Financial Condition or Results of Operations.* This section describes circumstances or events that could have a negative effect on our financial condition or results of operations, or that could change, for the worse, existing trends in some or all of our businesses. The factors discussed in this section are in addition to factors that may be described elsewhere in this Quarterly Report.

In this MD&A, dollar amounts are in thousands, unless otherwise noted.

**Introduction**

*Our Company*

HLTH Corporation is a Delaware corporation that was incorporated in December 1995 and commenced operations in January 1996 as Healtheon Corporation. We changed our name to Healtheon/WebMD Corporation in November

Edgar Filing: HLTH CORP - Form 10-Q

1999, to WebMD Corporation in September 2000, to Emdeon Corporation in October 2005 and to HLTH Corporation in May 2007. Our common stock began trading on the Nasdaq National Market under the symbol HLTH on February 11, 1999 and now trades under that symbol on the Nasdaq Global Select Market.

As of September 30, 2008, we owned 83.1% of the aggregate amount of outstanding shares of WebMD Health Corp. (which we refer to as WHC) Class A Common Stock (after accounting for the impact of certain WHC shares to be issued pursuant to the purchase agreement for the acquisition of Subimo, LLC) and Class B

**Table of Contents**

Common Stock and, accordingly, our consolidated financial statements reflect the minority shareholders' 16.9% share of equity and net income (loss) of WHC.

HLTH's 48% ownership in EBS Master LLC (which we refer to as EBSCo) was accounted for under the equity method through February 8, 2008, the date of the sale of our investment in EBS Master LLC. See Other Recent Transactions - Sale of EBSCo below.

*Segments*

As a result of our intentions to sell our Porex segment and due to the sale of our ViPS segment, see Pending Transactions and Other Recent Transactions below, our remaining operating segments are WebMD Online Services and WebMD Publishing and Other Services (which we refer to together, as our WebMD Segments or, sometimes, as WebMD). The following is a description of each of our operating segments and our corporate segment:

*WebMD Online Services.* This segment owns and operates both public and private online portals. The public portals enable consumers to become more informed about healthcare choices and assist them in playing an active role in managing their health. The public portals also enable physicians and other healthcare professionals to improve their clinical knowledge and practice of medicine, as well as their communication with patients. The public portals generate revenue primarily through the sale of advertising and sponsorship products, including continuing medical education (which we refer to as CME) services. Our sponsors and advertisers include pharmaceutical, biotechnology, medical device and consumer products companies. Through our private portals for employers and health plans, we provide information and services that enable their employees and members, respectively, to make more informed benefit, treatment and provider decisions. We also provide related services for use by such employees and members, including lifestyle education and personalized telephonic health coaching. We generate revenue from our private portals through the licensing of these portals to employers and health plans either directly or through distributors, as well as through the fees charged for our coaching services. We also distribute online content and services to other entities and generate revenue from these arrangements through the sale of advertising and sponsorship products and content syndication fees. We also provide e-detailing promotion and physician recruitment services for use by pharmaceutical, medical device and healthcare companies.

*WebMD Publishing and Other Services.* This segment provides offline products and services, including: *The Little Blue Book*, a physician directory; and *WebMD the Magazine*, a consumer-targeted publication that WebMD distributes free of charge to physician office waiting rooms. We generate revenue from sales of *The Little Blue Book* directories and advertisements in those directories, and sales of advertisements in *WebMD the Magazine*. Until December 31, 2007, we published *ACP Medicine* and *ACS Surgery: Principles of Practice*, its medical reference textbooks. We sold this business in 2007 and it has now been reflected as a discontinued operation in our financial statements. The WebMD Publishing and Other Services segment complements the WebMD Online Services segment and extends the reach of the WebMD brand and our influence among health-involved consumers and clinically-active physicians.

*Corporate.* Corporate includes personnel costs and other expenses related to functions that are not directly managed by one of our segments, or by the ViPS and Porex businesses which are reflected within discontinued operations. The personnel costs include executive personnel, legal, accounting, tax, internal audit, risk management, human resources and certain information technology functions. Other corporate costs and expenses include professional fees including legal and audit services, insurance, costs of leased property and facilities, telecommunication costs and software maintenance expenses. Corporate expenses are net of \$838 and \$2,572 for the three and nine months ended September 30, 2008, respectively, and \$845 and \$2,470 for the three and nine months ended September 30, 2007, respectively, which are costs allocated to WebMD for

services provided by the Corporate segment. In connection with the sale of our Emdeon Business Services (which we refer to as EBS) and Emdeon Practice Services (which we refer to as EPS) segments during the second half of 2006 and the sale of

**Table of Contents**

our ViPS segment during the three months ended September 30, 2008, we entered into transition services agreements whereby we provided EBSCO, Sage Software, Inc. (which we refer to as Sage Software) and ViPS certain administrative services, including payroll, accounting, purchasing and procurement, tax, and human resource services, as well as information technology support. Additionally, EBSCO provides us certain administrative services, including telecommunication infrastructure and management services, data center support and purchasing and procurement services. Some of the services provided by EBSCO to HLTH are, in turn, used to fulfill HLTH's obligations to provide transition services to Sage Software. These services are provided through the Corporate segment, and the related transition services fees we charge to EBSCO, Sage Software and ViPS, net of the fee we pay to EBSCO, are also included in the Corporate segment, which were intended to approximate the cost of providing these services. The transition services agreement with Sage Software was terminated on December 31, 2007 and, therefore, net transition services fees are for services related to EBSCO and ViPS for the three and nine months ended September 30, 2008.

*Termination of Proposed Merger with WHC*

On October 19, 2008, pursuant to the terms of a termination agreement (which we refer to as the Termination Agreement), HLTH and WHC mutually agreed, in light of recent turmoil in financial markets, to terminate the Agreement and Plan of Merger, dated as of February 20, 2008, between HLTH and WHC, as amended by Amendment No. 1, dated as of May 6, 2008, and Amendment No. 2, dated as of September 12, 2008 (which we refer to as the Merger Agreement). The Merger Agreement resulted from negotiations between HLTH and a Special Committee of the Board of Directors of WHC during late 2007 and early 2008. HLTH's Board of Directors had initiated the process leading to the entry into the Merger Agreement with WHC because it believed that the primary reason of many of the holders of HLTH Common Stock for owning those shares was HLTH's controlling interest in WHC and that the value of HLTH's other businesses was not adequately reflected in the trading price of HLTH Common Stock. In connection with the entry by HLTH and WHC into the Merger Agreement, the HLTH Board made a determination to divest Porex and ViPS (which divestitures were not, however, dependent on the merger occurring). See [Pending Transactions Proposed Divestiture of Porex](#) and [Other Recent Transactions ViPS Sale](#) below. The decisions relating to the divestitures of ViPS, Porex and HLTH's 48% interest in EBS (see [Other Recent Transactions Sale of EBSCO](#) below) were based on the corporate strategic considerations described above and not the performance of, or underlying business conditions affecting, the respective businesses.

The termination of the Merger Agreement was by mutual agreement of the companies and was unanimously approved by the Board of Directors of each of the companies and by a special committee of independent directors of WHC. The Boards determined that both HLTH, as controlling stockholder of WHC, and the public stockholders of WHC would benefit from WHC continuing as a publicly-traded subsidiary with no long-term debt and approximately \$340,000 in cash and investments. The Boards concluded that, by terminating the merger, HLTH and WHC would retain financial flexibility and be in a position to pursue potential acquisition opportunities expected to be available to companies with significant cash resources in a period of financial market uncertainty.

The Termination Agreement maintains HLTH's obligation, under the terms of the Merger Agreement, to pay the expenses of WHC incurred in connection with the merger. Under the Termination Agreement, HLTH and WHC have also agreed to amend the Amended and Restated Tax Sharing Agreement, dated as of February 15, 2006, between them (which we refer to as the Tax Sharing Agreement) so that, for tax years beginning after December 31, 2007, HLTH will no longer be required to reimburse WHC for use of net operating loss (which we refer to as NOL) carryforwards attributable to WebMD that may result from certain extraordinary transactions by HLTH. The Tax Sharing Agreement has not, other than with respect to certain extraordinary transactions by HLTH, required either HLTH or WHC to reimburse the other party for any net tax savings realized by the consolidated group as a result of the group's utilization of WHC's or HLTH's NOL carryforwards during the period of consolidation, and that will continue following the amendment. The Termination Agreement also provided for HLTH to assign to WHC the



Amended and Restated Data License Agreement, dated as of February 8, 2008, among HLTH, EBSCo and certain affiliated companies.

**Table of Contents***Pending Transactions*

*Pending Tender Offer.* On October 27, 2008, we commenced a tender offer to purchase up to 80,000,000 shares of our common stock at a price of \$8.80 per share (which we refer to as the Pending Tender Offer). The Pending Tender Offer is expected to be completed in November 2008, subject to a number of terms and conditions. Under the Merger Agreement, holders of HLTH Common Stock would have received merger consideration consisting of 0.1979 shares of WHC Common Stock and approximately \$6.63 in cash (subject to increase up to \$6.89 per share in cash in certain circumstances). In deciding to make the Pending Tender Offer, our Board of Directors considered that, following the termination of the Merger Agreement, some holders of HLTH common stock might wish to have the opportunity to sell some or all of their holdings for cash. In addition, our Board of Directors believes that investing in our shares through the Pending Tender Offer is an attractive use of our cash and investments on hand and an efficient means to provide value to our stockholders. The Pending Tender Offer represents an opportunity for us to return capital to our stockholders who elect to tender their shares. Additionally, stockholders who do not participate in the Pending Tender Offer will automatically increase their relative percentage interest in us and our future operations at no additional cost to them. We anticipate that we will pay for the shares tendered in the Pending Tender Offer and all expenses applicable to the Pending Tender Offer from cash and investments on hand. The Pending Tender Offer is not conditioned upon the receipt of financing.

*Proposed Divestiture of Porex.* On February 21, 2008, we announced our intention to divest our Porex segment. As a result of our intention to divest this segment and our expectation that the divestiture would be completed within one year, we reflected this segment as a discontinued operation within the consolidated financial statements contained elsewhere in this Quarterly Report.

*Pending Acquisition of Marketing Technology Solutions Inc.* On September 15, 2008, WHC announced that it had entered into a definitive agreement to acquire QualityHealth.com and its owner, Marketing Technology Solutions Inc. (which we refer to as MTS). MTS provides on-line performance-based marketing and media programs directed at pharmaceutical and other healthcare related advertisers. The purchase price for MTS is \$50,000 in cash, payable at closing, and WHC has agreed to pay up to an additional \$25,000 in cash if certain performance thresholds are achieved relating to calendar year 2009.

*Other Recent Transactions*

*ViPS Sale.* On February 21, 2008, we announced our intention to divest our ViPS segment. On June 3, 2008, we entered into a stock purchase agreement for the sale of our ViPS segment to an affiliate of General Dynamics Corporation. On July 22, 2008, we completed the sale of our ViPS business (which we refer to as the ViPS Sale). The purchase price was approximately \$224,842 in cash, which reflects the effect of a preliminary estimate of the amount of a customary working capital adjustment to the contractual purchase price of \$225,000 in cash. We have reflected ViPS as a discontinued operation within the consolidated financial statements contained elsewhere in this Quarterly Report.

*Sale of EBSCo.* On February 8, 2008, we entered into a Securities Purchase Agreement and simultaneously completed the sale of our 48% minority ownership interest in EBSCo (which we refer to as the 2008 EBSCo Sale) for \$575,000 in cash to an affiliate of General Atlantic LLC and affiliates of Hellman & Friedman, LLC.

*Sale of ACP Medicine and ACS Surgery.* As of December 31, 2007, through our WebMD Publishing and Other Services segment, WHC entered into an Asset Sale Agreement and completed the sale of certain assets and certain liabilities of our medical reference publications business, including the publications *ACP Medicine* and *ACS Surgery: Principles and Practice* (which we collectively refer to as the ACS/ACP Business). *ACP Medicine* and *ACS Surgery* are official publications of the American College of Physicians and the American College of Surgeons, respectively.

WebMD received net cash proceeds of \$2,809, consisting of \$1,734 received during the three months ended March 31, 2008 and the remaining \$1,075 to be received in the quarter ending December 31, 2008. WebMD incurred approximately \$800 of professional fees and other expenses associated with the sale of the ACS/ACP Business. In connection with the sale, WebMD recognized a gain of \$3,394 as of December 31, 2007. The decision to divest ACS/ACP Business was made because management determined that it was not a good fit with WebMD's core business.

**Table of Contents***Other Significant Developments and Trends*

*Auction Rate Securities; Non-Recourse Credit Facilities.* We hold investments in auction rate securities (which we refer to as ARS) backed by student loans, 97% of which are guaranteed under the Federal Family Education Loan Program (FFELP), and all had credit ratings of AAA or Aaa when purchased. Historically, the fair value of our ARS holdings approximated face value due to the frequent auction periods, generally every 7 to 28 days, which provided liquidity to these investments. However, since February 2008, virtually all auctions involving these securities have failed. The result of a failed auction is that these ARS holdings will continue to pay interest in accordance with their terms at each respective auction date; however, liquidity of the securities will be limited until there is a successful auction, the issuer redeems the securities, the securities mature or until such time as other markets for these ARS holdings develop. During the three months ended March 31, 2008, we concluded that the estimated fair value of the ARS holdings no longer approximated the face value due to the lack of liquidity.

As of March 31, 2008, we concluded the fair value of our ARS holdings was \$302,842 (of which \$141,044 related to WHC), compared to a face value of \$362,950 (of which \$168,450 related to WHC). The impairment in value, or \$60,108 (of which \$27,406 related to WHC), was considered to be other-than-temporary and, accordingly, was recorded as an impairment charge within the statement of operations during the three months ended March 31, 2008. During the three and nine months ended September 30, 2008, we received \$5,100 (of which \$2,000 relates to WHC) and \$7,900 (of which \$3,700 relates to WHC), respectively, associated with the partial redemption of certain of our ARS holdings which represented 100% of their face value. During the three months ended June 30, 2008 and September 30, 2008, we reduced the carrying value of our ARS holdings by \$3,019 and \$8,897, respectively. We assessed these declines in fair market value to be temporary as they resulted from fluctuations in interest rate assumptions and, therefore, recorded these declines as an unrealized loss in our stockholders' equity. As a result of the above activity, as of September 30, 2008, the total face value of our ARS holdings was \$355,800, of which \$165,500 relates to WHC, compared to a fair value of \$284,408, of which \$132,848 relates to WHC.

HLTH and WHC have each entered into a non-recourse credit facility (which we refer to as the Credit Facilities) with Citigroup that is secured by their respective ARS holdings (including, in some circumstances, interest payable on the ARS holdings), that will allow HLTH and WHC to borrow up to 75% of the face amount of the ARS holdings pledged as collateral under the respective Credit Facilities. The Credit Facilities are each governed by a loan agreement, dated as of May 6, 2008, containing customary representations and warranties of the borrower and certain affirmative covenants and negative covenants relating to the pledged collateral. Under each of the loan agreements, the borrower and the lender may, in certain circumstances, cause the pledged collateral to be sold, with the proceeds of any such sale required to be applied in full immediately to repayment of amounts borrowed.

No borrowings have been made under either of the Credit Facilities to date. HLTH and WHC can each make borrowings under their respective Credit Facilities until May 2009. The interest rate applicable to such borrowings will be one-month LIBOR plus 250 basis points. Any borrowings outstanding under the respective Credit Facilities after March 2009 become demand loans, subject to 60 days notice, with recourse only to the pledged collateral.

We continue to monitor the market for ARS as well as the individual ARS holdings we own. We may be required to record additional losses in future periods if the fair value of our ARS holdings deteriorates further.

*Directors & Officers Liability Insurance Coverage Litigation.* On July 23, 2007, we commenced litigation (which we refer to as the Coverage Litigation) in the Court of Chancery of the State of Delaware in and for New Castle County against ten insurance companies in which we are seeking to compel the defendant companies (which we refer to collectively as the Defendants) to honor their obligations under certain directors and officers liability insurance policies (which we refer to as the Policies). We are seeking an order requiring the Defendants to advance and/or reimburse expenses that we have incurred and expect to continue to incur for the advancement of the reasonable

defense costs of initially ten, and now eight, former officers and directors of our former EPS subsidiary who were indicted in connection with the previously disclosed investigation by the United States Attorney for the District of South Carolina (which we refer to as the

**Table of Contents**

Investigation) described in Note 12, Commitments and Contingencies located in the Notes to the Consolidated Financial Statements elsewhere in this Quarterly Report. We subsequently settled with two of the insurance companies during January 2008, through which we received an aggregate amount of \$14,625. This amount was included within (loss) income from discontinued operations in the accompanying statement of operations during the three months ended December 31, 2007 and is included within prepaid expenses and other current assets in our consolidated balance sheet as of December 31, 2007.

Pursuant to a stipulation among the parties, the Coverage Litigation was transferred on September 13, 2007 to the Superior Court of the State of Delaware in and for New Castle County. The Policies were issued to our company and to EPS, our former subsidiary, which is our co-plaintiff in the Coverage Litigation (which we refer to collectively as the Plaintiffs). EPS was sold in September 2006 to Sage Software and has changed its name to Sage Software Healthcare, Inc. (which we refer to as SSHI). In connection with our sale of EPS to Sage Software, we retained certain obligations relating to the Investigation and agreed to indemnify Sage Software and SSHI with respect to certain expenses in connection with the Investigation. We retained the right to assert claims and recover proceeds under the Policies on behalf of SSHI.

The Policies at issue in the Coverage Litigation consist of two separate groups of insurance policies. Each group of policies consists of several layers of coverage, with different insurers having agreed to provide specified amounts of coverage at various levels. The first group of policies was issued to EPS in the amount of \$20,000 (which we refer to as the EPS Policies) and the second group of policies was issued to Syntec, Inc. (the former parent of EPS, which merged into HLTH) in the amount of \$100,000, of which approximately \$3,600 was paid by the primary carrier with respect to another unrelated matter (which we refer to as the Syntec Policies). As of September 30, 2008, \$50,950 has been paid by insurance companies representing the EPS Policies and the Syntec Policies through a combination of payment under the terms of the Policies, payment under reservation of rights and settlement. Of this amount, \$19,912 has been reimbursed by the insurance companies subsequent to the Court's order on July 31, 2008 (described in more detail below). We have deferred recognizing this amount as income given the fact that the Coverage Litigation is ongoing and accordingly this amount has been deferred on the balance sheet as of September 30, 2008 within liabilities of discontinued operations. As a result of these payments, we have exhausted our coverage under the EPS Policies and have remaining coverage under the Syntec Policies of approximately \$60,000.

The carrier with the third level of coverage in the Syntec Policies filed a motion for summary judgment in the Coverage Litigation, which most of the carriers who have issued the Syntec policies joined, which sought summary judgment that any liability to pay defense costs should be allocated among the three sets of policies available to our company (including the policies with respect to which the Coverage Litigation relates and a third set of policies the issuers of which had not yet been named by our company) such that the Syntec Policies would only be liable to pay about \$23,000 of the \$96,400 total coverage available under such policies. We filed our opposition to the motion together with our motion for summary judgment against such carrier and several other carriers who have issued the Syntec Policies seeking to require such carriers to advance payment of the defense costs that we are obligated to pay while the Coverage Litigation is pending. On July 31, 2008 the Superior Court for the State of Delaware denied the motion filed by the carriers seeking allocation and granted HLTH's motion for partial summary judgment to enforce the duty of such carriers to advance and reimburse these costs. Pursuant to the Court's order the issuers of the Syntec Policies have been reimbursing us for our costs. Unless the carriers ultimately prevail in the Coverage Litigation or obtain an interim ruling from the court to the contrary, we expect to collect from the remaining carriers under the Syntec Policies who are subject to the Court's order the costs that it is obligated to pay subject to the limits of each carrier's policy. Our insurance policies provide that under certain circumstances, amounts advanced by the insurance companies in connection with the defense costs of the indicted individuals, may have to be repaid by us, although the \$14,625 that we have received in settlement from certain carriers is not subject to being repaid. We have obtained an undertaking from each indicted individual pursuant to which, under certain circumstances, such individual has agreed to repay defense costs advanced on such individual's behalf.

On October 29, 2008, we filed a Motion for Leave to File a Second Amended Complaint with the Superior Court. The Second Amended Complaint would add four new insurance companies as defendants in the Coverage Action. These carriers are the issuers of a third set of policies (which we refer to as Emdeon

**Table of Contents**

Policies) that provide coverage with respect to our indemnification obligations to the former officers and directors of our former EPS subsidiary who were indicted in connection with the Investigation described in Note 12,

Commitments and Contingencies located in the Notes to the Consolidated Financial Statements elsewhere in this Quarterly Report. Additionally, the Second Amended Complaint would add back as a defendant in the Coverage Action the issuer of one of the EPS Policies with whom we settled who is also the issuer of the eighth level of coverage under the Synetic Policies. At the time of that settlement we dismissed the eighth level carrier without prejudice with respect to that Synetic Policy and based upon the current estimate of the anticipated costs of its indemnification obligations we have determined that it is necessary to add back the carrier with respect to the Synetic Policy. Although we believe that such eighth level carrier is situated similarly to the other Synetic Policies, the eighth level carrier indicated on September 9, 2008 its position that it was not bound by the Court's July 31, 2008 order regarding the duty of the Synetic carriers to advance and reimburse defense costs. This resulted in us including the eighth level carrier in the Motion for Leave to File a Second Amended Complaint, described above.

Notwithstanding the fact that we have prevailed in the summary judgment motions described above, there can be no assurance that we will ultimately prevail in the Coverage Litigation or that the Defendants will be required to provide funding on an interim basis pending the resolution of the Coverage Litigation. We intend to continue to satisfy our legal obligations to the indicted individuals with respect to advancement of amounts for their defense costs.

*Indemnification Obligations.* We have certain indemnity obligations to advance amounts for reasonable defense costs for initially ten, and now eight, former officers and directors of EPS, who were indicted in connection with the Investigation. In connection with the sale of EPS, we agreed to indemnify Sage Software relating to these indemnity obligations. During the quarter ended June 30, 2007, based on information we had recently received at that time, we determined a reasonable estimate of the range of probable costs with respect to our indemnification obligation and recorded a pre-tax charge of \$57,774, which represented our estimate of the low end of the probable range of costs related to this matter. We reserved the low end of the probable range of costs because no estimate within the range was a better estimate than any other amount. That estimate included assumptions as to the duration of the trial and pre-trial periods, and the defense costs to be incurred during these periods. During the quarter ended December 31, 2007 and again during the quarter ended June 30, 2008, we updated the estimated range of our indemnification obligation based on new information received during those periods, and as a result, recorded additional pre-tax charges of \$15,573 and \$16,980, respectively, each of which reflected the increases in the low end of the probable range of costs related to this matter. The probable range of future costs with respect to this matter is estimated to be approximately \$47,400 to \$70,400, as of September 30, 2008, which includes costs that have been incurred prior to, but not yet paid, as of September 30, 2008. The ultimate outcome of this matter is still uncertain, and the estimate of future costs includes assumptions as to the duration of the trial and the defense costs to be incurred during the remainder of the pre-trial period and during the trial period. Accordingly, the amount of cost we may ultimately incur could be substantially more than the reserve we have currently provided. If the recorded reserves are insufficient to cover the ultimate cost of this matter, we will need to record additional charges to our consolidated statement of operations in future periods. The accrual related to this obligation was \$47,399 and \$55,563 as of September 30, 2008 and December 31, 2007, respectively, and is included within liabilities of discontinued operations in our consolidated financial statements.

*Use of the Internet by Consumers and Physicians.* The Internet has emerged as a major communications medium and has already fundamentally changed many sectors of the economy, including the marketing and sales of financial services, travel, and entertainment, among others. The Internet is also changing the healthcare industry and has transformed how consumers and physicians find and utilize healthcare information. As consumers are required to assume greater financial responsibility for rising healthcare costs, the Internet serves as a valuable resource by providing them with immediate access to searchable and dynamic interactive content to check symptoms, assess risks, understand diseases, find providers and evaluate treatment options. The Internet has also become a primary source of information for physicians seeking to improve clinical practice and is growing relative to traditional information



sources, such as conferences, meetings and offline journals.

**Table of Contents**

*Increased Online Marketing and Education Spending for Healthcare Products.* Pharmaceutical, biotechnology and medical device companies spend large amounts each year marketing their products and educating consumers and physicians about them; however, only a small portion of this amount is currently spent on online services. We believe that these companies, which comprise the majority of the advertisers and sponsors for our WebMD Online Services segment, are becoming increasingly aware of the effectiveness of the Internet relative to traditional media in providing health, clinical and product-related information to consumers and physicians, and this increasing awareness will result in increasing demand for our services. However, notwithstanding our general expectation for increased demand, our advertising and sponsorship revenue may vary significantly from quarter to quarter due to a number of factors, many of which are not in our control, and some of which may be difficult to forecast accurately, including the following:

The majority of our advertising and sponsorship contracts are for terms of approximately four to twelve months. We have relatively few longer term advertising and sponsorship contracts. In addition, we have noted a trend this year, among some of its advertisers and sponsors, of seeking to enter into shorter term contracts than they had entered into in the past.

The time between the date of initial contact with a potential advertiser or sponsor regarding a specific program and the execution of a contract with the advertiser or sponsor for that program may be subject to delays over which we have little or no control, including as a result of budgetary constraints of the advertiser or sponsor or their need for internal approvals.

Other factors that may affect the timing of contracting for specific programs with advertisers and sponsors, or receipt of revenue under such contracts, include: the timing of FDA approval for new products or for new approved uses for existing products; the timing of FDA approval of generic products that compete with existing brand name products; the timing of withdrawals of products from the market; seasonal factors relating to the prevalence of specific health conditions and other seasonal factors that may affect the timing of promotional campaigns for specific products; and the scheduling of conferences for physicians and other healthcare professionals.

*Changes in Health Plan Design; Health Management Initiatives.* In a healthcare market where a greater share of the responsibility for healthcare costs and decision-making has been increasingly shifting to consumers, use of information technology (including personal health records) to assist consumers in making informed decisions about healthcare has also increased. We believe that, through the WebMD Health and Benefits Manager tools of the private portals of our WebMD Online Services segment, including the personal health record application, we are well positioned to play a role in this consumer-directed healthcare environment, and these services will be a significant driver for the growth of our private portals during the next several years. However, our growth strategy depends, in part, on increasing usage of our private portal services by our employer and health plan clients' employees and members, respectively. Increasing usage of these services requires us to continue to deliver and improve the underlying technology and develop new and updated applications, features and services. In addition, we face competition in the area of healthcare decision-support tools and online health management applications and health information services. Many of our competitors have greater financial, technical, product development, marketing and other resources than we do, and may be better known than we are. We also expect that, for clients and potential clients in the industries most seriously affected by recent adverse changes in general economic conditions (including those in the financial services industry), we may experience some reductions in initial contracts, contract expansions and contract renewals for our private portal services.

The healthcare industry in the United States and relationships among healthcare payers, providers and consumers are very complicated. In addition, the Internet and the market for online services are relatively new and still evolving. Accordingly, there can be no assurance that the trends identified above will continue or that the expected benefits to our WebMD Online Services segment from our responses to those trends will be achieved. In addition, the market for healthcare information services is highly competitive and not only are our existing competitors seeking to benefit from

these same trends, but the trends may also attract additional competitors.

**Table of Contents***Seasonality*

The timing of our revenue is affected by seasonal factors. The advertising and sponsorship revenue within the WebMD Online Services segment is seasonal, primarily due to the annual budget approval process of the advertising and sponsorship clients of our public portals. This portion of our revenue is usually the lowest in the first quarter of each calendar year, and increases during each consecutive quarter throughout the year. Our private portal licensing revenue is historically highest in the second half of the year as new customers are typically added during this period in conjunction with their annual open enrollment periods for employee benefits. Additionally, the annual distribution cycle within the WebMD Publishing and Other Services segment results in a significant portion of the revenue in this segment being recognized in the second and third quarter of each calendar year. The timing of revenue in relation to the expenses of the WebMD Segments, much of which do not vary directly with revenue, has an impact on cost of operations, sales and marketing and general and administrative expenses as a percentage of revenue in each calendar quarter.

**Critical Accounting Policies and Estimates**

Our discussion and analysis of our financial condition and results of operations are based upon our Consolidated Financial Statements and Notes to Consolidated Financial Statements, contained elsewhere in this Quarterly Report, which were prepared in conformity with U.S. generally accepted accounting principles. The preparation of financial statements requires us to make certain estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience, current business factors, and various other assumptions that we believe are necessary to consider in order to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and disclosure of contingent assets and liabilities. We are subject to uncertainties such as the impact of future events, economic, environmental and political factors, and changes in our business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in preparation of our financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in reported results of operations; if material, the effects of changes in estimates are disclosed in the notes to our consolidated financial statements.

We evaluate our estimates on an ongoing basis, including those related to revenue recognition, investments in auction rate securities, income taxes and tax contingencies, collectibility of customer receivables, long-lived assets including goodwill and other intangible assets, software and Web site development costs, prepaid advertising services, certain accrued expenses, contingencies, litigation and related legal accruals and the value attributed to employee stock options and other stock-based awards.

We believe the following reflects our critical accounting policies and our more significant judgments and estimates used in the preparation of our consolidated financial statements:

*Revenue Recognition* Revenue from advertising is recognized as advertisements are delivered or as publications are distributed. Revenue from sponsorship arrangements, content syndication and distribution arrangements, and licenses of healthcare management tools and private portals as well as related health coaching services are recognized ratably over the term of the applicable agreement. Revenue from the sponsorship of CME is recognized over the period WebMD substantially completes its contractual deliverables as determined by the applicable agreements. When contractual arrangements contain multiple elements, revenue is allocated to each element based on its relative fair value determined using prices charged when elements are sold separately. In certain instances where fair value does not exist for all the elements, the amount of revenue allocated to the delivered elements equals the total consideration less the fair value of the

undelivered elements. In instances where fair value does not exist for the undelivered elements, revenue is recognized when the last element is delivered.

*Long-Lived Assets* Our long-lived assets consist of property and equipment, goodwill and other intangible assets. Goodwill and other intangible assets arise from the acquisitions we have made. The amount assigned to intangible assets is subjective and based on our estimates of the future benefit of

**Table of Contents**

the intangible assets using accepted valuation techniques, such as discounted cash flow and replacement cost models. Our long-lived assets, excluding goodwill, are amortized over their estimated useful lives, which we determine based on the consideration of several factors, including the period of time the asset is expected to remain in service. We evaluate the carrying value and remaining useful lives of long-lived assets, excluding goodwill, whenever indicators of impairment are present. We evaluate the carrying value of goodwill annually, or whenever indicators of impairment are present. We use a discounted cash flow approach to determine the fair value of goodwill. Long-lived assets held for sale are reported at the lower of cost or fair value less cost to sell. There was no impairment of goodwill noted as a result of our impairment testing in 2007.

*Fair Value of Investments* We hold investments in ARS which are backed by student loans, 97% of which are guaranteed under the Federal Family Education Loan Program (FFELP), and all of which had credit ratings of AAA or Aaa when purchased. Historically, the fair value of our ARS holdings approximated face value due to the frequent auction periods, generally every 7 to 28 days, which provided liquidity to these investments. However, since February 2008, virtually all auctions involving these securities have failed. The result of a failed auction is that these ARS will continue to pay interest in accordance with their terms at each respective auction date; however, liquidity of the securities will be limited until there is a successful auction, the issuer redeems the securities, the securities mature or until such time as other markets for these ARS develop. We cannot be certain regarding the amount of time it will take for an auction market or other markets to develop. Accordingly, during the three months ended March 31, 2008, we concluded that the estimated fair value of the ARS holdings no longer approximated the face value due to the lack of liquidity.

We estimated the fair value of our ARS holdings using an income approach valuation technique. Using this approach, expected future cash flows were calculated over the expected life of each security and were discounted to a single present value using a market required rate of return. Some of the more significant assumptions made in the present value calculations include (i) the estimated weighted average lives for the loan portfolios underlying each individual ARS, which range from 4 to 14 years and (ii) the required rates of return used to discount the estimated future cash flows over the estimated life of each security, which considered both the credit quality for each individual ARS and the market liquidity for these investments. As of March 31, 2008, we concluded the fair value of our ARS holdings was \$302,842 (of which \$141,044 related to WHC), compared to a face value of \$362,950 (of which \$168,450 related to WHC). The impairment in value, or \$60,108 (of which \$27,406 related to WHC), was considered to be other-than-temporary, and accordingly, was recorded as an impairment charge within the statement of operations during the three months ended March 31, 2008. During the three and nine months ended September 30, 2008, we received \$5,100 (of which \$2,000 relates to WHC) and \$7,900 (of which \$3,700 relates to WHC), respectively, associated with the partial redemption of certain of our ARS holdings which represented 100% of their face value. Also during the three months ended June 30, 2008 and September 30, 2008, we reduced the carrying value of our ARS holdings by \$3,019 and \$8,897. We assessed these declines in fair market value to be temporary as they resulted from fluctuations in interest rate assumptions and, therefore, recorded these declines as an unrealized loss in other comprehensive income within stockholders' equity.

Our ARS have been classified as Level 3 assets in accordance with Statement of Financial Accounting Standards (which we refer to as SFAS) No. 157, Fair Value Measurements, as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market due to the lack of trading in the securities. If different assumptions were used for the various inputs to the valuation approach including, but not limited to, assumptions involving the estimated lives of the ARS investments, the estimated cash flows over those estimated lives, and the estimated discount rates applied to those cash flows, the estimated fair value of these investments could be significantly higher or lower than the fair value we determined. We continue to monitor the market for ARS as well as the individual ARS investments we own. We may be required to record additional losses in future periods if the fair value of our ARS deteriorate further.



**Table of Contents**

*Sale of Subsidiary Stock* Our WHC subsidiary issues its Class A Common Stock in various transactions, which results in a dilution of our percentage ownership in WHC. We account for the sale of WHC Class A Common Stock in accordance with the SEC's Staff Accounting Bulletin No. 51, Accounting for Sales of Stock by a Subsidiary. The difference between the carrying amount of our investment in WHC before and after the issuance of WHC Class A Common Stock is considered either a gain or loss and is reflected as a component of our stockholders' equity. During the three and nine months ended September 30, 2008, WHC stock options were exercised and restricted stock awards were released in accordance with WHC's equity plans. The issuance of these shares resulted in an aggregate gain of \$1,768 and \$3,715 during the three and nine months ended September 30, 2008, respectively, and our ownership in WHC decreased to 83.1% as of September 30, 2008 from 83.5% as of December 31, 2007 (after accounting for the impact of certain WHC shares to be issued pursuant to the purchase agreement for the acquisition of Subimo, LLC). We expect to continue to record gains in the future related to future issuances of WHC Class A Common Stock.

*Stock-Based Compensation* On January 1, 2006, we adopted SFAS No. 123, (Revised 2004): Share-Based Payment (which we refer to as SFAS 123R), which replaces SFAS No. 123, Accounting for Stock-Based Compensation (which we refer to as SFAS 123) and supersedes Accounting Principles Board (which we refer to as APB) Opinion No. 25, Accounting for Stock Issued to Employees (which we refer to as APB 25). SFAS 123R requires all share-based payments to employees, including grants of employee stock options, to be recognized as compensation expense over the service period (generally the vesting period) in the consolidated financial statements based on their fair values. We elected to use the modified prospective transition method. Under the modified prospective transition method, awards that were granted or modified on or after January 1, 2006 are measured and accounted for in accordance with SFAS 123R. Unvested stock options and restricted stock awards that were granted prior to January 1, 2006 will continue to be accounted for in accordance with SFAS 123, using the same grant date fair value and same expense attribution method used under SFAS 123, except that all awards are recognized in the results of operations over the remaining vesting periods. The impact of forfeitures that may occur prior to vesting is also estimated and considered in the amount recognized for all stock-based compensation beginning January 1, 2006. As of September 30, 2008, approximately \$13,035 and \$31,887 of unrecognized stock-based compensation expense related to unvested awards (net of estimated forfeitures) is expected to be recognized over a weighted-average period of approximately 0.7 years and 1.5 years, related to the HLTH and WHC stock-based compensation plans, respectively. The total recognition period for the remaining unrecognized stock-based compensation expense for both the HLTH and WHC stock-based compensation plans is approximately four years; however, the majority of this cost will be recognized over the next two years, in accordance with our vesting provisions.

The fair value of each option granted is estimated on the date of grant using the Black-Scholes option pricing model. The assumptions used in this model are expected dividend yield, expected volatility, risk-free interest rate and expected term. The expected volatility for stock options to purchase HLTH Common Stock is based on implied volatility from traded options of HLTH Common Stock combined with historical volatility of HLTH Common Stock. Prior to August 1, 2007, the expected volatility for stock options to purchase WHC Class A Common Stock was based on implied volatility from traded options of stock of comparable companies combined with historical stock price volatility of comparable companies. Beginning on August 1, 2007, expected volatility is based on implied volatility from traded options of WHC Class A Common Stock combined with historical volatility of WHC Class A Common Stock.

*Deferred Taxes* Our deferred tax assets are comprised primarily of NOL carryforwards. At December 31, 2007, we had NOL carryforwards of approximately \$1.3 billion, which expire at varying dates from 2011 through 2028. These NOL carryforwards may be used to offset taxable income in future periods, reducing the amount of taxes we might otherwise be required to pay. Based on information available at the time of this filing, we currently estimate that the NOL carryforwards that were available as of December 31, 2007 will be



reduced by an aggregate of approximately \$550,000 as a result of offsetting our gains on the sale of ViPS on July 22, 2008 and the 2008 EBSCo Sale on February 8, 2008. Approximately \$120,000 of this

## **Table of Contents**

amount will be NOL carryforwards attributable to WHC. These estimates are based on various assumptions and are subject to material change. The actual amount of the NOL carryforwards we utilize, including the portion attributable to WHC, will not be finalized until we complete the calculation of our 2008 federal income taxes.

Substantially all of our NOL carryforwards are reserved for by a valuation allowance. In determining the need for a valuation allowance, management determined the probability of realizing deferred tax assets, taking into consideration factors including historical operating results, expectations of future earnings and taxable income. Management will continue to evaluate the need for a valuation allowance, and in the future, should management determine that realization of the net deferred tax asset is more likely than not, some or all of the remaining valuation allowance will be reversed, and our effective tax rate may be reduced by such reversal.

*Tax Contingencies* Our tax contingencies are recorded to address potential exposures involving tax positions we have taken that could be challenged by tax authorities. These potential exposures result from applications of various statutes, rules, regulations and interpretations. Our estimates of tax contingencies reflect assumptions and judgments about potential actions by taxing jurisdictions. We believe that these assumptions and judgments are reasonable; however, our accruals may change in the future due to new developments in each matter and the ultimate resolution of these matters may be greater or less than the amount that we have accrued. Consistent with our historical financial reporting, we have elected to reflect interest and penalties related to uncertain tax positions as part of the income tax provision.

## **Recent Accounting Pronouncements**

On May 9, 2008, the FASB issued FSP APB Opinion No. 14-1, *Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)* (which we refer to as FSP APB 14-1). The FSP will require cash settled convertible debt to be separated into debt and equity components at issuance and a value to be assigned to each. The value assigned to the debt component will be the estimated fair value, as of the issuance date, of a similar bond without the conversion feature. The difference between the bond cash proceeds and this estimated fair value will be recorded as a debt discount and amortized to interest expense over the life of the bond. Although FSP APB 14-1 would have no impact on our actual past or future cash flows, it will require us to record a significant amount of non-cash interest expense as the debt discount is amortized. As a result, there will be a material adverse impact on the results of operations and earnings per share. In addition, if the convertible debt is redeemed or converted prior to maturity, any unamortized debt discount will result in a loss on extinguishment. FSP APB 14-1 will become effective January 1, 2009, and will require retrospective application.

On April 25, 2008, the FASB issued FSP FAS 142-3, *Determination of the Useful Life of Intangible Assets*. This FSP amends the factors that should be considered in developing renewal or extension assumptions used to determine the useful life of a recognized intangible asset under SFAS No. 142, *Goodwill and Other Intangible Assets* (which we refer to as SFAS 142). The intent of this FSP is to improve the consistency between the useful life of a recognized intangible asset under SFAS 142 and the period of expected cash flows used to measure the fair value of the asset under SFAS No. 141 (Revised 2007), *Business Combinations*, and other U.S. GAAP. This FSP is effective for financial statements issued for fiscal years beginning after December 15, 2008, and interim periods within those fiscal years. Early adoption is prohibited. We are currently evaluating the impact that this FSP will have on our operations, financial position and cash flows.

In December 2007, the FASB issued SFAS No. 141 (Revised 2007), *Business Combinations* (which we refer to as SFAS 141R), a replacement of SFAS No. 141. SFAS 141R is effective for fiscal years beginning on or after December 15, 2008 and applies to all business combinations. SFAS 141R provides that, upon initially obtaining control, an acquirer shall recognize 100 percent of the fair values of acquired assets, including goodwill, and assumed

liabilities, with only limited exceptions, even if the acquirer has not acquired 100 percent of its target. As a consequence, the current step acquisition model will be eliminated. Additionally,

**Table of Contents**

SFAS 141R changes current practice, in part, as follows: (1) contingent consideration arrangements will be fair valued at the acquisition date and included on that basis in the purchase price consideration; (2) transaction costs will be expensed as incurred, rather than capitalized as part of the purchase price; (3) pre-acquisition contingencies, such as legal issues, will generally have to be accounted for in purchase accounting at fair value; and (4) in order to accrue for a restructuring plan in purchase accounting, the requirements in SFAS No. 146, Accounting for Costs Associated with Exit or Disposal Activities, would have to be met at the acquisition date. While there is no expected impact to our consolidated financial statements on the accounting for acquisitions completed prior to December 31, 2008, the adoption of SFAS 141R on January 1, 2009 could materially change the accounting for business combinations consummated subsequent to that date and for tax matters relating to prior acquisitions settled subsequent to December 31, 2008.

In December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated Financial Statements An Amendment of ARB No. 51 (which we refer to as SFAS 160). SFAS 160 requires the recognition of a noncontrolling interest (minority interest) as equity in the financial statements and separate from the parent's equity. The amount of net income attributable to the noncontrolling interest will be included in consolidated net income on the face of the results of operations. SFAS 160 clarifies that changes in a parent's ownership interest in a subsidiary that do not result in deconsolidation are equity transactions if the parent retains its controlling financial interest. In addition, this statement requires that a parent recognize a gain or loss in net income when a subsidiary is deconsolidated. Such gain or loss will be measured using the fair value of the noncontrolling equity investment on the deconsolidation date. SFAS 160 also includes expanded disclosure requirements regarding the interests of the parent and its noncontrolling interest. SFAS 160 is effective for financial statements issued for fiscal years beginning after December 15, 2008 and is to be applied prospectively as of the beginning of the fiscal year in which the statement is applied. Early adoption is not permitted. We are currently evaluating the impact that SFAS 160 will have on our operations, financial position and cash flows.

**Table of Contents****Results of Operations**

The following table sets forth our consolidated statements of operations data and expresses that data as a percentage of revenue for the periods presented (amounts in thousands):

	Three Months Ended September 30,				Nine Months Ended September 30,			
	2008		2007		2008		2007	
	\$	%	\$	%	\$	%	\$	%
Revenue	\$ 100,367	100.0	\$ 86,034	100.0	\$ 271,185	100.0	\$ 235,112	100.0
Costs and expenses:								
Cost of operations	35,322	35.2	30,021	34.9	99,655	36.7	87,636	37.3
Sales and marketing	26,441	26.4	22,459	26.1	77,731	28.7	67,258	28.6
General and administrative	22,928	22.9	25,718	29.8	67,253	24.8	81,111	34.5
Depreciation and amortization	7,265	7.2	7,390	8.6	21,468	7.9	20,954	8.9
Interest income	9,386	9.4	10,864	12.6	29,384	10.8	30,638	13.0
Interest expense	4,636	4.6	4,660	5.4	13,871	5.1	13,985	5.9
Gain on sale of EBS Master LLC					538,024	198.4		
Impairment of auction rate securities					60,108	22.2		
Other (expense) income, net	(997)	(1.0)	989	1.1	(5,807)	(2.1)	5,267	2.2
Income from continuing operations before income tax provision	12,164	12.1	7,639	8.9	492,700	181.7	73	0.0
Income tax provision	7,679	7.7	2,977	3.5	34,623	12.8	4,404	1.8
Minority interest in WHC income (loss)	1,845	1.8	1,800	2.1	(929)	(0.3)	2,758	1.2
Equity in earnings of EBS Master LLC			8,005	9.3	4,007	1.5	22,679	9.6
Income from continuing operations	2,640	2.6	10,867	12.6	463,013	170.7	15,590	6.6
Income (loss) from discontinued operations	93,241	92.9	5,704	6.7	93,159	34.4	(38,780)	(16.5)

operations, net of  
tax

Net income (loss)	\$	95,881	95.5	\$	16,571	19.3	\$	556,172	205.1	\$	(23,190)	(9.9)
-------------------	----	--------	------	----	--------	------	----	---------	-------	----	----------	-------

Revenue is derived from the WebMD Segments. The WebMD Online Services segment derives revenue from advertising, sponsorship (including online CME services), e-detailing promotion and physician recruitment services, content syndication and distribution, and licenses of private online portals to employers, healthcare payers and others, along with related services including lifestyle education and personalized telephonic coaching. The WebMD Publishing and Other Services segment derives revenue from sales of, and advertising in, its physician directories, and advertisements in *WebMD the Magazine*. Additionally, WebMD sold its ACS/ACP Business as of December 31, 2007 and the revenue and expenses of this business are shown as discontinued operations for the three and nine months ended September 30, 2007.

WebMD's customers include pharmaceutical, biotechnology, medical device and consumer products companies, as well as employers and health plans. WebMD's customers also include physicians and other healthcare providers who buy its physician directories.

Cost of operations consists of costs related to services and products WebMD provides to customers and costs associated with the operation and maintenance of WebMD's public and private portals. These costs relate to editorial and production operations, Web site operations, non-capitalized Web site development costs, and costs related to the production and distribution of WebMD's publications. These costs consist of expenses related to salaries and related expenses, non-cash stock-based compensation, creating and licensing content, telecommunications, leased properties, printing and distribution.

Sales and marketing expense consists primarily of advertising, product and brand promotion, salaries and related expenses, and non-cash stock-based compensation. These expenses include items related to salaries and related expenses of account executives, account management and marketing personnel, costs and expenses for marketing programs, and fees for professional marketing and advertising services. Also included in sales and marketing expense are the non-cash advertising expenses, which are discussed below.

**Table of Contents**

General and administrative expense consists primarily of salaries, non-cash stock-based compensation and other salary-related expenses of administrative, finance, legal, information technology, human resources and executive personnel. These expenses include costs of general insurance and costs of accounting and internal control systems to support our operations.

Our discussions throughout this MD&A make references to certain non-cash expenses. We consider non-cash expenses to be those expenses that result from the issuance of our equity instruments. The following is a summary of our principal non-cash expenses:

*Non-cash advertising expense.* Expense related to the use of WebMD's prepaid advertising inventory that WHC received from News Corporation in exchange for equity instruments we issued in connection with an agreement we entered into with News Corporation in 1999 and subsequently amended in 2000. This non-cash advertising expense is included in cost of operations when WebMD utilizes this advertising inventory in conjunction with offline advertising and sponsorship programs and is included in sales and marketing expense when WebMD uses the asset for promotion of WebMD's brand.

*Non-cash stock-based compensation expense.* Expense related to the awards of all share-based payments to employees and non-employee directors, including grants of employee stock options, to be recognized as compensation expense over the service period (generally the vesting period) in the consolidated financial statements based on their fair values. Non-cash stock-based compensation expense is reflected in the same expense captions as the related salary cost of the respective employee.

The following table is a summary of our non-cash expenses included in the respective statements of operations captions.

	<b>Three Months Ended</b>		<b>Nine Months</b>	
	<b>September 30,</b>		<b>Ended</b>	
	<b>2008</b>	<b>2007</b>	<b>September 30,</b>	<b>2007</b>
Advertising expense included in:				
Sales and marketing	\$ 178	\$ 169	\$ 1,736	\$ 2,489
Stock-based compensation expense included in:				
Cost of operations	\$ 1,005	\$ 1,597	\$ 2,950	\$ 4,159
Sales and marketing	1,222	1,252	3,624	3,889
General and administrative	4,304	6,436	12,400	18,198
Total	\$ 6,531	\$ 9,285	\$ 18,974	\$ 26,246

***Three and Nine Months Ended September 30, 2008 and 2007***

The following discussion is a comparison of our results of operations on a consolidated basis for the three and nine months ended September 30, 2008 and 2007.

*Revenue*

Our total revenue increased 16.7% and 15.3% to \$100,367 and \$271,185 for the three and nine months ended September 30, 2008 from \$86,034 and \$235,112 in the prior year periods. These increases were primarily due to higher advertising and sponsorship revenue from WebMD's public portals. WebMD Online Services accounted for \$14,999 and \$36,690 of the revenue increases for the three and nine months ended September 30, 2008, partially offset by decreases of \$710 and \$757 for the three and nine months ended September 30, 2008 within the WebMD Publishing and Other Services. A more detailed discussion regarding changes in revenue is included below under Results of Operations by Operating Segment.

*Costs and Expenses*

*Cost of Operations.* Cost of operations was \$35,322 and \$99,655 for the three and nine months ended September 30, 2008, compared to \$30,021 and \$87,636 in the prior year periods. Our cost of operations



**Table of Contents**

represented 35.2% and 36.7% of revenue for the three and nine months ended September 30, 2008, compared to 34.9% and 37.3% of revenue in the prior year periods. Included in cost of operations are non-cash expenses related to stock-based compensation of \$1,005 and \$2,950 for the three and nine months ended September 30, 2008, compared to \$1,597 and \$4,159 in the prior year periods. These decreases in non-cash stock-based compensation expense for the three and nine months ended September 30, 2008, compared to the prior year periods were primarily related to the graded vesting methodology used in determining stock-based compensation expense relating to WebMD's stock options and restricted stock awards granted at the time of its initial public offering.

Cost of operations, excluding the non-cash stock-based compensation expense discussed above, was \$34,317 and \$96,705, or 34.2% and 35.7% of revenue, for the three and nine months ended September 30, 2008, compared to \$28,424 and \$83,477, or 33.0% and 35.5% of revenue, in the prior year periods. These increases in absolute dollars, as well as the increases as a percentage of revenue, were primarily attributable to increases in compensation-related costs due to higher staffing levels relating to WebMD's Web site operations and development.

*Sales and Marketing.* Sales and marketing expense was \$26,441 and \$77,731 for the three and nine months ended September 30, 2008, compared to \$22,459 and \$67,258 in the prior year periods. Our sales and marketing expense represented 26.4% and 28.7% of revenue for the three and nine months ended September 30, 2008, compared to 26.1% and 28.6% of revenue in the prior year periods. Included in sales and marketing expense were non-cash expenses related to advertising of \$178 and \$1,736 for the three and nine months ended September 30, 2008, compared to \$169 and \$2,489 in the prior year periods. Non-cash advertising expense decreased during the nine months ended September 30, 2008, compared to the prior year period, due to lower utilization of WebMD's prepaid advertising inventory. Also included in sales and marketing expense were non-cash expenses related to stock-based compensation of \$1,222 and \$3,624 for the three and nine months ended September 30, 2008, compared to \$1,252 and \$3,889 in the prior year periods. The decreases in non-cash stock-based compensation expense were primarily related to the graded vesting methodology used in determining stock-based compensation expense relating to WebMD's stock options and restricted stock awards granted at the time of its initial public offering.

Sales and marketing expense, excluding the non-cash expenses discussed above, was \$25,041 and \$72,371, or 24.9% and 26.7% of revenue, for the three and nine months ended September 30, 2008, compared to \$21,038 and \$60,880, or 24.5% and 25.9% of revenue in the prior year periods. The increases in absolute dollars, as well as the increases as a percentage of revenue, were primarily attributable to increases of approximately \$2,800 and \$8,200 for the three and nine months ended September 30, 2008 in compensation-related costs due to increased staffing and sales commissions related to higher revenue.

*General and Administrative.* General and administrative expense was \$22,928 and \$67,253 for the three and nine months ended September 30, 2008, compared to \$25,718 and \$81,111 in the prior year periods. Our general and administrative expenses represented 22.9% and 24.8% of revenue for the three and nine months ended September 30, 2008, compared to 29.8% and 34.5% of revenue in the prior year periods. Included in general and administrative expense was non-cash stock-based compensation expense of \$4,304 and \$12,400 for the three and nine months ended September 30, 2008, compared to \$6,436 and \$18,198 in the prior year periods. Non-cash stock-based compensation expense was lower for the three and nine months ended September 30, 2008, when compared to the prior year periods, in our WebMD Segments by approximately \$1,500 and \$3,300, respectively, due to the graded vesting methodology used in determining stock-based compensation expense relating to WebMD's stock options and restricted stock awards granted at the time of its initial public offering, as well as lower non-cash stock-based compensation expense of approximately \$600 and \$2,500, respectively, in our Corporate segment.

General and administrative expense, excluding the non-cash stock-based compensation expense discussed above, was \$18,624 and \$54,853, or 18.6% and 20.2% of revenue for the three and nine months ended September 30, 2008, compared to \$19,282 and \$62,913, or 22.4% and 26.8% of revenue in the prior year periods. The decreases in absolute

dollars were primarily attributable to lower costs in our Corporate segment as a result of the sales of EPS and EBS during the latter part of 2006, partially offset by a net reduction of \$881 and \$4,704 in transition services income during the three and nine months ended September 30, 2008

**Table of Contents**

and by approximately \$1,000 in higher compensation related costs due to increased staffing in our WebMD Segments for the three months ended September 30, 2008, as compared to the prior year periods. In the aggregate, expenses related to the Corporate segment, net of the transition services income, represented approximately \$2,000 and \$8,100 of the year-over-year decrease for the three and nine months ended September 30, 2008.

*Depreciation and Amortization.* Depreciation and amortization expense was \$7,265 and \$21,468, or 7.2% and 7.9% of revenue for the three and nine months ended September 30, 2008, compared to \$7,390 and \$20,954, or 8.6% and 8.9% of revenue, in the prior year periods. The decrease for the three months ended September 30, 2008, as compared to the prior year period, was due to approximately \$1,000 in lower amortization expense resulting from certain WHC intangible assets becoming fully amortized, partially offset by approximately \$1,000 in depreciation expense resulting from WHC capital expenditures made in 2007 and 2008. The increase for the nine months ended September 30, 2008, as compared to the prior year period, was primarily due to approximately \$3,500 in depreciation expense resulting from WHC's capital expenditures in 2007 and 2008, which was partially offset by a decrease in amortization expense of approximately \$2,400 resulting from certain WHC intangible assets becoming fully amortized, and lower depreciation expense of approximately \$500 in our Corporate segment as a result of certain information technology systems being written off during 2007 as a result of the sales of EBS and EPS.

*Interest Income.* Interest income was \$9,386 and \$29,384 for the three and nine months ended September 30, 2008, compared to \$10,864 and \$30,638 in the prior year periods. These decreases for the three and nine months ended September 30, 2008, primarily relate to a decrease in the average rates of return for the period, partially offset by higher average investment balances.

*Interest Expense.* Interest expense of \$4,636 and \$13,871 for the three and nine months ended September 30, 2008 was consistent with interest expense of \$4,660 and \$13,985 in the prior year periods. Interest expense in the three and nine months ended September 30, 2008 and 2007 primarily included the interest expense and the amortization of debt issuance costs for our \$350,000 of 1.75% Convertible Subordinated Notes due 2023 and our \$300,000 of 31/8% Convertible Notes due 2025.

*Gain on Sale of EBS Master LLC.* The gain on sale of EBS Master LLC of \$538,024 represented a pre-tax gain recognized in connection with the 2008 EBSCo Sale on February 8, 2008. See Introduction Other Recent Transactions Sale of EBSCo with respect to this matter.

*Impairment of Auction Rate Securities.* Impairment of auction rate securities represents a charge of \$60,108 related to an other-than-temporary reduction of the fair value of our ARS holdings during the three months ended March 31, 2008. For additional information, see Introduction Other Significant Developments and Trends Impairment of Auction Rate Securities; Non-Recourse Credit Facilities above.

*Other (Expense) Income, Net.* For the three and nine months ended September 30, 2008, other expense, net was \$997 and \$5,807 compared to other income, net of \$989 and \$5,267 in the prior year periods. Other (expense) income, net for the three and nine months ended September 30, 2008 includes \$1,135 and \$6,159 of advisory expenses for professional fees, primarily consisting of legal, accounting and financial advisory services related to the terminated merger transaction with WHC. See Introduction Termination of Proposed Merger with WHC for more information. Also included in other (expense) income, net was \$403 and \$1,164 for the three and nine months ended September 30, 2008, compared to \$373 and \$1,164 in the prior year periods of external legal costs and expenses we incurred related to the investigation by the United States Attorney for the District of South Carolina and the SEC. Transition services income of \$104 and \$205 for the three and eight months ended September 30, 2008, compared to \$985 and \$4,909 in the prior year periods, represents amounts earned from the service fee charged to EBSCo, Sage Software and ViPS, net of services EBSCo provides to us, for services rendered under each of their respective transition services agreements. The transition services agreement with Sage Software was terminated during the fourth quarter of 2007

and the transition services agreement for ViPS began during the third quarter of 2008. Therefore, net transition services fees for the three and nine months ended September 30, 2008 are for services related to EBSCO and ViPS, while transition services fees for the three and nine months ended September 30, 2007 are for services related to EBSCO and Sage Software.

**Table of Contents**

*Income Tax Provision.* The income tax provision of \$7,679 and \$34,623 for the three and nine months ended September 30, 2008, respectively, and \$2,977 and \$4,404 for the three and nine months ended September 30, 2007, respectively, represents taxes related to federal, state and other jurisdictions. While the majority of the gain on the 2008 EBSCo Sale was offset by NOL carryforwards, certain alternative minimum tax and other state taxes were not offset resulting in a provision of approximately \$24,000 for the nine months ended September 30, 2008. The income tax provision for the nine months ended September 30, 2008 excludes a benefit for the impairment of ARS, as it is currently not deductible for tax purposes.

*Minority Interest in WHC Income (Loss).* Minority interest expense of \$1,845 and income of \$929 for the three and nine months ended September 30, 2008, compared to expense of \$1,800 and \$2,758 in the prior year periods represents the minority stockholders' proportionate share of net income or loss for WHC. The ownership interest of minority shareholders fluctuates based on the net income or loss reported by WHC, combined with changes in the percentage ownership of WHC held by the minority interest shareholders. The minority interest shareholders' percentage ownership changes as a result of the issuance of WHC Class A Common Stock for the exercise of stock options and the release of restricted awards.

*Income (Loss) from Discontinued Operations, Net of Tax.* Income from discontinued operations, net of tax, was \$93,241 and \$93,159 for the three and nine months ended September 30, 2008, compared to income of \$5,704 and a loss of \$38,780 in the prior year periods. Included in income (loss) from discontinued operations, net of tax, is a pre-tax gain of \$96,566 from the ViPS Sale. In addition, income from discontinued operations includes the aggregate pre-tax operating results of our ViPS and Porex segments of \$5,271 and \$21,123 for the three and nine months ended September 30, 2008, and \$6,232 and \$19,798 for the three and nine months ended September 30, 2007. Also included in loss from discontinued operations are pre-tax charges of approximately \$16,980 for the nine months ended September 30, 2008 and \$57,774 for the nine months ended September 30, 2007 related to our indemnity obligations to advance amounts for reasonable defense costs for initially ten and now eight former officers and directors of EPS, who were indicted in connection with the investigation by the United States Attorney for the District of South Carolina and the SEC.

**Results of Operations by Operating Segment**

We monitor the performance of our business based on earnings before interest, taxes, non-cash and other items. Other items include: legal expenses we incurred, which reflect costs and expenses related to the investigation by the United States Attorney for the District of South Carolina and the SEC; income related to the reduction of certain sales and use tax contingencies; professional fees in 2008, primarily consisting of legal, accounting and financial advisory services, related to the terminated WHC Merger; the gain on the 2008 EBSCo Sale; the gain recognized in connection with the working capital adjustment associated with the EBS sale during the second half of 2006; and the impairment charge related to our ARS. Inter-segment revenue primarily represents certain services provided by our WebMD Segments to our Corporate segment.

*Reclassification of Segment Information.* As a result of our intention to divest the Porex segment and due to the ViPS Sale and the December 31, 2007 sale of WHC's ACS/ACP business, the financial information for these businesses has been reclassified to discontinued operations for the current and prior year periods. As a result of the discontinued operations presentation for ViPS and Porex, our only remaining operating segment is WebMD. We expanded our segment disclosure for WebMD to provide additional information related to the WebMD Online Services segment and the WebMD Publishing and Other Services segment. This additional information for WebMD has been provided for all periods presented.

**Table of Contents**

Summarized financial information for our WebMD Segments and Corporate segment and a reconciliation to income from continuing operations are presented below:

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2008</b>	<b>2007</b>	<b>2008</b>	<b>2007</b>
<b>Revenue</b>				
WebMD Online Services:				
Advertising and sponsorship	\$ 72,046	\$ 59,087	\$ 190,494	\$ 158,944
Licensing	22,139	20,001	65,928	59,915
Content syndication and other	392	490	1,154	2,027
Total WebMD Online Services	94,577	79,578	257,576	220,886
WebMD Publishing and Other Services	5,810	6,520	13,669	14,426
Inter-segment eliminations	(20)	(64)	(60)	(200)
	\$ 100,367	\$ 86,034	\$ 271,185	\$ 235,112
<b>Earnings before interest, taxes, non-cash and other items</b>				
WebMD Online Services	\$ 25,956	\$ 21,948	\$ 61,287	\$ 48,982
WebMD Publishing and Other Services	1,212	2,138	1,485	2,643
Corporate	(4,679)	(5,811)	(15,311)	(18,874)
	22,489	18,275	47,461	32,751
<b>Interest, taxes, non-cash and other items</b>				
Interest income	9,386	10,864	29,384	30,638
Interest expense	(4,636)	(4,660)	(13,871)	(13,985)
Income tax provision	(7,679)	(2,977)	(34,623)	(4,404)
Depreciation and amortization	(7,265)	(7,390)	(21,468)	(20,954)
Non-cash stock-based compensation	(6,531)	(9,285)	(18,974)	(26,246)
Non-cash advertising	(178)	(169)	(1,736)	(2,489)
Minority interest in WHC income (loss)	(1,845)	(1,800)	929	(2,758)
Equity in earnings of EBS Master LLC		8,005	4,007	22,679
Gain on sale of EBS Master LLC			538,024	
Impairment of auction rate securities			(60,108)	
Other (expense) income, net	(1,101)	4	(6,012)	358
Income from continuing operations	2,640	10,867	463,013	15,590
Income (loss) from discontinued operations, net of tax	93,241	5,704	93,159	(38,780)
Net income (loss)	\$ 95,881	\$ 16,571	\$ 556,172	\$ (23,190)

The following discussion is a comparison of the results of operations for our WebMD Segments and Corporate segment for the three and nine months ended September 30, 2008 and 2007.

*WebMD Online Services.* Revenue was \$94,577 and \$257,576 for the three and nine months ended September 30, 2008, an increase of \$14,999 or 18.8% and \$36,690 or 16.6%, compared to the prior year periods. Advertising and sponsorship revenue increased \$12,959 or 21.9% and \$31,550 or 19.8% for the three and nine months ended September 30, 2008, compared to the prior year periods. The increases in advertising and sponsorship revenue were attributable to an increase in the number of unique sponsored programs on WebMD's sites, including both brand sponsorship and educational programs. The number of such programs grew to approximately 800 compared to approximately 500 last year. In general, pricing remained relatively stable for WebMD's advertising and sponsorship programs and was not a significant source of the revenue increase. Licensing revenue increased \$2,138 or 10.7% and \$6,013 or 10.0% for the three and nine months

**Table of Contents**

ended September 30, 2008, compared to the prior year periods. These increases were due to an increase in the number of companies using WebMD's private portal platform to 129 from 112 last year. In general, pricing remained relatively stable for WebMD's private portal licenses and was not a significant source of the revenue increase. WebMD also had approximately 140 additional customers who purchased stand-alone decision-support services from them. Content syndication and other revenue decreased to \$392 and \$1,154 for the three and nine months ended September 30, 2008 from \$490 and \$2,027 in the prior year periods, primarily as a result of the completion of certain contracts and WebMD's decision not to seek new content syndication business.

WebMD Online Services earnings before interest, taxes, non-cash and other items was \$25,956 and \$61,287 for the three and nine months ended September 30, 2008, compared to \$21,948 and \$48,982 in the prior year periods. As a percentage of revenue, earnings before interest, taxes, non-cash and other items was 27.4% and 23.8% for the three and nine months ended September 30, 2008, compared to 27.6% and 22.2% in the prior year periods. The increase as a percentage of revenue for the nine months ended September 30, 2008 was due to higher revenue from the increase in the number of brands and sponsored programs in WebMD's public portals as well as the increase in companies using WebMD's private online portal without incurring a proportionate increase in overall expenses.

*WebMD Publishing and Other Services.* Revenue was \$5,810 and \$13,669 for the three and nine months ended September 30, 2008, compared to \$6,520 and \$14,426 in the prior year periods. The decrease for the three months ended September 30, 2008 was attributable to \$698 of lower advertising revenue in *The Little Blue Book*. The decrease for the nine months ended September 30, 2008 was attributable to \$1,503 of lower advertising in *The Little Blue Book*, offset by \$746 of higher advertising in *WebMD the Magazine*. In general, pricing remained relatively stable for advertising in both *The Little Blue Book* and *WebMD the Magazine* and was not a significant source for changes in revenue.

WebMD Publishing and Other Services earnings before interest, taxes, non-cash and other items was \$1,212 and \$1,485 for the three and nine months ended September 30, 2008, compared to \$2,138 and \$2,643 in the prior year periods. These decreases were primarily attributable to lower advertising, as noted above.

*Corporate.* Corporate includes costs and expenses for functions not directly managed by one of our segments, including the Porex and ViPS businesses which are reflected within discontinued operations. Corporate expenses decreased to \$4,679 or 4.7% of revenue and \$15,311 or 5.6% of revenue for the three and nine months ended September 30, 2008, compared to \$5,811 or 6.8% of revenue and \$18,874 or 8.0% of revenue in the prior year periods. These decreases in our Corporate segment were due to lower personnel and other costs and expenses associated with our overall management of HLTH and our subsidiaries, including certain insurance, professional and information technology costs. These lower costs and expenses were attributable to the sales of EPS and EBS during the third and fourth quarters of 2006. Offsetting the reduction in expenses is a net reduction of transition service income of \$881 and \$4,704 when comparing the three and nine months ended September 30, 2008 to the same periods in 2007. The transition services income is lower for the three and nine months ended September 30, 2008, as compared to the prior year periods, as a result of the termination of the transition services agreement with Sage Software during the fourth quarter of 2007 as well as fewer services are being performed under the EBSCo agreement in the current year periods as compared to the prior year periods.

*Inter-Segment Eliminations.* Inter-segment eliminations primarily represents certain services provided by the WebMD Segments to our Corporate segment.

**Liquidity and Capital Resources*****Cash Flows***



Cash provided by operating activities from our continuing operations was \$50,328 for the nine months ended September 30, 2008, compared to \$22,860 for the prior year period. The \$27,468 increase in cash provided by operating activities from our continuing operations when compared to a year ago primarily relates to the timing of tax payments for the sale of our EBS segment in the latter part of 2006 that were paid during

**Table of Contents**

the nine months ended September 30, 2007. In addition, the period-over-period increase in cash provided by operating activities from continuing operations is due to the continuing operating activities of our WebMD Segments in the amount of \$7,943.

Cash provided by investing activities from our continuing operations was \$748,352 for the nine months ended September 30, 2008, compared to cash used in investing activities from our continuing operations of \$317,971 for the prior year period. Cash provided by investing activities from our continuing operations for the nine months ended September 30, 2008 included \$574,617 of net proceeds received from the 2008 EBSCo Sale, \$222,771 of net proceeds received from the ViPS Sale and \$23,333 we received, which was released from escrow, from the sale of our EPS segment, which was sold in the latter part of 2006. Also included in cash provided by investing activities from our continuing operations for the nine months ended September 30, 2008 are net purchases of \$59,611, net of maturities and sales, of available for sale securities, compared to net purchases of \$338,030, net of maturities and sales, in the prior year period.

Cash provided by financing activities from our continuing operations was \$21,068 for the nine months ended September 30, 2008, compared to \$71,257 for the prior year period. Cash provided by financing activities for the nine months ended September 30, 2008 and 2007 principally related to proceeds of \$20,725 and \$114,077, respectively, from the issuance of HLTH Common Stock and WHC Class A Common Stock resulting from the exercises of employee stock options, partially offset by the repurchases of HLTH Common Stock for \$47,120 in the prior year period.

Included in our consolidated statements of cash flows are cash flows from discontinued operations of the ViPS and Porex segments and the ACS/ACP Business. Our cash flows provided by operating activities from discontinued operations for the nine months ended September 30, 2008 included an aggregate of \$19,104 related to our ViPS and Porex segments while cash flows provided by operating activities from discontinued operations for the nine months ended September 30, 2007 primarily included an aggregate of \$33,705 related to our ViPS segment, Porex segment and the ACS/ACP Business. Also included in cash flows from discontinued operations provided by operating activities for the nine months ended September 30, 2008 is the receipt of \$34,537 of insurance settlements related to our Director & Officer insurance policies, offset by \$25,144 and \$9,339 in payments made during the nine months ended September 30, 2008, and 2007, respectively, in connection with legal costs and expenses incurred related to the investigation by the United States Attorney for the District of South Carolina and the SEC. For additional information, see Introduction Other Significant Developments and Trends Directors & Officers Liability Insurance Coverage Litigation .

***Outlook on Future Liquidity***

As of September 30, 2008, we had approximately \$1.38 billion in consolidated cash and cash equivalents, and we owned investments in ARS with a face value of \$355,800 and a fair value of \$284,408. While liquidity for our ARS investments is currently limited, HLTH and WHC entered into non-recourse credit facilities with Citigroup that will allow each of us to borrow up to 75% of the face amount of our respective ARS holdings. See Introduction Other Significant Developments and Trends Impairment of Auction Rate Securities and Related Credit Facilities above. Our working capital, including discontinued operations, as of September 30, 2008 was approximately \$1.66 billion.

Our liquidity is expected to be significantly impacted as a result of the Pending Tender Offer. The Pending Tender Offer could result in the purchase of 80,000,000 shares of our common stock at a price of \$8.80 per share, which would result in the use of cash of approximately \$704,000. In addition, WHC entered into a definitive agreement to acquire MTS. See Introduction Pending Transactions Pending Acquisition of Marketing Technology Solutions Inc. above. The pending acquisition will result in \$50,000 in cash, payable at closing, and payment of up to an additional \$25,000 in cash if certain performance thresholds are achieved relating to calendar year 2009.

We believe that our available cash resources and future cash flow from operations will provide sufficient cash resources to meet the cash commitments of the Pending Tender Offer, the pending acquisition of MTS, our \$350,000 of 1.75% Convertible Subordinated Notes due 2023, our \$300,000 of 3 1/8% Convertible Notes

**Table of Contents**

due 2025 and to fund our currently anticipated working capital and capital expenditure requirements, for up to twenty-four months. Our future liquidity and capital requirements will depend upon numerous factors, including retention of customers at current volume and revenue levels, implementation of new or updated application and service offerings, competing technological and market developments, and potential future acquisitions. In addition, our ability to generate cash flow is subject to numerous factors beyond our control, including general economic, regulatory and other matters affecting us and our customers. We plan to continue to enhance our online services and to continue to invest in acquisitions, strategic relationships, facilities and technological infrastructure and product development. We intend to grow each of our existing businesses and enter into complementary ones through both internal investments and acquisitions. We may need to raise additional funds to support expansion, develop new or enhanced applications and services, respond to competitive pressures, acquire complementary businesses or technologies or take advantage of unanticipated opportunities. If required, we may raise such additional funds through public or private debt or equity financing, strategic relationships or other arrangements. We cannot assure that such financing will be available on acceptable terms, if at all, or that such financing will not be dilutive to our stockholders. Future indebtedness may impose various restrictions and covenants on us that could limit our ability to respond to market conditions, to provide for unanticipated capital investments or to take advantage of business opportunities.

**Factors That May Affect Our Future Financial Condition or Results of Operations**

This section describes circumstances or events that could have a negative effect on our financial results or operations or that could change, for the worse, existing trends in some or all of our businesses. The occurrence of one or more of the circumstances or events described below could have a material adverse effect on our financial condition, results of operations and cash flows or on the trading prices of the common stock and convertible notes that we have issued or securities we may issue in the future. The risks and uncertainties described in this Quarterly Report are not the only ones facing us. Additional risks and uncertainties that are not currently known to us or that we currently believe are immaterial may also adversely affect our business and operations.

**Risks Related to WebMD**

*If WebMD is unable to provide content and services that attract and retain users to The WebMD Health Network on a consistent basis, its advertising and sponsorship revenue could be reduced*

Users of *The WebMD Health Network* have numerous other online and offline sources of healthcare information services. WebMD's ability to compete for user traffic on its public portals depends upon its ability to make available a variety of health and medical content, decision-support applications and other services that meet the needs of a variety of types of users, including consumers, physicians and other healthcare professionals, with a variety of reasons for seeking information. WebMD's ability to do so depends, in turn, on:

its ability to hire and retain qualified authors, journalists and independent writers;

its ability to license quality content from third parties; and

its ability to monitor and respond to increases and decreases in user interest in specific topics.

We cannot assure you that WebMD will be able to continue to develop or acquire needed content, applications and tools at a reasonable cost. In addition, since consumer users of WebMD's public portals may be attracted to *The WebMD Health Network* as a result of a specific condition or for a specific purpose, it is difficult for WebMD to predict the rate at which they will return to the public portals. Because WebMD generates revenue by, among other

things, selling sponsorships of specific pages, sections or events on *The WebMD Health Network*, a decline in user traffic levels or a reduction in the number of pages viewed by users could cause WebMD's revenue to decrease and could have a material adverse effect on its results of operations.

**Table of Contents**

*Developing and implementing new and updated applications, features and services for WebMD's public and private portals may be more difficult than expected, may take longer and cost more than expected and may not result in sufficient increases in revenue to justify the costs*

Attracting and retaining users of WebMD's public portals and clients for its private portals requires WebMD to continue to improve the technology underlying those portals and to continue to develop new and updated applications, features and services for those portals. If WebMD is unable to do so on a timely basis or if WebMD is unable to implement new applications, features and services without disruption to its existing ones, it may lose potential users and clients.

WebMD relies on a combination of internal development, strategic relationships, licensing and acquisitions to develop its portals and related applications, features and services. WebMD's development and/or implementation of new technologies, applications, features and services may cost more than expected, may take longer than originally expected, may require more testing than originally anticipated and may require the acquisition of additional personnel and other resources. There can be no assurance that the revenue opportunities from any new or updated technologies, applications, features or services will justify the amounts spent.

*WebMD faces significant competition for its products and services*

The markets in which WebMD operates are intensely competitive, continually evolving and, in some cases, subject to rapid change.

WebMD's public portals face competition from numerous other companies, both in attracting users and in generating revenue from advertisers and sponsors. WebMD competes for users with online services and Web sites that provide health-related information, including commercial sites as well as public sector and not-for-profit sites. WebMD competes for advertisers and sponsors with: health-related Web sites; general purpose consumer Web sites that offer specialized health sub-channels; other high-traffic Web sites that include both healthcare-related and non-healthcare-related content and services; search engines that provide specialized health search; and advertising networks that aggregate traffic from multiple sites.

WebMD's private portals compete with: providers of healthcare decision-support tools and online health management applications; wellness and disease management vendors; and health information services and health management offerings of healthcare benefits companies and their affiliates.

WebMD's offline publications compete with numerous other offline publications, some of which have better access to traditional distribution channels than WebMD has, and also compete with online information sources.

Many of WebMD's competitors have greater financial, technical, product development, marketing and other resources than it does. These organizations may be better known than WebMD and have more customers or users than WebMD does. WebMD cannot provide assurance that it will be able to compete successfully against these organizations or any alliances they have formed or may form. Since there are no substantial barriers to entry into the markets in which WebMD's public portals participate, we expect that competitors will continue to enter these markets.

*Failure to maintain and enhance the WebMD brand could have a material adverse effect on WebMD's business*

We believe that the WebMD brand identity that WebMD has developed has contributed to the success of its business and has helped it achieve recognition as a trusted source of health and wellness information. We also believe that maintaining and enhancing that brand is important to expanding the user base for WebMD's public portals, to its relationships with sponsors and advertisers and to its ability to gain additional employer and healthcare payer clients

for our private portals. WebMD has expended considerable resources on establishing and enhancing the WebMD brand and its other brands, and it has developed policies and procedures designed to preserve and enhance its brands, including editorial procedures designed to provide

**Table of Contents**

quality control of the information it publishes. WebMD expects to continue to devote resources and efforts to maintain and enhance its brand. However, WebMD may not be able to successfully maintain or enhance awareness of its brands and circumstances or events, including ones outside of its control, may have a negative effect on its brands. If WebMD is unable to maintain or enhance awareness of its brand, and do so in a cost-effective manner, its business could be adversely affected.

*WebMD's online businesses have a limited operating history*

WebMD's online businesses have a limited operating history and participate in relatively new markets. These markets, and WebMD's online businesses, have undergone significant changes during their short history and can be expected to continue to change. Many companies with business plans based on providing healthcare information and related services through the Internet have failed to be profitable and some have filed for bankruptcy and/or ceased operations. Even if demand from users exists, we cannot assure you that WebMD's businesses will continue to be profitable.

*WebMD's success depends, in part, on its attracting and retaining qualified executives and employees*

The success of WebMD depends, in part, on its ability to attract and retain qualified executives, writers and editors, software developers and other technical and professional personnel and sales and marketing personnel. WebMD anticipates a continuing need to hire and retain qualified employees in these areas. Competition for qualified personnel in the healthcare information technology and healthcare information services industries is intense, and we cannot assure you that WebMD will be able to hire or retain a sufficient number of qualified personnel to meet its requirements, or that it will be able to do so at salary, benefit and other compensation costs that are acceptable to it. Failure to do so may have an adverse effect on its business.

*If WebMD is unable to provide healthcare content for its offline publications that attracts and retains users, its revenue will be reduced*

Interest in WebMD's offline publications, such as *The Little Blue Book*, is based upon WebMD's ability to make available up-to-date health content that meets the needs of its physician users. Although WebMD has been able to continue to update and maintain the physician practice information that it publishes in *The Little Blue Book*, if WebMD is unable to continue to do so for any reason, the value of *The Little Blue Book* would diminish and interest in this publication and advertising in this publication would be adversely affected.

*WebMD the Magazine* was launched in April 2005 and, as a result, has a very short operating history. We cannot assure you that *WebMD the Magazine* will be able to attract and retain the advertisers needed to make this publication successful in the future.

*The timing of WebMD's advertising and sponsorship revenue may vary significantly from quarter to quarter*

WebMD's advertising and sponsorship revenue may vary significantly from quarter to quarter due to a number of factors, many of which are not in WebMD's control, and some of which may be difficult to forecast accurately. The majority of WebMD's advertising and sponsorship programs are for terms of approximately four to twelve months. WebMD has relatively few longer term advertising and sponsorship programs. In addition, WebMD has noted a trend this year, among some of its advertisers and sponsors, of seeking to enter into shorter term contracts than they had entered into in the past. We cannot assure you that WebMD's current advertisers and sponsors will continue to use its services beyond the terms of their existing contracts or that they will enter into any additional contracts.

In addition, the time between the date of initial contact with a potential advertiser or sponsor regarding a specific program and the execution of a contract with the advertiser or sponsor for that program may be lengthy, especially for



larger contracts, and may be subject to delays over which WebMD has little or no control, including as a result of budgetary constraints of the advertiser or sponsor or their need for internal

**Table of Contents**

approvals. Other factors that could affect the timing of contracting for specific programs with advertisers and sponsors, or receipt of revenue under such contracts, include:

the timing of FDA approval for new products or for new approved uses for existing products;

the timing of FDA approval of generic products that compete with existing brand name products;

the timing of withdrawals of products from the market;

seasonal factors relating to the prevalence of specific health conditions and other seasonal factors that may affect the timing of promotional campaigns for specific products; and

the scheduling of conferences for physicians and other healthcare professionals.

*Lengthy sales and implementation cycles for WebMD's private online portals make it difficult to forecast revenues from these applications and may have an adverse impact on that business*

The period from WebMD's initial contact with a potential client for a private online portal and the first purchase of its solution by the client is difficult to predict. In the past, this period has generally ranged from six to twelve months, but in some cases has been longer. Potential sales may be subject to delays or cancellations due to a client's internal procedures for approving large expenditures and other factors beyond WebMD's control, including the effect of general economic conditions on the willingness of potential clients to commit to licensing our private portals. The time it takes to implement a private online portal is also difficult to predict and has lasted as long as six months from contract execution to the commencement of live operation. Implementation may be subject to delays based on the availability of the internal resources of the client that are needed and other factors outside of WebMD's control. As a result, we have limited ability to forecast the timing of revenue from new clients. This, in turn, makes it more difficult to predict WebMD's financial performance from quarter to quarter.

During the sales cycle and the implementation period, we may expend substantial time, effort and money preparing contract proposals, negotiating contracts and implementing the private online portal without receiving any related revenue. In addition, many of the expenses related to providing private online portals are relatively fixed in the short term, including personnel costs and technology and infrastructure costs. Even if WebMD's private portal revenue is lower than expected, it may not be able to reduce related short-term spending in response. Any shortfall in such revenue would have a direct impact on its results of operations.

*WebMD's ability to provide comparative information on hospital cost and quality depends on its ability to obtain the required data on a timely basis and, if it is unable to do so, its private portal services would be less attractive to clients*

WebMD provides, in connection with its private portal services, comparative information about hospital cost and quality. WebMD's ability to provide this information depends on its ability to obtain comprehensive, reliable data. WebMD currently obtains this data from a number of public and private sources, including the Centers for Medicare and Medicaid Services (CMS), 24 individual states and the Leapfrog Group. We cannot provide assurance that WebMD would be able to find alternative sources for this data on acceptable terms and conditions. Accordingly, WebMD's business could be negatively impacted if CMS or WebMD's other data sources cease to make such information available or impose terms and conditions for making it available that are not consistent with WebMD's planned usage. In addition, the quality of the comparative information services that WebMD provides depends on the reliability of the information that it is able to obtain. If the information WebMD uses to provide these services contains errors or is otherwise unreliable, WebMD could lose clients and its reputation could be damaged.



**Table of Contents**

*WebMD's ability to renew existing licenses with employers and health plans will depend, in part, on WebMD's ability to continue to increase usage of our private portal services by their employees and plan members*

In a healthcare market where a greater share of the responsibility for healthcare costs and decision-making has been increasingly shifting to consumers, use of information technology (including personal health records) to assist consumers in making informed decisions about healthcare has also increased. We believe that through WebMD's Health and Benefits Manager tools, including WebMD's personal health record application, WebMD is well positioned to play a role in this consumer-directed healthcare environment, and these services will be a significant driver for the growth of WebMD's private portals during the next several years. However, WebMD's growth strategy depends, in part, on increasing usage of WebMD's private portal services by WebMD's employer and health plan clients' employees and members, respectively. Increasing usage of WebMD's services requires WebMD to continue to deliver and improve the underlying technology and develop new and updated applications, features and services. In addition, WebMD faces competition in the area of healthcare decision-support tools and online health management applications and health information services. Many of WebMD's competitors have greater financial, technical, product development, marketing and other resources than WebMD does, and may be better known than WebMD's. We cannot provide assurance that WebMD will be able to meet its development and implementation goals, nor that WebMD will be able to compete successfully against other vendors offering competitive services and, as a result, may experience static or diminished usage for WebMD's private portal services and possible non-renewals of WebMD's license agreements.

*WebMD may be unsuccessful in its efforts to increase advertising and sponsorship revenue from consumer products companies*

Most of WebMD's advertising and sponsorship revenue has, in the past, come from pharmaceutical, biotechnology and medical device companies. WebMD has been focusing on increasing sponsorship revenue from consumer products companies that are interested in communicating health-related or safety-related information about their products to WebMD's audience. However, while a number of consumer products companies have indicated an intent to increase the portion of their promotional spending used on the Internet, we cannot assure you that these advertisers and sponsors will find WebMD's consumer Web sites to be as effective as other Web sites or traditional media for promoting their products and services. If WebMD encounters difficulties in competing with the other alternatives available to consumer products companies, this portion of WebMD's business may develop more slowly than we expect or may fail to develop.

*WebMD could be subject to breach of warranty or other claims by clients of our online portals if the software and systems we use to provide them contain errors or experience failures*

Errors in the software and systems WebMD uses could cause serious problems for clients of its online portals. WebMD may fail to meet contractual performance standards or client expectations. Clients of WebMD's online portals may seek compensation from WebMD or may seek to terminate their agreements with WebMD, withhold payments due to WebMD, seek refunds from WebMD of part or all of the fees charged under those agreements or initiate litigation or other dispute resolution procedures. In addition, WebMD could face breach of warranty or other claims by clients or additional development costs. WebMD's software and systems are inherently complex and, despite testing and quality control, we cannot be certain that they will perform as planned.

WebMD attempts to limit, by contract, its liability to its clients for damages arising from its negligence, errors or mistakes. However, contractual limitations on liability may not be enforceable in certain circumstances or may otherwise not provide sufficient protection to WebMD from liability for damages. WebMD maintains liability insurance coverage, including coverage for errors and omissions. However, it is possible that claims could exceed the amount of WebMD's applicable insurance coverage, if any, or that this coverage may not continue to be available on

acceptable terms or in sufficient amounts. Even if these claims do not result in liability to WebMD, investigating and defending against them could be expensive and time consuming and would divert management's attention away from WebMD's operations. In addition, negative publicity

**Table of Contents**

caused by these events may delay or hinder market acceptance of WebMD's services, including unrelated services.

*Any service interruption or failure in the systems that WebMD uses to provide online services could harm WebMD's business*

WebMD's online services are designed to operate 24 hours a day, seven days a week, without interruption. However, WebMD has experienced and expects that it will in the future experience interruptions and delays in services and availability from time to time. WebMD relies on internal systems as well as third-party vendors, including data center providers and bandwidth providers, to provide its online services. WebMD may not maintain redundant systems or facilities for some of these services. In the event of a catastrophic event with respect to one or more of these systems or facilities, WebMD may experience an extended period of system unavailability, which could negatively impact its relationship with users. To operate without interruption, both WebMD and its service providers must guard against:

- damage from fire, power loss and other natural disasters;
- communications failures;
- software and hardware errors, failures and crashes;
- security breaches, computer viruses and similar disruptive problems; and
- other potential interruptions.

Any disruption in the network access or co-location services provided by third-party providers to WebMD or any failure by these third-party providers or WebMD's own systems to handle current or higher volume of use could significantly harm WebMD's business. WebMD exercises little control over these third-party vendors, which increases its vulnerability to problems with the services they provide.

Any errors, failures, interruptions or delays experienced in connection with these third-party technologies and information services or WebMD's own systems could negatively impact WebMD's relationships with users and adversely affect its brand and its business and could expose WebMD to liabilities to third parties. Although WebMD maintains insurance for its business, the coverage under its policies may not be adequate to compensate it for all losses that may occur. In addition, we cannot provide assurance that WebMD will continue to be able to obtain adequate insurance coverage at an acceptable cost.

*WebMD's online services are dependent on the development and maintenance of the Internet infrastructure*

WebMD's ability to deliver its online services is dependent on the development and maintenance of the infrastructure of the Internet by third parties. The Internet has experienced a variety of outages and other delays as a result of damages to portions of its infrastructure, and it could face outages and delays in the future. The Internet has also experienced, and is likely to continue to experience, significant growth in the number of users and the amount of traffic. If the Internet continues to experience increased usage, the Internet infrastructure may be unable to support the demands placed on it. In addition, the reliability and performance of the Internet may be harmed by increased usage or by denial-of-service attacks. Any resulting interruptions in WebMD's services or increases in response time could, if significant, result in a loss of potential or existing users of and advertisers and sponsors on WebMD's Web sites and, if sustained or repeated, could reduce the attractiveness of WebMD's services.

Customers who utilize WebMD's online services depend on Internet service providers and other Web site operators for access to WebMD's Web sites. All of these providers have experienced significant outages in the past and could

experience outages, delays and other difficulties in the future due to system failures unrelated to WebMD's systems. Any such outages or other failures on their part could reduce traffic to WebMD's Web sites.

**Table of Contents**

*Implementation of additions to or changes in hardware and software platforms used to deliver WebMD's online services may result in performance problems and may not provide the additional functionality that was expected*

From time to time, WebMD implements additions to or changes in the hardware and software platforms that it uses for providing its online services. During and after the implementation of additions or changes, a platform may not perform as expected, which could result in interruptions in operations, an increase in response time or an inability to track performance metrics. In addition, in connection with integrating acquired businesses, WebMD may move their operations to its hardware and software platforms or make other changes, any of which could result in interruptions in those operations. Any significant interruption in WebMD's ability to operate any of its online services could have an adverse effect on its relationships with users and clients and, as a result, on its financial results. WebMD relies on a combination of purchasing, licensing, internal development, and acquisitions to develop its hardware and software platforms. WebMD's implementation of additions to or changes in these platforms may cost more than originally expected, may take longer than originally expected, and may require more testing than originally anticipated. In addition, we cannot provide assurance that additions to or changes in these platforms will provide the additional functionality and other benefits that were originally expected.

*If the systems WebMD uses to provide online portals experience security breaches or are otherwise perceived to be insecure, WebMD's business could suffer*

WebMD retains and transmits confidential information, including personal health records, in the processing centers and other facilities it uses to provide online services. It is critical that these facilities and infrastructure remain secure and be perceived by the marketplace as secure. A security breach could damage WebMD's reputation or result in liability. WebMD may be required to expend significant capital and other resources to protect against security breaches and hackers or to alleviate problems caused by breaches. Despite the implementation of security measures, this infrastructure or other systems that WebMD interfaces with, including the Internet and related systems, may be vulnerable to physical break-ins, hackers, improper employee or contractor access, computer viruses, programming errors, denial-of-service attacks or other attacks by third parties or similar disruptive problems. Any compromise of WebMD's security, whether as a result of its own systems or the systems that they interface with, could reduce demand for its services and could subject WebMD to legal claims from its clients and users, including for breach of contract or breach of warranty.

*WebMD faces potential liability related to the privacy and security of personal information it collects from or on behalf of users of its services*

Privacy of personal health information, particularly personal health information stored or transmitted electronically, is a major issue in the United States. The Privacy Standards under the Health Insurance Portability and Accountability Act of 1996 (or HIPAA) establish a set of basic national privacy standards for the protection of individually identifiable health information by health plans, healthcare clearinghouses and healthcare providers (referred to as covered entities) and their business associates. Only covered entities are directly subject to potential civil and criminal liability under the Privacy Standards. Accordingly, the Privacy Standards do not apply directly to WebMD. However, portions of WebMD's business, such as those managing employee or plan member health information for employers or health plans, are or may be business associates of covered entities and are bound by certain contracts and agreements to use and disclose protected health information in a manner consistent with the Privacy Standards. Depending on the facts and circumstances, WebMD could potentially be subject to criminal liability for aiding and abetting or conspiring with a covered entity to violate the Privacy Standards. We cannot assure you that WebMD will adequately address the risks created by the Privacy Standards. In addition, we are unable to predict what changes to the Privacy Standards might be made in the future or how those changes could affect our business. Any new legislation or regulation in the area of privacy of personal information, including personal health information, could also affect the way WebMD operates its business and could harm its business.



In addition, Internet user privacy and the use of consumer information to track online activities are major issues both in the United States and abroad. For example, in December 2007, the Federal Trade Commission

**Table of Contents**

(FTC) published for comment proposed principles to govern tracking of consumers' activities online in order to deliver advertising targeted to the interests of individual consumers. WebMD has privacy policies posted on its Web sites that it believes comply with applicable laws requiring notice to users about WebMD's information collection, use and disclosure practices. However, whether and how existing privacy and consumer protection laws in various jurisdictions apply to the Internet is still uncertain. WebMD also notifies users about its information collection, use and disclosure practices relating to data it receives through offline means such as paper health risk assessments. We cannot assure you that the privacy policies and other statements WebMD provides to users of its products and services, or WebMD's practices will be found sufficient to protect it from liability or adverse publicity in this area. A determination by a state or federal agency or court that any of WebMD's practices do not meet applicable standards, or the implementation of new standards or requirements, could adversely affect WebMD's business.

*Failure to comply with regulations related to advertising and promotion may result in enforcement action and loss of sponsorship*

*The WebMD Health Network* provides services involving advertising and promotion of prescription and over-the-counter drugs and medical devices. If the Food and Drug Administration (FDA) or the FTC finds that any information on *The WebMD Health Network* or in *WebMD the Magazine* violates FDA or FTC regulations, they may take regulatory or judicial action against WebMD and/or the advertiser or sponsor of that information. State attorneys general may also take similar action based on their state's consumer protection statutes. Any increase or change in regulation of drug or medical device advertising and promotion could make it more difficult for WebMD to contract for sponsorships and advertising. Members of Congress, physician groups and others have criticized the FDA's current policies, and have called for restrictions on advertising of prescription drugs and medical devices to consumers and increased FDA enforcement. We cannot predict what actions the FDA or industry participants may take in response to these criticisms. It is also possible that new laws will be enacted that impose restrictions on such advertising and promotion. WebMD's advertising and sponsorship revenue could be materially reduced by additional restrictions on the advertising of prescription drugs and medical devices to consumers, whether imposed by law or regulation or required under policies adopted by industry members.

*Failure to maintain its CME accreditation could adversely affect WebMD's ability to provide online CME offerings*

Medscape's continuing medical education (CME) activities are planned and implemented in accordance with the current Essential Areas and Policies of the Accreditation Council for Continuing Medical Education, or ACCME, which oversees providers of CME credit, and other applicable accreditation standards. In 2007, ACCME revised its standards for commercial support of CME. The revised standards are intended to ensure, among other things, that CME activities of ACCME-accredited providers, such as Medscape, are independent of commercial interests, which are now defined as entities that produce, market, re-sell or distribute healthcare goods and services, excluding certain organizations. Commercial interests, and entities owned or controlled by commercial interests, are ineligible for accreditation by ACCME. The revised standards also provide that accredited CME providers may not place their CME content on Web sites owned or controlled by a commercial interest. In addition, accredited CME providers may no longer ask commercial interests for speaker or topic suggestions, and are also prohibited from asking commercial interests to review CME content prior to delivery.

As a result of the revised standards, WebMD has made certain adjustments to its corporate structure, management and operations intended to ensure that Medscape will continue to provide CME activities that are developed independently from those programs developed by its sister companies, which may not be independent of commercial interests. ACCME required accredited providers to implement changes relating to placing CME content on Web sites owned or controlled by commercial interests by January 1, 2008, and is requiring accredited providers to implement any corporate structural changes necessary to meet the revised standards regarding the definition of commercial interest by August 2009. We believe that the adjustments that WebMD and Medscape have made to their structure and operations

satisfy the revised standards.

## **Table of Contents**

In June 2008, the ACCME announced a call-for-comments on several ACCME proposals, including the following:

*Potential New Paradigm for Commercial Support:* The ACCME has stated that it believes that due consideration should be given to the possibility of eliminating commercial support of CME. The ACCME has requested the medical profession, the public and CME providers to weigh in on the debate on this subject. To frame the debate, the ACCME has proposed several possible scenarios: (a) maintaining the current system of commercial support; (b) completely eliminating commercial support; (c) a new paradigm that provides for commercial support if the following conditions are met: (1) educational needs are identified and verified by organizations that do not receive commercial support and are free of financial relationships with industry; (2) the CME addresses a professional practice gap of a particular group of learners that is corroborated by bona fide performance measurements of the learners' own practice; (3) the CME content is from a continuing education curriculum specified by a bona fide organization or entity; and (4) the CME is verified as free of commercial bias; and (d) an alternative new paradigm in which the four conditions described above would provide a basis for a mechanism to distribute commercial support derived from industry-donated, pooled funds.

*Defining Appropriate Interactions between ACCME Accredited Providers and Commercial Supporters.* The ACCME has proposed that (a) accredited providers must not receive communications from commercial interests announcing or prescribing any specific content that would be a preferred, or sought-after, topic for commercially supported CME (e.g., therapeutic area, product-line, patho-physiology); and (b) receiving communications from commercial interests regarding a commercial interest's internal criteria for providing commercial support would also not be permissible.

The ACCME sought comments on the above, and the comment period ended on September 12, 2008. The comments submitted to the ACCME indicated significant backing from the medical profession for commercially-supported CME and, accordingly, we believe that it is unlikely that a proposal for complete elimination of such support would be adopted. However, we cannot predict the ultimate outcome of the process, including what other alternatives may be considered by ACCME as a result of comments it has received. The elimination of, or restrictions on, commercial support for CME could adversely affect the volume of sponsored online CME programs implemented through our Web sites.

Medscape's current ACCME accreditation expires at the end of July 2010. In order for Medscape to renew its accreditation, it will be required to demonstrate to the ACCME that it continues to meet ACCME requirements. If Medscape fails to maintain its status as an accredited ACCME provider (whether at the time of such renewal or at an earlier time as a result of a failure to comply with existing additional ACCME standards), it would not be permitted to accredit ACCME activities for physicians and other healthcare professionals. Instead, it would be required to use third parties to provide such CME-related services. That, in turn, could discourage potential sponsors from engaging Medscape to develop CME or education-related activities, which could have a material adverse effect on our business.

*Government regulation and industry initiatives could adversely affect the volume of sponsored online CME programs implemented through WebMD's Web sites or require changes to how WebMD offers CME*

CME activities may be subject to government regulation by Congress, the FDA, the Department of Health and Human Services, the federal agency responsible for interpreting certain federal laws relating to healthcare, and by state regulatory agencies. Medscape and/or the sponsors of the CME activities that Medscape accredits may be subject to enforcement actions if any of these CME activities are deemed improperly promotional, potentially leading to the termination of sponsorships.

During the past several years, educational activities, including CME, directed to physicians have been subject to increased governmental scrutiny to ensure that sponsors do not influence or control the content of the activities. In

response, pharmaceutical companies and medical device companies have developed and implemented internal controls and procedures that promote adherence to applicable regulations and requirements. In implementing these controls and procedures, Medscape's various sponsors may interpret the

## **Table of Contents**

regulations and requirements differently and may implement varying procedures or requirements. These controls and procedures:

may discourage pharmaceutical companies from providing grants for independent educational activities;

may slow their internal approval for such grants;

may reduce the volume of sponsored educational programs that Medscape produces to levels that are lower than in the past, thereby reducing revenue; and

may require Medscape to make changes to how it offers or provides educational programs, including CME.

In addition, future changes to laws and regulations, or to the internal compliance programs of supporters or potential supporters, may further discourage, significantly limit or prohibit supporters or potential supporters from engaging in educational activities with Medscape, or may require Medscape to make further changes in the way it offers or provides educational programs.

## **Risks Related to Porex**

*Porex's success depends upon demand for its products, which in some cases ultimately depends upon end-user demand for the products of its customers*

Demand for our Porex products may change materially as a result of economic or market conditions and other trends that affect the industries in which Porex participates. In addition, because a significant portion of our Porex products are components that are eventually integrated into or used with products manufactured by customers for resale to end-users, the demand for these product components is dependent on product development cycles and marketing efforts of these other manufacturers, as well as variations in their inventory levels, which are factors that we are unable to control. Accordingly, the amount of Porex's sales to manufacturer customers can be difficult to predict and subject to wide quarter-to-quarter variances. Porex's sales to manufacturer customers that sell products used by consumers have been adversely affected by economic conditions during recent months. We cannot predict how long that adverse effect will continue and it could, depending on future economic conditions, become worse in future periods.

*Porex faces significant competition for its products*

Porex operates in competitive markets and its products are, in general, used in applications that are affected by technological change and product obsolescence. The competitors for Porex's porous plastic products include other producers of porous plastic materials as well as companies that manufacture and sell products made from materials other than porous plastics that can be used for the same purposes as Porex's products. For example, Porex's porous plastic pen nibs compete with felt and fiber tips manufactured by a variety of suppliers worldwide. Other Porex porous plastic products compete, depending on the application, with membrane material, porous metals, metal screens, fiberglass tubes, pleated paper, resin-impregnated felt, ceramics and other substances and devices. Some of Porex's competitors may have greater financial, technical, product development, marketing and other resources than Porex does. We cannot provide assurance that Porex will be able to compete successfully against these companies or against particular products they provide or may provide in the future.

*Porex's product offerings must meet changing customer requirements*

A significant portion of our Porex products are integrated into end products used by manufacturing companies in various industries, some of which are characterized by rapidly changing technology, evolving industry standards and frequent new product introductions. Accordingly, to satisfy its customers, Porex must develop and introduce, in a timely manner, products that meet changing customer requirements at competitive prices. To do this, Porex must:

develop new uses of existing porous plastics technologies and applications;

innovate and develop new porous plastics technologies and applications;

**Table of Contents**

commercialize those technologies and applications;

manufacture at a cost that allows it to price its products competitively;

manufacture and deliver its products in sufficient volumes and on time;

accurately anticipate customer needs; and

differentiate its offerings from those of its competitors.

We cannot assure you that Porex will be able to develop new or enhanced products or that, if it does, those products will achieve market acceptance. If Porex does not introduce new products in a timely manner and make enhancements to existing products to meet the changing needs of its customers, some of its products could become obsolete over time, in which case Porex's customer relationships, revenue and operating results would be negatively impacted.

*Potential new or enhanced Porex products may not achieve sufficient sales to be profitable or justify the cost of their development*

We cannot be certain, when we engage in Porex research and development activities, whether potential new products or product enhancements will be accepted by the customers for whom they are intended. Achieving market acceptance for new or enhanced products may require substantial marketing efforts and expenditure of significant funds to create awareness and demand by potential customers. In addition, sales and marketing efforts with respect to these products may require the use of additional resources for training our existing Porex sales forces and customer service personnel and for hiring and training additional salespersons and customer service personnel.

There can be no assurance that the revenue opportunities from new or enhanced products will justify amounts spent for their development and marketing. In addition, there can be no assurance that any pricing strategy that we implement for any new or enhanced Porex products will be economically viable or acceptable to the target markets.

*Porex may not be able to source the raw materials it needs or may have to pay more for those raw materials*

Some of Porex's products require high-grade plastic resins with specific properties as raw materials. While Porex has not experienced any material difficulty in obtaining adequate supplies of high-grade plastic resins that meet its requirements, it relies on a limited number of sources for some of these plastic resins. If Porex experiences a reduction or interruption in supply from these sources, it may not be able to access alternative sources of supply within a reasonable period of time or at commercially reasonable rates, which could have a material adverse effect on its business and financial results.

In addition, the prices of some of the raw materials that Porex uses depend, to a great extent, on the price of petroleum. As a result, increases in the price of petroleum could have an adverse effect on Porex's margins and on the ability of Porex's porous plastics products to compete with products made from other raw materials.

*Disruptions in Porex's manufacturing operations could have a material adverse effect on its business and financial results*

Any significant disruption in Porex's manufacturing operations, including as a result of fire, power interruptions, equipment malfunctions, labor disputes, material shortages, earthquakes, floods, computer viruses, sabotage, terrorist acts or other force majeure, could have a material adverse effect on Porex's ability to deliver products to customers



and, accordingly, its financial results.

**Table of Contents**

*Porex may not be able to keep third parties from using technology it has developed*

Porex uses proprietary technology for manufacturing its porous plastics products and its success is dependent, to a significant extent, on its ability to protect the proprietary and confidential aspects of its technology. Although Porex owns certain patents, it relies primarily on non-patented proprietary manufacturing processes. To protect its proprietary processes, Porex relies on a combination of trade secret laws, license agreements, nondisclosure and other contractual provisions and technical measures, including designing and manufacturing its porous molding equipment and most of its molds in-house. Trade secret laws do not afford the statutory exclusivity possible for patented processes. There can be no assurance that the legal protections afforded to Porex or the steps taken by Porex will be adequate to prevent misappropriation of its technology. In addition, these protections do not prevent independent third-party development of competitive products or services.

*The nature of Porex's products exposes it to product liability claims that may not be adequately covered by indemnity agreements or insurance*

The products sold by Porex, whether sold directly to end-users or sold to other manufacturers for inclusion in the products that they sell, expose it to potential risk of product liability claims, particularly with respect to Porex's life sciences, clinical, surgical and medical products. In addition, Porex is subject to the risk that a government authority or third party may require it to recall one or more of its products. Some of Porex's products are designed to be permanently implanted in the human body. Design defects and manufacturing defects with respect to such products sold by Porex or failures that occur with the products of Porex's manufacturer customers that contain components made by Porex could result in product liability claims and/or a recall of one or more of Porex's products. Porex believes that it carries adequate insurance coverage against product liability claims and other risks. We cannot assure you, however, that claims in excess of Porex's insurance coverage will not arise. In addition, Porex's insurance policies must be renewed annually. Although Porex has been able to obtain adequate insurance coverage at an acceptable cost in the past, we cannot assure you that Porex will continue to be able to obtain adequate insurance coverage at an acceptable cost.

In most instances, Porex enters into indemnity agreements with its manufacturing customers. These indemnity agreements generally provide that these customers would indemnify Porex from liabilities that may arise from the sale of their products that incorporate Porex components to, or the use of such products by, end-users. While Porex generally seeks contractual indemnification from its customers, any such indemnification is limited, as a practical matter, to the creditworthiness of the indemnifying party. If Porex does not have adequate contractual indemnification available, product liability claims, to the extent not covered by insurance, could have a material adverse effect on its business and its financial results.

*Porex's manufacturing of medical devices is subject to extensive regulation by the U.S. Food and Drug Administration and its failure to meet strict regulatory requirements could require it to pay fines, incur other costs or close facilities*

Porex's Surgical Products Group manufactures and markets medical devices, such as reconstructive and aesthetic surgical implants used in craniofacial applications and post-surgical drains. In addition, Porex manufactures and markets blood serum filters as a medical device for use in laboratory applications. These products are subject to extensive regulation by the FDA under the FDC Act. The FDA's regulations govern, among other things, product development, testing, manufacturing, labeling, storage, premarket clearance (referred to as 510(k) clearance), premarket approval (referred to as PMA approval), advertising and promotion, and sales and distribution. In addition, the Porex facilities and manufacturing techniques used for manufacturing medical devices generally must conform to standards that are established by the FDA and other government agencies, including those of European and other foreign governments. These regulatory agencies may conduct periodic audits or inspections of such facilities or processes to monitor Porex's compliance with applicable regulatory standards. If the FDA finds that Porex has failed to

comply with applicable regulations, the agency can institute a wide variety of enforcement actions, including: warning letters or untitled letters; fines and civil penalties; unanticipated expenditures to address or defend such actions; delays in clearing or approving, or refusal to clear or approve, products; withdrawal or suspension of approval of products; product

## **Table of Contents**

recall or seizure; orders for physician notification or device repair, replacement or refund; interruption of production; operating restrictions; injunctions; and criminal prosecution. Any adverse action by an applicable regulatory agency could impair Porex's ability to produce its medical device products in a cost-effective and timely manner in order to meet customer demands. Porex may also be required to bear other costs or take other actions that may have a negative impact on its future sales of such products and its ability to generate profits.

*Economic, political and other risks associated with Porex's international sales and geographically diverse operations could adversely affect Porex's operations and financial results*

Since Porex sells its products worldwide, its business is subject to risks associated with doing business internationally. In addition, Porex has manufacturing facilities in the United Kingdom, Germany and Malaysia. Accordingly, Porex's operations and financial results could be harmed by a variety of factors, including:

changes in foreign currency exchange rates;

changes in a specific country's or region's political or economic conditions, particularly in emerging markets;

trade protection measures and import or export licensing requirements;

changes in tax laws;

differing protection of intellectual property rights in different countries; and

changes in regulatory requirements.

*Environmental regulation could adversely affect Porex's business*

Porex is subject to foreign and domestic environmental laws and regulations and is subject to scheduled and random checks by environmental authorities. Porex's business involves the handling, storage and disposal of materials that are classified as hazardous. Although Porex's safety procedures for handling, storage and disposal of these materials are designed to comply with the standards prescribed by applicable laws and regulations, Porex may be held liable for any environmental damages that result from Porex's operations. Porex may be required to pay fines, remediation costs and damages, which could have a material adverse effect on its results of operations.

## **Risks Related to Providing Products and Services to the Healthcare Industry**

*Developments in the healthcare industry and its funding could adversely affect our businesses*

Most of the revenue of WebMD is derived from healthcare industry participants and could be affected by changes affecting healthcare spending. In addition, a significant portion of Porex's revenue comes from products used in healthcare or related applications. WebMD's advertising and sponsorship revenue is particularly dependent on pharmaceutical, biotechnology and medical device companies. General reductions in expenditures by healthcare industry participants could result from, among other things:

government regulation or private initiatives that affect the manner in which healthcare providers interact with patients, payers or other healthcare industry participants, including changes in pricing or means of delivery of healthcare products and services;

consolidation of healthcare industry participants;

reductions in governmental funding for healthcare or in tax benefits applicable to healthcare expenditures; and

adverse changes in business or economic conditions affecting healthcare payers or providers, pharmaceutical companies, medical device manufacturers or other healthcare industry participants.

**Table of Contents**

Even if general expenditures by healthcare industry participants remain the same or increase, developments in the healthcare industry may result in reduced spending in some or all of the specific markets we serve. For example, use of our products and services could be affected by:

changes in the design of health insurance plans;

a decrease in the number of new drugs or medical devices coming to market; and

decreases in marketing expenditures by pharmaceutical companies or medical device manufacturers, including as a result of governmental regulation or private initiatives that discourage or prohibit promotional activities by pharmaceutical or medical device companies.

In addition, healthcare industry participants' expectations regarding pending or potential industry developments may also affect their budgeting processes and spending plans with respect to products and services of the types we provide.

The healthcare industry has changed significantly in recent years, and we expect that significant changes will continue to occur. However, the timing and impact of developments in the healthcare industry are difficult to predict. We cannot provide assurance that the markets for our products and services will continue to exist at current levels or that we will have adequate technical, financial and marketing resources to react to changes in those markets.

*Government regulation of healthcare creates risks and challenges with respect to our compliance efforts and business strategies*

The healthcare industry is highly regulated and is subject to changing political, legislative, regulatory and other influences. Existing and new laws and regulations affecting the healthcare industry could create unexpected liabilities for us, could cause us to incur additional costs and could restrict our operations. Many healthcare laws are complex and their application to specific products and services may not be clear. In particular, many existing healthcare laws and regulations, when enacted, did not anticipate the online services that WebMD provides. However, these laws and regulations may nonetheless be applied to our products and services. Our failure to accurately anticipate the application of these laws and regulations, or other failure to comply, could create liability for us, result in adverse publicity and negatively affect our businesses. Some of the risks that we face from healthcare regulation are as follows:

because WebMD's public portals business involves advertising and promotion of prescription and over-the-counter drugs and medical devices, any increase in regulation of these areas could make it more difficult for WebMD to contract for sponsorships and advertising;

because WebMD is the leading distributor of online CME to healthcare professionals, any failure to maintain its status as an accredited CME provider or any change in government regulation of CME or in industry practices could adversely affect WebMD's business;

because Porex manufactures medical devices for implantation, it is subject to extensive FDA regulation, as well as foreign regulatory requirements;

because we provide products and services to healthcare providers, our sales and promotional practices must comply with federal and state anti-kickback laws; and

in providing health information to consumers, we must not engage in activities that could be deemed to be practicing medicine and a violation of applicable laws.

**Table of Contents**

**Risks Applicable to Our Entire Company and to Ownership of Our Securities**

*The ongoing investigations by the United States Attorney for the District of South Carolina and the SEC could negatively impact our company and divert management attention from our business operations*

The United States Attorney for the District of South Carolina is conducting an investigation of our company. Based on the information available to HLTH as of the date of this Quarterly Report on Form 10-Q, we believe that the investigation relates principally to issues of financial accounting improprieties for Medical Manager Corporation, a predecessor of HLTH (by its merger into HLTH in September 2000), and Medical Manager Health Systems, a former subsidiary of HLTH; however, we cannot be sure of the investigation's exact scope or how long it may continue. In addition, HLTH understands that the SEC is conducting a formal investigation into this matter. Adverse developments in connection with the investigations, if any, including as a result of matters that the authorities or HLTH may discover, could have a negative impact on our company and on how it is perceived by investors and potential investors and customers and potential customers. In addition, the management effort and attention required to respond to the investigations and any such developments could have a negative impact on our business operations.

HLTH intends to continue to fully cooperate with the authorities in this matter. We believe that the amount of the expenses that we will incur in connection with the investigations will continue to be significant and we are not able to determine, at this time, what portion of those amounts may ultimately be covered by insurance or may ultimately be repaid to us by individuals to whom we are advancing amounts for their defense costs. In connection with the sale of Emdeon Practice Services to Sage Software, we have agreed to indemnify Sage Software with respect to this matter.

*If certain transactions occur with respect to our capital stock, limitations may be imposed on our ability to utilize our net operating loss carryforwards and tax credits to reduce our income taxes*

As of December 31, 2007, we had net operating loss carryforwards of approximately \$1.3 billion for federal income tax purposes and federal tax credits of approximately \$35.7 million, which excludes the impact of any unrecognized tax benefits. Based on information available at the time of this filing, we currently estimate that the net operating loss carryforwards that were available as of December 31, 2007 will be reduced by an aggregate of approximately \$550 million as a result of offsetting our gains on the sale of our ViPS business on July 22, 2008 and the February 8, 2008 sale of our 48% interest in Emdeon Business Services. These estimates are based on various assumptions and are subject to material change.

If certain transactions occur with respect to our capital stock, including issuances, redemptions, recapitalizations, exercises of options, conversions of convertible debt, purchases or sales by 5%-or-greater shareholders and similar transactions, that result in a cumulative change of more than 50% of the ownership of our capital stock, over a three-year period, as determined under rules prescribed by the U.S. Internal Revenue Code and applicable Treasury regulations, an annual limitation would be imposed with respect to our ability to utilize our net operating loss carryforwards and federal tax credits. The tender offer being made by HLTH for its Common Stock that began on October 27, 2008 may result in a cumulative change of more than 50% of the ownership of our capital, as determined under rules prescribed by the U.S. Internal Revenue Code and applicable Treasury regulations. However, we currently are unable to calculate the annual limitation that would be imposed on our ability to utilize our net operating loss carryforwards and federal tax credits if such ownership change were to occur, which would depend on various factors including the level of participation in the tender offer. Because substantially all of our net operating loss carryforwards are reserved for by a valuation allowance, we would not expect an annual limitation on the utilization of our net operating loss carryforwards to significantly reduce our net deferred tax assets, although the timing of our cash flows may be impacted to the extent any such annual limitation deferred the utilization of our net operating loss carryforwards to future tax years.





**Table of Contents**

*We may not be successful in protecting our intellectual property and proprietary rights*

Intellectual property and proprietary rights are important to our businesses. The steps that we take to protect our intellectual property, proprietary information and trade secrets may prove to be inadequate and, whether or not adequate, may be expensive. We rely on a combination of trade secret, patent and other intellectual property laws and confidentiality procedures and non-disclosure contractual provisions to protect our intellectual property. We cannot assure you that we will be able to detect potential or actual misappropriation or infringement of our intellectual property, proprietary information or trade secrets. Even if we detect misappropriation or infringement by a third party, we cannot assure you that we will be able to enforce our rights at a reasonable cost, or at all. In addition, our rights to intellectual property, proprietary information and trade secrets may not prevent independent third-party development and commercialization of competing products or services.

*Third parties may claim that we are infringing their intellectual property, and we could suffer significant litigation or licensing expenses or be prevented from selling products or services*

We could be subject to claims that we are misappropriating or infringing intellectual property or other proprietary rights of others. These claims, even if not meritorious, could be expensive to defend and divert management's attention from our operations. If we become liable to third parties for infringing these rights, we could be required to pay a substantial damage award and to develop non-infringing technology, obtain a license or cease selling the products or services that use or contain the infringing intellectual property. We may be unable to develop non-infringing products or services or obtain a license on commercially reasonable terms, or at all. We may also be required to indemnify our customers if they become subject to third-party claims relating to intellectual property that we license or otherwise provide to them, which could be costly.

*Acquisitions, business combinations and other transactions may be difficult to complete and, if completed, may have negative consequences for our business and our securityholders*

We may seek to acquire or to engage in business combinations with companies engaged in complementary businesses. In addition, we may enter into joint ventures, strategic alliances or similar arrangements with third parties. These transactions may result in changes in the nature and scope of our operations and changes in our financial condition. Our success in completing these types of transactions will depend on, among other things, our ability to locate suitable candidates and negotiate mutually acceptable terms with them, as well as the availability of financing. Significant competition for these opportunities exists, which may increase the cost of and decrease the opportunities for these types of transactions.

Financing for these transactions may come from several sources, including:

cash and cash equivalents on hand and marketable securities;

proceeds from the incurrence of indebtedness; and

proceeds from the issuance of additional common stock, preferred stock, convertible debt or other securities.

Our issuance of additional securities could:

cause substantial dilution of the percentage ownership of our stockholders at the time of the issuance;

cause substantial dilution of our earnings per share;

subject us to the risks associated with increased leverage, including a reduction in our ability to obtain financing or an increase in the cost of any financing we obtain;

subject us to restrictive covenants that could limit our flexibility in conducting future business activities; and

adversely affect the prevailing market price for our outstanding securities.

We do not intend to seek securityholder approval for any such acquisition or security issuance unless required by applicable law or regulation or the terms of existing securities.

**Table of Contents**

*Our business will suffer if we fail to successfully integrate acquired businesses and technologies or to assess the risks in particular transactions*

We have in the past acquired, and may in the future acquire, businesses, technologies, services, product lines and other assets. The successful integration of the acquired businesses and assets into our operations, on a cost-effective basis, can be critical to our future performance. The amount and timing of the expected benefits of any acquisition, including potential synergies between HLTH and the acquired business, are subject to significant risks and uncertainties. These risks and uncertainties include, but are not limited to, those relating to:

our ability to maintain relationships with the customers of the acquired business;

our ability to cross-sell products and services to customers with which we have established relationships and those with which the acquired businesses have established relationships;

our ability to retain or replace key personnel;

potential conflicts in payer, provider, strategic partner, sponsor or advertising relationships;

our ability to coordinate organizations that are geographically diverse and may have different business cultures; and

compliance with regulatory requirements.

We cannot guarantee that any acquired businesses will be successfully integrated with our operations in a timely or cost-effective manner, or at all. Failure to successfully integrate acquired businesses or to achieve anticipated operating synergies, revenue enhancements or cost savings could have a material adverse effect on our business, financial condition and results of operations.

Although our management attempts to evaluate the risks inherent in each transaction and to value acquisition candidates appropriately, we cannot assure you that we will properly ascertain all such risks or that acquired businesses and assets will perform as we expect or enhance the value of our company as a whole. In addition, acquired companies or businesses may have larger than expected liabilities that are not covered by the indemnification, if any, that we are able to obtain from the sellers.

*We will incur significant additional non-cash interest expense upon the adoption of FASB Staff Position No. APB 14-1, Accounting for Convertible Debt Instruments that May be Settled in Cash upon Conversion (Including Partial Cash Settlement)*

On May 9, 2008, the Financial Accounting Standard Board (or FASB) issued FASB Staff Position No. APB 14-1, Accounting for Convertible Debt Instruments that May be Settled in Cash upon Conversion (Including Partial Cash Settlement), which will significantly impact the accounting for convertible debt when it is adopted during the first quarter of 2009. The FSP will require cash settled convertible debt to be separated into debt and equity components at issuance and a value to be assigned to each. The value assigned to the debt component will be the estimated fair value, as of the issuance date, of a similar bond without the conversion feature. The difference between the bond cash proceeds and this estimated fair value will be recorded as a debt discount and amortized to interest expense over the life of the bond. Although FSP APB 14-1 will have no impact on our actual past or future cash flows, it will require us to record a significant amount of non-cash interest expense as the debt discount is amortized. As a result, there will be an adverse impact on our results of operations and earnings per share and that impact could be material.

*We may not be able to raise additional funds when needed for our business or to exploit opportunities*

Our future liquidity and capital requirements will depend upon numerous factors, including the success of the integration of our businesses, our existing and new applications and service offerings, competing technologies and market developments, potential future acquisitions and dispositions of companies or businesses, and additional repurchases of our common stock. We may need to raise additional funds to support expansion, develop new or enhanced applications and services, respond to competitive pressures, acquire complementary businesses or technologies or take advantage of unanticipated opportunities. If required, we may raise such additional funds through public or private debt or equity financing, strategic relationships or other arrangements. There can be no assurance that such financing will be available on acceptable terms, if at all, or that such financing will not be dilutive to our stockholders.

**Table of Contents**

*Negative conditions in the market for certain auction rate securities may result in us incurring a loss on such investments*

As of September 30, 2008, HLTH had a total of approximately \$355.8 million (face value) of investments in certain auction rate securities (ARS) of which \$165.5 million (face value) relate to WebMD. Those ARS had a fair value of \$284.4 million of which (\$132.8 million relates to WebMD). The types of ARS investments that HLTH owns are backed by student loans, 97% of which are guaranteed under the Federal Family Education Loan Program (FFELP), and all had credit ratings of AAA or Aaa when purchased. HLTH and its subsidiaries do not own any other type of ARS investments.

Since February 2008, negative conditions in the regularly held auctions for these securities have prevented holders from being able to liquidate their holdings through that type of sale. In the event HLTH needs to or wants to sell its ARS investments, it may not be able to do so until a future auction on these types of investments is successful or until a buyer is found outside the auction process. If potential buyers are unwilling to purchase the investments at their carrying amount, HLTH would incur a loss on any such sales.

*Our decision to sell Porex may have a negative impact on that business*

As a result of our announcement that we plan to divest Porex, the financial results and operations of that business may be adversely affected by the diversion of management resources to the sale process and by uncertainty regarding the outcome of the process. For example, the uncertainty of who will own Porex in the future could lead Porex to lose or fail to attract employees, customers or business partners. Although we have taken steps to address these risks, there can be no assurance that any such losses or distractions will not adversely affect the operations or financial results of Porex and, as a result, the sale price that we may receive for Porex.

**Table of Contents**

**ITEM 3. *Quantitative and Qualitative Disclosures about Market Risk***

**Interest Rate Sensitivity**

The primary objective of our investment activities is to preserve principal and maintain adequate liquidity, while at the same time maximizing the yield we receive from our investment portfolio.

Changes in prevailing interest rates will cause the fair value of certain of our investments to fluctuate, such as our investments in auction rate securities that generally bear interest at rates indexed to LIBOR. As of September 30, 2008, the fair market value of our auction rate securities was approximately \$284 million. However, the fair values of our cash and money market investments, which approximated \$1.4 billion at September 30, 2008 are not subject to changes in interest rates.

The 31/8% Notes and the 1.75% Notes that we have issued have fixed interest rates; changes in interest rates will not impact our financial condition or results of operations as it relates to these Notes.

HLTH and WHC have each entered into a non-recourse credit facility (each a Credit Facility ) with Citigroup that is secured by their respective ARS holdings (including, in some circumstances, interest payable on the ARS holdings), that will allow HLTH and WHC to borrow up to 75% of the face amount of the ARS holdings pledged as collateral under the respective Credit Facilities. The interest rate applicable to such borrowings will be one-month LIBOR plus 250 basis points. No borrowings have been made under either Credit Facility to date.

**Exchange Rate Sensitivity**

Currently, substantially all of our sales and expenses are denominated in United States dollars; however, certain of our Porex subsidiaries (currently reflected as discontinued operations) are exposed to fluctuations in foreign currency exchange rates, primarily the rate of exchange of the United States dollar against the Euro. This exposure arises primarily as a result of translating the results of Porex's foreign operations to the United States dollar at exchange rates that have fluctuated from the beginning of the accounting period. Porex has not engaged in foreign currency hedging activities to date. Foreign currency translation losses were \$4.5 million and \$1.2 million for the three and nine months ended September 30, 2008, respectively, and foreign currency translation gains were \$1.6 million and \$2.4 million for the three and nine months ended September 30, 2007, respectively. We believe that future exchange rate sensitivity related to Porex will not have a material effect on our financial condition or results of operations.

**ITEM 4. *Controls and Procedures***

As required by Exchange Act Rule 13a-15(b), HLTH management, including the Chief Executive Officer and Chief Financial Officer, conducted an evaluation of the effectiveness of HLTH's disclosure controls and procedures, as defined in Exchange Act Rule 13a-15(e), as of September 30, 2008. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that HLTH's disclosure controls and procedures were effective as of September 30, 2008.

In connection with the evaluation required by Exchange Act Rule 13a-15(d), HLTH management, including the Chief Executive Officer and Chief Financial Officer, concluded that no changes in HLTH's internal control over financial reporting occurred during the third quarter of 2008 that have materially affected, or are reasonably likely to materially affect, HLTH's internal control over financial reporting.

**Table of Contents****PART II  
OTHER INFORMATION****ITEM 1. *Legal Proceedings***

The information relating to legal proceedings contained in Note 12 to the Consolidated Financial Statements included in Part I, Item 1 of this Quarterly Report is incorporated herein by this reference.

**ITEM 2. *Unregistered Sales of Equity Securities and Use of Proceeds***

(c) The following table provides information about purchases by HLTH during the three months ended September 30, 2008 of equity securities that are registered by us pursuant to Section 12 of the Exchange Act:

**Issuer Purchases of Equity Securities**

<b>Period</b>	<b>Total Number of Shares Purchased (1)</b>	<b>Average Price Paid per Share</b>	<b>Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)</b>	<b>Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs (2)</b>
7/01/08 - 7/31/08	6,448	\$ 11.41		\$ 41,553,120
8/01/08 - 8/31/08	3,295	\$ 11.88		\$ 41,553,120
9/01/08 - 9/30/08	2,745	\$ 12.35		\$ 41,553,120
<b>Total</b>	<b>12,488</b>	<b>\$ 11.74</b>		<b>\$ 41,553,120</b>

(1) Represents shares withheld from HLTH Restricted Stock that vested during the respective periods in order to satisfy withholding tax requirements related to the vesting of the awards. The value of these shares was determined based on the closing price of HLTH Common Stock on the date of vesting.

(2) Relates to the repurchase program that we announced in December 2006, at which time HLTH was authorized to use up to \$100 million to purchase shares of its common stock from time to time. For additional information and for information regarding the tender offer commenced by HLTH on October 27, 2008 (the Pending Tender Offer), see Note 8 to the Consolidated Financial Statements included in this Quarterly Report. The Pending Tender Offer is being conducted under a separate authorization and does not affect the amount available under this repurchase program.

**ITEM 6. *Exhibits***



The exhibits listed in the accompanying Exhibit Index on page E-1 are filed or furnished as part of this Quarterly Report.

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HLTH Corporation

By: /s/ Mark D. Funston

Mark D. Funston  
*Executive Vice President and  
Chief Financial Officer*

Date: November 10, 2008

**Table of Contents****EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
2.1*	Agreement and Plan of Merger, dated as of September 12, 2008, by and among WebMD Health Corp., Charlotte's Corporation and Marketing Technology Solutions Inc. (incorporated by reference to Exhibit 2.1 to the Quarterly Report on Form 10-Q filed by the WebMD Health Corp. on November 10, 2008)
2.2*	Agreement and Plan of Merger, dated as of February 20, 2008, between WebMD Health Corp. and the Registrant (incorporated by reference to Exhibit 2.1 to Amendment No. 1, filed by the Registrant on February 25, 2008, to the Current Report on Form 8-K filed by the Registrant on February 21, 2008)
2.3	Amendment No. 1, dated as of May 6, 2008, to Agreement and Plan of Merger, dated as of February 20, 2008, between WebMD Health Corp. and the Registrant (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the WebMD Health Corp. on May 7, 2008)
2.4	Amendment No. 2, dated as of September 12, 2008, to Agreement and Plan of Merger, dated as of February 20, 2008, between WebMD Health Corp. and the Registrant (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Registrant on September 15, 2008)
2.5	Termination Agreement, dated as of October 19, 2008, between HLTH Corporation and WebMD Health Corp. (incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by the Registrant on October 20, 2008)
3.1	Eleventh Amended and Restated Certificate of Incorporation of the Registrant, as amended (incorporated by reference to Exhibit 3.1 to the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004)
3.2	Certificate of Ownership and Merger Amending the Registrant's Eleventh Amended and Restated Certificate of Incorporation to Change the Registrant's Name to HLTH Corporation (incorporated by reference to Exhibit 3.1 to Registrant's Current Report on Form 8-K filed on May 21, 2007)
3.3	Amended and Restated Bylaws of Registrant, as currently in effect (incorporated by reference to Exhibit 3.2 of the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2004)
31.1	Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer of Registrant
31.2	Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer of Registrant
32.1	Section 1350 Certification of Chief Executive Officer of Registrant
32.2	Section 1350 Certification of Chief Financial Officer of Registrant

\* Certain of the exhibits and schedules to this agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Registrant will furnish copies of any of the exhibits and schedules to the Securities and Exchange Commission upon request.